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The mammalian HPRT gene is a housekeeping gene. 	It is 
expressed constitu.tively at a low level in all cell-types, 
with the exception of the brain where expression is elevated. 
It has been shown in human brains that HPRT expression is 
particularly high in the basal ganglia. Total HPRT 
deficiency in man is the causal defect in the Lesch-Nyhan 
syndrome, a severe and complex neurological disorder. 
Partial HPRT deficiency leads to gouty arthritis. 
The expression of the mouse HPRT gene has been extensively 
studied in cultured cells and promoter elements essential 
for a basal level of transcription have been identified. The 
aim of the work presented in this thesis was to identify the 
nucleotide sequence elements responsible for the elevation 
of HPRT expression in brain. A line of mice transgenic for 
an HPRT minigene was produced. The HPRT minigene contains 
635bp of HPRT 5' flanking sequence and the HPRT 5' and 3' 
untranslated regions. This minigene contains sufficient 
nucleotide sequence to be expressed at an elevated level in 
brain relative to other tissues. Gene targeting in ES cells 
was also used to manipulate the HPRT gene in the mouse germ 
line. An HPRT mutant gene corrected by gene targeting and 
also containing 635bp of 5' flanking sequence is expressed at 
elevated levels in brain. This experiment provided 
important information about gene targeting and its potential 
as a way of manipulating the mammalian genome to study the 
expression of endogenous genes. 
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A adenine 
bp base pair(s) 
BSA bovine serum albumin 
C cytosine 
cDNA DNA complementary to mRNA 
CNS central nervous system 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
EDTA ethylenediamine tetraacetic acid 
ES cells embryonic stem cells 
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HAT hypoxanthine, 	aminopterin, 	thymidine 
HEPES N'-2-hydroxyethyl piperazine-N'-2-ethanesulfonic 
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IMP inosine monophosphate 
kb kilobase pairs 
MOPS 3-[N-Morpholino] propanesulfonic acid 
mRNA messenger RNA 
OD optical density 
PBS phosphate bufferred saline 
RNA ribonucleic acid 
SDS sodium dodecyl sulphate 
SSC standard saline citrate 
ssDNA single-stranded DNA 
T thymine 
TEMED N,N,N' ,N'-tetramethyl ethylene diamine 
Tris Tris-(hydroxymethyl) -methylamine 
U Uracil 
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1. 	INTRODUCTION 
1.1 	HPRT enzyme function and tissue distribution 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT; IMP: 
pyrophosphate phosphoribosyltransferase; EC 2.4.2.8) is an 
enzyme of the purine salvage pathway. The role of HPRT in 
purine metabolism is illustrated in Figure 1.1. It catalyses 
the conversion of hypoxanthine and guanine to 5'-IMP and 5'-
GMP, respectively (Kornberg et al., 1955; Korn et al., 1955). 
These products are precursors in DNA and RNA synthesis, and 
in the synthesis of cofactors for a range of enzymatic 
reactions. This activity is required in all mammalian cells 
and so the HPRT enzyme is said to be a 'housekeeping enzyme' 
and the gene a 'housekeeping gene'. 
Mammals are also able to synthesise nucleotides de novo from 
simple precursors. After these nucleotides have been 
metabolized, the free purine bases can be reconverted 
directly to the respective nucleotides by 
phosphoribosyltransf erase activity in the presence of 5'-
phosphoribosyl - 1 - pyrophosphate (PRPP). HPRT is the key 
enzyme in the salvage of guanine and hypoxanthine. Adenine 
phosphor ibosyltransferase (APRT) catalyses the salvage of 
adenine (Figure 1.1). In humans 90% of free purines are 
recycled in this way. 
HPRT is a soluble, cytoplasmic enzyme which constitutes 
between 0.005 and 0.04% of total cell protein (Kelley and 
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Wyngaarden, 1983). The native enzyme is probably a tetramer. 
Each subunit is 217 amino acids long with a mass of 24,000 
daltons (Wilson et al., 1982). 
The tissue distribution of HPRT activity has been analysed in 
humans (Rosenbloom et al.,1967). While HPRT enzyme activity 
is detectable in all tissues, there is considerable 
variation in the level of activity between tissues. Enzyme 
assays on human autopsy material showed that many tissues, 
including liver, spleen, kidney and pancreas have low and 
approximately equivalent levels of HPRT activity. However, 
in brain tissue the level of activity is elevated. This 
elevation is particularly, pronounced in the basal ganglia 
where the level of HPRT specific activity is approximately 
20-fold higher than in liver tissue. The level of HPRT 
activity in each tissue is inversely proportional to the 
level of activity of amidophosphoribosyltransferase (ANPRT) 
enzyme, which catalyses the rate limiting step in the purine 
de novo synthesis pathway (Figure 1.1). Perhaps, therefore, 
the basal ganglia are particularly dependent upon purine 
salvage. This may be related to the neurological dysfunction 
associated with HPRT deficiency in humans, the Lesch-Nyhan 
syndrome. 
Rats also demonstrate elevated HPRT enzyme activity in the 
central nervous system (CNS) (Gutensohn and Guroff, 1972). 
HPRT activity was assayed in the basal ganglia but was found 
to be no higher than in the brain as a whole. Gutensohn and 
Guroff (1972) also demonstrated that in rat brain there is a 
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Figure 1. 1. 
Purine Metabolism. PRPP,5'-phosphoribosyl-l-pyrophosphate; 
ATP, adenosine triphosphate; AMP, adenosine monophosphate; 
IMP, inosine monophosphate; GMP, guanosine monophosphate; 
AMPRT, amidophosphoribosyltransferase; APRT, adenine 
phosphoribosyltransferase; ADA, adenosine deaminase; PNP, 
purine nucleotide phosphorylase. 
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threefold increase in HPRT activity during the first 15 to 20 
days of life. Similarly, enzyme assays on mouse tissues show 
that protein derived from brain has the highest specific 
activity of HPRT (Lo and Palmour, 1979). There are no 
reports of attempts to localise, more specifically, the 
elevated level of expression in mice. 
There are no published studies of HPRT mRNA levels in tissues 
for any organism and consequently the mechanism which 
elevates HPRT expression in the brain has not been 
determined. Electrophoretic variants of the HPRT enzyme 
have been observed (Lo and Palmour, 1979; Gutensohn and 
Guroff, 1972). The basis of this variation has not been 
established and it has no apparent functional significance 
(Kelley and Wyngaarden, 1979). There is no correlation 
between the electrophoretic variants and levels of enzyme 
activity. 
1.2 	The Lesch-Nyhan syndrome 
The Lesch-Nyhan syndrome, first described by Lesch and Nyhan 
in 1964, is the inherited neurological disorder associated 
with a complete deficiency of HPRT enzyme activity 
(Seegmiller et al., 1967). Because the HPRT gene is X-
chromosome linked the syndrome almost exclusively affects 
males, with an estimated frequency of 1 in 10,000 (Kelley and 
Wyngaarden, 1983). The Lesch-Nyhan syndrome is reviewed 
extensively by Stout and Caskey (1989).. A partial deficiency 
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of HPRT activity results in gouty arthritis. 
Lesch-Nyhan patients generally appear normal at birth. 
However, by three to four months of age most patients exhibit 
delayed motor development. Between eight and twelve months 
of age more pronounced signs become evident. Initially, 
these may be slow involuntary and sometimes rhythmical 
movements of the limbs and hands, but later develop to 
include more sudden and violent uncontrollable actions. The 
most disturbing and curious feature of the Lesch-Nyhan 
syndrome is the compulsive self-injurious behaviour which 
presents in 85% of patients. The onset of self-mutilation 
can be as early as 1 year of age or as late as 16 years of age, 
and is characterised by biting of the fingers, lips and the 
inside of the cheeks. This may become so extreme that it is 
necessary to keep the elbows of a patient in extension with 
splints to protect the fingers. In many patients it has been 
necessary to extract teeth to prevent mutilation of the lips. 
If physical restraints are removed the patient often pleads 
for them to be replaced. Other neurological disorders also 
exhibit self-injurious behaviour but only in Lesch-Nyhan 
syndrome is this so severe that it leads to the loss of 
tissue. 
Most Lesch-Nyhan patients appear to *be mentally deficient. 
Although, poor performance in IQ tests is in part due to 
communication difficulties arising as a result of the lack of 
muscle control. One patient was found to have normal 
intelligence when testing was adapted to compensate for 
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these disabilities. 
Autopsies on Lesch-Nyhan patients have revealed no 
consistent distinctive pathological changes in the CNS, and 
the connection between HPRT enzyme deficiency and the 
complexities of the Lesch-Nyhan behavioural phenotype is not 
known. The analysis of autopsy tissues is complicated by 
damage due to hyperuricemia, which is common in patients with 
partial and complete HPRT deficiency. Hyperuricemia, the 
accumulation of excess uric acid, results because HPRT 
deficiency leads to a build up of hypoxanthine which is 
converted to uric acid by xanthine oxidase (Figure 1.1). 
Levels of the neurotransmitter dopamine in the basal ganglia 
of Lesch-Nyhan patients are consistently lower than 30% of 
the normal level (Rosenbloom et al., 1967). It has been 
suggested that a deficiency of purine nucleotides due to the 
absence of HPRT activity could impair the arborisation of 
nigrostriatal neurones, which in humans reaches a peak a few 
months after birth, at the same time as the behavioural 
disorders become evident (Baumeister and Frye, 1985). Thus 
it is interesting that HPRT activity in rat brains increases 
threefold during the first few weeks after birth (Gutensohn 
and Guroff, 1972). If as a result of HPRT deficiency a 
critical stage in neural development is disrupted, it may not 
be possible to alleviate the neurological symptoms by 
restoring HPRT activity at a later stage. 
A partial HPRT deficiency is associated with hyperuricemia 
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and gouty arthritis. Hypoxanthine levels become elevated as 
a result of diminished feedback inhibition of the de novo 
purine synthesis pathway (Figure 1.1). Excess hypoxanthine 
is converted by xanthine oxidase to uric acid which 
precipitates in the joints. Self-injurious behaviour has 
not been observed in patients with a partial HPRT deficiency. 
However, evidence of spasticity, cerebellar ataxia, and mild 
mental retardation can be found in approximately 20% of 
patients. 	Approximately 50% of patients with partial 
deficiency have 	vidence of mental retardation without 
accompanying cerebellar symptoms (Stout and Caskey, 1989). 
1.3 	Therapy for HPRT deficiency 
Allopurinol, which inhibits xanthine oxidase and thereby 
prevents the build up of uric acid (Figure 1.1), is an 
effective treatment for hyperuricemia in patients with 
either complete or partial HPRT deficiency. However, there 
is no therapy for the behavioural disturbances of Lesch-
Nyhan syndrome. Many drug therapies have been tested without 
success and development is hindered by the lack of knowledge 
about the basic physiological defect. Failure to identify a 
successful therapy may reflect irreversible neural damage 
early in development. 
The Lesch-Nyhan syndrome has been considered a candidate for 
gene replacement therapy. Retroviral vectors have been used 
to introduce the human HPRT gene into cultured fibroblasts 
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and lymphoblasts 	(Miller et al., 	1983). 	Transient 
expression of human HPRT in mice has been obtained by 
transplanting bone marrow cells infected with a retrovirus 
expressing human HPRT into lethally irradiated mice (Miller 
et al., 1984). However, this may not be a profitable 
strategy because the restoration of HPRT activity in 
circulating blood by either blood transfusion (Edwards et 
al., 1984) or bone marrow transplantation (Nyhan et al., 
1986) has no effect on neurological function in Lesch-Nyhan 
patients. With the aim of HPRT gene replacement directly 
into neuronal cells the neurotropic herpes simplex virus 
type 1 (HSV-1) has been used as a vector. An HSV-1 vector 
with the human HPRT cDNA under the transcriptional control of 
the viral thymidine kinase gene has been used to obtain 
transient HPRT expression in an HPRT deficient rat neuroma 
cell line (Palella et al., 1988). The vectors used in this 
study have the considerable disadvantage that they are 
cytopathic to the target cells. Before such a strategy can 
be pursued the mechanism which controls the elevated 
expression of HPRT in specific regions of the CNS needs to be 
determined,, and more suitable vectors need to be developed. 
1.4 	Animal models for HPRT deficienc 
Early attempts at producing an animal equivalent of Lesch-
Nyhan syndrome involved the administration of caffeine, a 
methyixanthine, to rats. This resulted in self-mutilation 
similar to that seen in Lesch-Nyhan patients (Boyd et al., 
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1965). Various dopamine agonists have been used to induce 
abnormal behaviour in monkeys (Goldstein et al., 1986). 
Surgical denervation of nigrostriatal dopamine neurons was 
performed when monkeys were 2 to 4 years old. Eight to twelve 
years later the administration of dopamine agonists, such as 
L-dopa, resulted in self-mutilative biting of the forelimb 
digits and spasticity of the hindlimbs. 
Recently, mouse models for HPRT deficiency have been 
produced by Hooper et al. (1987) and Kuehn et al. (1987). 
Both groups used embryonic stem (ES) cells as a way of 
introducing an HPRT deficiency into the mouse germ line. 
Mouse ES cells, obtained from disrupted 3 day embryos, can 
be cultured in vitro and still retain their pluripotency 
(Evans and Kaufman, 1981; Martin, 1981); ES cells taken 
from a cultured line can be reintroduced into host 
blastocysts which develop to produce chimeric adult mice. 
Cells derived from the cultured ES cells may contribute to 
the germ line of those chimeras (Bradley et al., 1984). 
Hooper et al. (1987) obtained an HPRT deficient ES cell line, 
named E14TG2a, by culturing a wild-type ES cell line, derived 
from strain 129 mice, in selective medium containing 6-
thioguanine (6-TG). The characterisation of the genetic 
mutation in E14TG2a cells is described in Chapter 5 of this 
thesis. 	Germ line chimeras were obtained from blastocyst 
injections of E14TG2a cells. 	Kuehn et al. (1987) used 
multiple retroviral infections to generate ES cells with 
insertion, mutations in the HPRT gene. 	They also obtained 
chimeras that transmitted the HPRT deficiency through the 
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germ line. 	Disappointingly, although these mice have an 
absolute HPRT deficiency, they have none of the symptoms 
associated with Lesch-Nyhan syndrome. In fact, they appear 
perfectly normal. However, the levels of striatal dopamine 
are reduced by approximately 20% in HPRT deficient mice 
relative to their normal littermates (Finger et al., 1988). 
In Lesch-Nyhan patients the levels of striatal dopamine are 
reduced by between 70% and 90% relative to normal levels. 
Jinnah et al. (1989) have demonstrated that it is possible to 
induce behavioural abnormalities in HPRT deficient mice by 
the administration of intermediate doses (8mg/kg) of d-
amphetamine. This treatment produced different behavioural 
patterns in HPRT deficient mice to wild-type mice. Normal 
mice exhibited predominantly locomotor hyperactivity, while 
HPRT deficient mice engaged in a brief phase of locomotor 
hyperactivity followed by continuous stereotypic behaviour 
-  characterised by gnawing, grooming, sniffing or ,  licking, 
with little or no locomotor activity. At higher doses (16 to 
32mg/kg) and lower doses (2 to 4mg/kg) of amphetamine wild-
type and HPRT deficient animals behaved similarly. Why HPRT 
deficiency leads to increased amphetamine sensitivity is not 
known although it does suggest a dopaminergic dysfunction in 
the HPRT deficient mice. Possible mechanisms include 
enhanced release of dopamine, dopamine receptor sensitivity, 
reduced metabolism of dopamine or inhibitory systems in the 
striatum. The neurological abnormalities associated with 
Lesch-Nyhan syndrome are also thought to result from 
dysfunction of dopaminergic systems in the striatum 
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(Baumeister and Frye, 1985). This behavioural difference at 
least provides an observable test for the effectiveness of 
new therapies. 
Why HPRT deficient mice have none of the symptoms associated 
with Lesch-Nyhan syndrome remains unknown, but presumably 
represents a basic metabolic difference between the species. 
This may be connected with the finding that while HPRT 
expression is elevated specifically in the basal ganglia of 
human brains (Rosenbloom et al., 1967), in rats HPRT 
expression is homogeneously -high throughout the brain with 
no specific elevation in the basal ganglia (Gutensohn and 
Guroff, 1972). Perhaps this indicates increased de novo 
purine synthesis and les.s dependence on the salvage pathway 
in rodents. Humans also differ from mice in that they lack 
urate oxidase enzyme activity (Lee et al., 1988). In most 
mammals urate oxidase is present in the liver and catalyses 
the oxidation of uric acid to allantoin (Figure 1.1). Humans 
and certain primates lack this activity and this may 
influence the consequences of HPRT deficiency. 
1.5 	Structure of the mammalian HPRT gene 
HPRT .gene sequences have been cloned from three mammalian 
species. Mouse HPRT cDNA sequences were first cloned from 
NBR4, an HPRT revertant mouse neuroblastoma cell line which 
1. 
	
	overproduces a mutant HPRT protein approximately 20-fold 
(Brennand et al., 1982; Konecki et al., 1982). The longest 
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mouse cDNA clone, pHPT5, was used to isolate cDNA clones from 
a Chinese hamster cell line (Konecki et al., 1982) and from 
human cell lines (Brennand et al., 1983). Jolly et al. 
(1983) independently isolated a human cDNA clone by 
screening a cDNA library with a human HPRT genomic fragment, 
obtained from an HPRT deficient mouse cell line into which 
the human gene had been introduced by DNA-mediated gene 
transfer. 
Comparison of the nucleotide sequences of the cDNA from 
mouse, human and Chinese hamster shows that they each code 
for a 217 amino acid protein. The initiating methionine is 
removed by post-translational processing (Wilson et al., 
1982). Within the protein coding regions there is greater 
than 90% nucleotide sequence identity between the three 
species (Helton, 1987). The mouse and human proteins differ 
in the amino acid sequence at just seven positions. A high 
level of nucleotide sequence conservation between species is 
also found in the 3' untranslated region of the HPRT cDNA. 
This is discussed in greater detail in the context of gene 
expression. 
The HPRT cDNA clones were used as hybridisation probes to 
identify HPRT genomic recombinants in libraries from both 
mouse (Melton 	et 	al., 1984) 	and 	human 	cells 	(Kim 	et 	al., 
- 1986; Patel 	et 	al., 	1986). 	The 	structure 	of 	the mouse 	and 
human HPRT genes, with selected restriction enzyme sites, is 
fr)' shown in 	Figure 	1.2. Characterisation 	of 	genomic 	EcoRI 
fragments 	and 	use 	of parts 	of 	the 	mouse 	HPRT 	cDNA clone, 
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Figure 1. 2. 
The structures of the mouse and human HPRT genes, with 
selected restriction enzyme sites. The genes are drawn to 
scale and exons are depicted as vertical bars. The size of 
each intron and the sizes of restriction fragments in the 
mouse gene are indicated (in kb). 
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Figure 1.2 
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pHPT5, as hybridisation probes in Southern analysis of wild-
type genomic DNA showed that the gene extends over 33kb of 
the mouse X-chromosome. DNA-mediated gene transfer 
experiments and the comparison of the HPRT Southern 
hybridisation patterns for a wild-type cell line and NBR4, in 
which the gene is amplified, allowed the identification of 
fragments containing HPRT exons and demonstrated the 
presence of an HPRT pseudogene. 	The mouse HPRT gene is 
divided into nine exons. 	The first exon contains the 5'- 
untranslated sequence and 27bp of protein coding sequence. 
The size of the 5' untranslated region is 118bp or smaller 
depending on which transcription initiation site is used. 
The ninth exon contains 45bp of coding sequence and the 
entire 548bp of 3' untranslated sequence. The intron sizes 
are shown in Figure 1.2. Five of the introns are positioned 
between codons and three are positioned within codons. 
The human gene is also divided into nine exons by introns 
which nucleotide sequence analysis showed are in identical 
positions to those of the mouse gene (Kim et al., 1986). The 
human gene spans 42kb of the X-chromosome, the greater length 
relative to the mouse gene, being due to larger introns. The 
sizes of the exons differ between the two species only in the 
lengths of the 5' and 3'untranslated regions. The structure 
of the Chinese hamster HPRT gene has not been completely 
determined, but where introns have been mapped they are in 
identical positions to human and mouse introns. 
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1.6 	The HPRT promoter 
Si nuclease protection and primer extension analyses showed 
that the major transcription initiation site of the mouse 
HPRT gene was just 13bp upstream of the start of pHPT5, the 
longest eDNA clone (Melton et al., 1984). Nucleotide 
sequencing of the region upstream of this transcription 
initiation site (which is denoted nucleotide position +1) in 
the mouse gene failed to reveal the sequence motifs which at 
the time were believed to be normally present in eukaryotic 
gene promoters, having been identified in tissue-specific 
genes. For instance, the nearest match to the TATA box 
consensus, usually located 20 to 30bp upstream of the 
transcription start site (Corden et al., 1980), occurs 
greater than 700bp upstream of the gene. Furthermore, there 
is no sequence match for the CAAT box which is situated about 
80bp upstream of many eukaryotic genes (Benoist et al., 
1980). The 5' end of the gene was assayed for promoter 
activity. An HPRT minigene was constructed (Melton et al., 
1984) which consisted of 845bp of 5' flanking sequence, the 
putative promoter region, fused onto the wild-type human 
HPRT cDNA sequence through a restriction site in the 5' 
untranslated region. In DNA-mediated gene transfer 
experiments 	this minigene, 	pHPT44, 	transformed HPRT 
deficient Chinese hamster, RJK88, cells to the HPRT+ 
phenotype. 	Thus, it was demonstrated that the 845bp 
immediately upstream of the mouse HPRT gene, while not 
necessarily 	containing 	all 	the 	elements 	regulating 
transcription, does have promoter activity in cultured 
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cells. 
Further analysis of the mouse HPRT promoter region was 
reported by Melton et al. (1986). Figure 1.3 shows the 
nucleotide sequence around the 5' end of the HPRT gene. As 
stated previously there are no TATA or CAAT consensus 
sequence matches in the expected positions. However, the 
region in which the 5' end of the gene is situated is highly 
CG-rich. In particular, the lOObp immediately upstream of 
the start site is 80% CG-rich. The possible significance of 
this is discussed below in relation to X-inactivation and DNA 
methylat ion. 
Computer-assisted analysis of the nucleotide sequence of the 
promoter region revealed a complex pattern of direct repeats 
(Figure 1.3). There are two 12bp perfect repeats in tandem, 
between 30 and 60bp upstream of the transcription start site. 
Between nucleotide positions -80 and -15 there are two 
imperfect 18bp repeats, the central region of which is 
repeated a third time. Nine out of ten bases from the centre 
of the 18bp repeat are found in the enhancer region of the DNA 
tumour virus SV40 (Moreau et al., 1981). In the same region 
of the mouse HPRT promoter there are three matches to the 
consensus sequence for the binding site of the transcription 
factor Spi (Kadonaga et al., 1986). Spi is discussed in 
detail in section 1.7.. A match to the consensus sequence for 
the AP2 binding site is also found in this region of the HPRT 
promoter. AP2 binding sites together with AP3 binding sites 
constitute the functional core of the SV40 enhancer (Herr and 
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Figure 1. 3. 
Structure of the mouse HPRT promoter region. The sequence is 
numbered from the main transcription -initiation site (+1). 
The 145bp first exon is underlined and within it the 
transcription initiation sites at +28 and +34 are indicated. 
Three asterisks indicate the translation initiating codon. 
The 18bp imperfect direct repeats and the third repeat of 
part of the central section are boxed. The 12bp direct 
repeats are underlined. Three matches to the consensus Spi 
binding site are heavily underlined. The sequence enclosed 
by the square bracket has been used as a synthetic promoter 
(Section 1.7). The end points of 5' deletions used to map 
functional elements (Section 1.6) are indicated by a dot over 
the position of the first base present. The arrow indicates 
the 5' boundary of the CG-rich region. 
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Figure 1.3 
AATTCACAGT TGTAATTCTC CTACCTCTGT AGTGCTGGGA TTACACATAT GTGTCGCCAC ACCTGACTAA AATCAACATG TAAGAAATCG CATCTTATTT 
GGTAATATAT GAATCTCTAT CAGCATTTCT TTTGTGTGTG TTGCAGTCAT GTGCAAGATG TCTTTCTCCA TCCCTATTCC ACCTTAACAA TTTTTATTTT 
-638 
GAAGCAAAT CTTAATTGTC TGGGTAGGTC GAATATGTAT GTGATTCTCC TTTCTTGGTA GCTGGGCATA A.&&GCCTTTT TTTTTTTTTT AAACCATACT 
-60 
TGGCTTAAAA TGCTCATTTT ATGTAAAGGC AAAAAGCATT TTAGGGTCTA TTTCTCCTAA GGTTACTMG TAGTTTATTT TTCCTTTTGG ATTGGTACTC 
CACTTTGTAG ACCAGACTGG CCTTGAACTC AGAAATCCGC CTGCCTCTGC CTCCTAAATG CTGGGATTAA AGGCGTGCGC CACCACCGCC CGGCTGGATC 
-306 
TCAAATCTTA TGACTAAGTA AAAATTTGTG AAAGAACTGG GCCTAAATCT TGAGGAATCA CATCATGATT TAGAGCTGTT TAGACTCATG AGGAGGGAGA 
-186 	 -152 
AAAATGCGGA GTGAITATCT GGGAATCCTC TGGGAGACGA CAGAGGGCCT GGGGGCTGCG GTATGGCCAG TACCATTTTC TTCAGAAAGA AAAtTATCAG 
-32 	 -116 ________ -8 
	
GCCCACCTAG TCAGATAAGA GTTCCGGAA TGCCTTTGGT GGCGCGCGCG CGGGAGAACG CCCAGGAG_CCTtc 	GAGCCTGG GUgGCCGAG 
-39 	•7 	-2 	I 	 3 	 +28 	+34 
AGGGCGGGCC GPUVkSj AGCCtGXGJ CAGCGTTTCT GAGCCATTGC TGAGGCGGCG AGGGAGAGCG TTGGCT1C CTCACTGCTT TCCGGAGCGG 
TAGCACCTCC TCCGCCGGCT TCCTCCTCAG ACCGCTTTTT GCCGCGAGCC GACCGGTCCC GTCATGCCGA CCCGCAGTCC CAGCGTCGTG GTGAGCCAAG 
GGGACTCCAG CAGAGCCCCA CAGCCGGGCC CCATGCGCCC GGTGGCACAG 
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Gluzman, 1985). Mutations which prevent AP2 binding reduce 
enhancer activity in HeLa cells by approximately 60%. 
The nucleotide sequence of the promoter region of the human 
gene has also been determined (Kim et al., 1986; Patel et 
al., 1986). The overall homology between the mouse and human 
sequences for a region including the 5' untranslated region 
and extending 150bp upstream of the major transcription 
initiation site is only 51% (Kim et al., 1986). However, 
localised similarity becomes obvious if the two sequences 
are aligned around the common region of multiple Spi binding 
sites. Allowing for up to three mismatches,. five putative 
binding sites are present in the mouse promoter and six in 
the human. The spacing between sites is similar in both 
species, with a tendency for adjacent sites to be 
approximately one helical turn apart. There are also 
sequences similar to the central region of the 18bp imperfect 
repeats in the mouse in equivalent positions in the human 
promoter. Both Patel et al. (1986) and Kim et al. (1986) have 
identified additional regions of homology between the two 
species, some of which also occur in the SV40 enhancer. In 
addition, one region of the human promoter has 17 out of 22 
residues in common with the SV40 enhancer but has no 
equivalent in the mouse promoter. 
To facilitate functional analysis of the mouse HPRT 
promoter, an HPRT minigene, pDWM1, was constructed in which 
the 33kb chromosomal gene is represented in 3kb of sequence 
(Melton et al., 1986). The pDWM1minigene contains 845bp of 
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5' flanking sequence, the entire 	5' and 3' untranslated 
regions and the HPRT protein coding sequence interrupted by 
the last two introns. This minigene can transform HPRT-
deficient Chinese hamster cells to the HPRT+ phenotype (as 
assayed by the ability to grow in HAT-containing medium) at 
a frequency of 2 to 5 x 10 per 5pg of plasmid DNA. 
Deletional analysis of the 845bp of 5' flanking sequence 
present in pDWM1 was used to identify functionally important 
regions. Exonuclease Bal3l was used to generate a 
progressive series of deletions of the promoter region 
extending towards the gene from the 5' end. The end points 
of the 5' deletions are indicated in Figure 1.3, numbered 
relative to the major transcription initiation site +1. Each 
deletion construct was used to transform RJK88 cells 
(Chinese hamster fibroblasts with a deletion of the HPRT 
gene) to the HPRT+ phenotype. HAT-resistant clones were 
assayed for their ability to incorporate [ 3H]-hypoxanthine. 
Because less than 10% of normal HPRT activity is sufficient 
to support growth in HAT-containing medium (Melton, 1981), a 
wide range of expression levels can be detected using this 
assay. Melton et al. (1986) showed that it is possible to 
delete as far as nucleotide -39 and still retain greater than 
30% of the incorporation for the starting minigene pDWM1. 
However, a minigene in which the promoter was deleted as far 
as -27 gave an incorporation level of just 2.5% of the 
original value. The sequence between -39 and -27 contains 
one of the putative Spi binding sites. Deletions further 
'into the promoter region towards the initiation site gave 
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similar low levels of incorporation. A reproducibly higher 
level of incorporation than for pDWM1 was obtained for 
deletion mutants with end points between -306 and -152. This 
may indicate the presence of a negative control element but 
has not been analysed further. 
3' deletions of the promoter region fused to the neomycin 
phosphotransferase (neo) transcription unit, from pSV2 neo, 
lacking its own promoter were assayed for the ability to 
transform RJK88 cells to G418 resistance. Deletion to -38 
gave a transformation frequency of 40% of a construct 
containing HPRT sequences from -638 to +113 fused to neo. 
While deleting as far as -44 reduces the transformation 
frequency by 95%. Thus, it is possible to delete from the 3' 
side of the promoter as far as -38, which loses the proximal 
18bp repeat and Spi site, and still retain transcriptional 
activity. 	While, from the 5' direction it is possible to 
delete as far as -39 with a similar lack of effect. 	The 
conclusion has to be that the mouse HPRT promoter is 
functionally duplicated. Functional redundancy has also 
been identified in the HMGCoA reductase promoter (Osbourne 
et al., 1987). 
The wild-type endogenous HPRT gene has three main 
transcription initiation sites at nucleotides +1, +28 and 
+34, as determined by Si nuclease protection and primer 
extension analysis. The transcription initiation sites used 
by the deletion mutants were analysed. For all the 5' 
deletion mutants only the three wild-type initiation sites 
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were used, although HPRT mRNA was barely detectable for the 
mutant deleted to -27. For the 3' deletion mutants 
initiation occurred at each of the three wild-type sites 
until they were deleted. Then initiation was directed to 
sites in the equivalent position with respect to the 
promoter. If the promoter region was deleted beyond -38, 
transcription initiation occurred from many sites extending 
up to 350bp upstream of +1. Nucleotide -350 is close to the 
boundary of the CG-rich region. 
The experiments described above demonstrated that the DNA 
sequences essential for transcription of the HPRT gene in 
cultured Chinese hamster fibroblasts are all contained 
within the 50bp immediately upstream of the major 
transcription initiation site. Less detailed analysis of 
the human HPRT promoter (Patel et al., 1986) demonstrated 
that lOObp of 5' flanking sequence is sufficient for 
transcription of a human minigene. 
1.7 	The organisation of cis-acting DNA elements that 
regulate transcription initiation 
Eukaryotic genes can be defined as either housekeeping genes 
or specialised genes, dependent upon their pattern of 
expression. Housekeeping genes, of which HPRT is an example, 
are constitutively expressed in all the cells of an organism. 
The expression of specialised genes is restricted to certain 
cell types or defined stages in development. In general 
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terms the organisation of the DNA elements involved in the 
control of transcription is different in specialised genes 
to housekeeping genes. However, there are no hard rules and 
some genes show characteristics of both housekeeping genes 
and specialised genes. Rather than representing two 
distinct classes, housekeeping genes and specialised genes, 
as defined above, are probably the extremes of a spectrum. 
The transcription of specialised genes is characteristically 
regulated by two noniiraUy distinct cis-acting DNA 
elements, the promoter and the enhancer (reviewed in 
Maniatis et al., 1987). The promoter region is typically 
situated within approximately lOObp immediately upstream of 
the transcription initiation site. Promoters contain a 
combination of binding sites for general transcription 
factors and factors which determine promoter specificity. 
The promoters of most specialised genes contain a binding 
site for the general transcription factor TFIID. This 
binding site, the TATA box, is usually situated between 20 
and 30bp upstream of the transcription start site. The 
binding of TFIID to the TATA box is the first step in 
transcription initiation (Davison et al., 1983; Fire et al., 
1984; Van Dyke et al., 1988; Buratowski et al., 1989) and 
focuses the assembly of RNA polymerase II with other general 
transcription factors to form the active transcription 
complex. The yeast gene encoding TFIID has been cloned (Hahn 
et al., 1989; Eisenmann et al., 1989; Horikoshi et al., 
1989). TATA box-containing promoters usually have a single 
transcription initiation site. If the TATA box is deleted 
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transcription is then initiated from heterogeneous sites 
(Grosschedl and Birnstiel, 1980; 	Grosveld et al., 1982; 
Benoist and Chambon, 1981). 	Hence TFIID and associated 
factors determine the site of transcription initiation. 
Additional promoter elements, 30 to llObp upstream of the 
start 	site regulate 	the 	frequency of 	transcription 
initiation. 	A consensus sequence commonly found in this 
region is the CAAT box. 	A group of proteins has been 
identified which bind to the CAAT box (Santoro et al., 1988). 
The protein factors that bind these upstream elements 
interact with the TFIID protein:DNA complex to regulate the 
frequency of transcription initiation (reviewed in Maniatis 
et al., 1987). The best characterised of the general 
transcription factors is Spi (reviewed in Kadonaga et al., 
1986). Spl binding is essential for the expression of both 
the early and late genes of the SV40 virus (Gidoni et al., 
1984). The consensus sequence for the Spi binding site is 
GGGCGG and is functional in either orientation. Matches to 
this consensus are found in the promoter regions of many 
7 
genes, including HPRT. The human Spi gene has been cloned 
(Kadonaga et al., 1987). 
In addition to these general transcription factor binding 
sites, specialised promoters contain sites for factors which 
determine the specialised properties of the promoter. An 
example of such a binding site is the heat shock element 
(HSE). Three matches to the HSE consensus sequence are found 
in the Xenopus hsp70 promoter and are responsible for 
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activation of that gene in response to hyperthermia. HSE 
consensus matches are found in a range of species. HSEs can 
act over considerable distances in an orientation 
independent manner and have optimal activity in combination 
with both a CAAT box and a TATA box. The same factor-binding 
sites from the Drosophila hsp70 gene can function either as 
regulatory promoter elements in proximity to the TATA box or, 
when duplicated, as inducible enhancer elements, active over 
distances of several kilobase pairs (Bienz and Pelham, 
1986) 
The human metallothionein promoter contains at least five 
distinct elements that regulate transcription and its cell 
specificity. The general transcription factor binding sites 
include a TFIID binding site, an Spl binding site and two APi 
binding sites (Lee et al., 1987). API binding sites are also 
present in the SV40 enhancer and the promoters of a number of 
other genes (reviewed by Jones et al., 1988). Two other 
types of element exist in the metallothionein promoter. The 
metal regulatory elements which confer responsiveness to 
induction by heavy metals and the glucocorticoid responsive 
elements which confer responsiveness to induction by steroid 
hormones (Karin et al., 1984). Hence, promoters consist of 
a combination of general elements that are required for the 
transcription of many genes and specialised elements which 
determine the expression pattern specific to that gene. 
The transcription of many specialised genes is also 
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regulated by enhancers. 	The enhancer effect was first 
identified for sequences upstream of the SV40 early promoter 
(Banerji et al., 1981; Moreau et al., 1981; Fromm and Berg, 
1983). Enhancers can stimulate transcription from distances 
of greater than 10kb either upstream or downstream of the 
gene, or from within the gene itself. Enhancers like 
upstream 	promoter 	element 	function 	independent 	of 
orientation. Enhancers have now been identified for many 
genes although the SV40 enhancer remains the best 
characterised (reviewed in Jones et al., 1988). Like 
promoters, enhancers are composed of sequence elements which 
bind one or more protein factors. The short sequence 
elements, combinations of which constitute the enhancer, 
have been termed enhansons (Ondek et al., 1988; reviewed, 
Dynan, 1989). These protein binding sites often occur in 
pairs separated by a precise distance indicating a 
requirement for stereoscopic alignment to allow protein-
protein interaction. Binding site pairs have been called 
modules (Dynan, 1989). Mutation of a single module in the 
SV40 enhancer which leads to diminished transcription 
stimulation, can be suppressed, or reverted, by duplication 
of remaining unmutated modules (Herr and Clarke, 1986). 
Enhancers may contain binding sites for many transcription 
factors with different tissue-specificities. The 
specificity of transcription stimulation is determined by 
the particular combination in a given enhancer. 
The distinction between enhancers and promoters is 
- nominal, that is, relating only to their position 
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relative to the gene. Structurally they are essentially the 
same and many transcription factors, including APi (Lee et 
al., 1987), bind to both promoters and enhancers (reviewed in 
Jones et al., 1988). Furthermore, elements taken from 
promoters can act as enhancers with heterogeneous promoters 
(Bienz and Pelham, 1986). 	A notable exception to these 
generalisations is the TATA box 	which is peculiar to 
promoters. This is not surprising, in light of its function, 
as discussed previously. 
Mammalian HPRT is a housekeeping gene. It is expressed in 
all cell-types. A comparison of the HPRT promoter with the 
promoters of other housekeeping genes reveals a tendency 
towards certain characteristics which are different to 
specialised genes. All housekeeping gene promoters so far 
studied are in highly CG-rich regions of the genome. The 
HPRT promoter sits in a CG-rich island approximately 2kb 
long. More locally, the lOObp immediately upstream of the 
major transcription start site of the mouse HPRT gene are 80% 
CG-rich. The mouse adenine phosphoribosyl transferase 
(APRT) gene has a 200bp region which is 66% CG-rich (Dush et 
al., 1985), the mouse and hamster dihydrofolate reductase 
(D1-IFR) genes have a 140bp region which is 65% CG-rich 
(Farnham et al., 1985; Mitchell et al., 1986), and the 
hamster 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) 
reductase gene promoter has a iOObp region which is also 65% 
CG-rich (Reynolds et al., 1984). Other housekeeping genes 
with CG-rich promoter sequences include human adenosine 
deaminase (Valerio et al., 1985), human phosphoglycerate 
\ 
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kinase (Singer-Sam et al., 1984) and human triose phosphate 
isomerase (Brown et al., 1985). All of the housekeeping 
genes listed above contain multiple copies of the consensus 
sequence for the Spi binding site (reviewed Kadonaga, 
1986). 
Most housekeeping genes lack matches to the TATA box 
consensus sequence in their promoter regions. Of the 
housekeeping genes discussed above, only triose phosphate 
isomerase appears to contain a TATA box (Brown et al., 1985). 
Presumably, a different protein performs the apparently 
pivotal role of TFIID in promoters that lack a TFIID binding 
site. 	Interestingly, housekeeping gene promoters initiate 
transcription from heterogeneous sites. 	As described 
previously, TFIID positions the site of transcription 
initiation in specialised genes. 
Bidirectionality is a property that has been demonstrated 
for some housekeeping promoters. That is, the ability to 
promote the transcription of both DNA strands divergently 
from the promoter region. A 34bp sequence from the mouse 
HPRT promoter, from -49 to -16 (Figure 1.3), which 
corresponds to the region identified as being important by 
deletional analysis, has been synthesised chemically and 
analysed for its ability to initiate transcription. This 
synthetic promoter, which contains two putative Spi binding 
sites and the putative AP2 binding site, was able to direct 
transcription from the normal sites when placed upstream of 
a promoterless HPRT minigene, or a neo gene. Interestingly, 
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the synthetic promoter was able to promote transcription 
when placed in either orientation relative to the reporter 
gene. It was also capable of simultaneously promoting the 
transcription of both an HPRT minigene and a divergent neo 
gene when placed between the two. Si nuclease protection and 
Northern analyses of wild-type mouse mRNA, using probes from 
the HPRT promoter region, indicate the presence of 
additional transcripts, some of which are divergent. 
Further analysis of these transcripts has been hindered by 
the presence of highly repeated sequences in the same 
region. 
Divergent transcripts have also been identified originating 
adjacent to the DHFR gene (Farnham et al., 1985). The mouse 
DHFR gene has two promoter regions, approximately 300bp 
apart, both of which contain Spi binding sites and lack TATA 
boxes. Either promoter is able to initiate bidirectional 
transcription. The DHFR divergent transcripts have sequence 
identity with bacterial genes involved in DNA mismatch ( 
repair (Linton et al., 1989). 	Many transcription factor 
binding sites, 	including the Spi binding site, are 
functionally bidirectional or orientation independent, 
despite being asymmetrical. This combined with the absence 
of the focusing influence of a TATA box probably explains the 
bidirectional properties of these promoters. 
In summary,while specialised genes tend to have control 
elements divided into promoters and enhancers which can be 
many kilobases from the gene, housekeeping genes tend to have 
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all control elements relatively close to the gene. The less 
regulated pattern of expression of housekeeping genes seems 
to be reflected in less strictly organised control regions 
which lack specialised elements. 	Having said that, 
housekeeping genes are not unregulated. 	The HMGCoA 
reductase gene (Reynolds et al., 1984) is subject to negative 
feedback regulation in response to cholesterol levels and 
DHFR (Farnham et al., 1985) expression increases during DNA 
synthesis. HPRT enzyme activity is elevated in brain tissue. 
While the mechanism of expression elevation is undetermined, 
data presented in this thesis demonstrate that the increased 
enzyme activity is paralleled by increased steady-state 
levels of HPRT mRNA. 
1.8 DNA methylation and gene expression 
As described earlier, the HPRT promoter region is highly CG-
rich. The lOObp immediately upstream of the transcription 
start site, are 80% CG-rich which compares to the average of 
40% for bulk DNA. This concentrated CG-richness, lies within 
a more extensive CG-rich island spanning approximately 2kb. 
It has been noticed by Bird (1986) that large CG-rich islands 
tend to be associated with genes, predominantly but not 
exclusively with housekeeping genes as opposed to 
specialised genes. Within these CG-rich islands the density 
of CpG dinucleotides may be more than ten times higher than 
in bulk DNA. In mammals the majority of CpG dinucleotides 
are methylated at the cytosine residue. The low frequency of 
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CpG dinucleotides in bulk DNA may be due to the mutation of 
methylcytosines. CpG-rich islands tend to be hypomethylated 
and can consequently be identified using methyl CpG 
sensitive restriction enzymes, such as HpaII. Consequently, 
they are also known as HTF (HpaII tiny fragment) islands. 
Lavia et al., (1987) randomly isolated two HTF islands from 
mouse chromosomal DNA. Both islands were found to be the 
origin of divergent transcripts that were detectable in a 
range of mouse tissues. Bidirectional initiation may 
therefore be a property of many housekeeping gene promoters. 
The apparent correlation between transcriptional activity 
and hypomethylation of HTF islands leads to the question of 
whether methylation is directly involved in the control of 
gene expression. 
In female mammalian cells only one copy of the HPRT gene is 
expressed due to X-chromosome inactivation (Lyon, 1972), 
which occurs early in embryogenesis. The first evidence for 
the involvement of methylation in X-inactivation, albeit 
indirect, came from DNA transfection experiments. DNA from 
an active X-chromosome was much more efficient at 
transforming HPRT deficient cells to HPRT expressing cells 
than DNA from the inactive X-chromosome (Liskay and Evans, 
1980; Chapman et al., 1982; Lester et al., 1982; Venolia 
and Gartler, 1983). In addition, the incorporation into DNA 
of the cytidine analogue, 5-azacytidine, which cannot be 
methylated results in a high frequency of reactivation of 
genes on the inactive X-chromosome (Nohandas et al., 1981; 
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Lester et al., 1982; 	Graves, 1982). 	It has subsequently 
been demonstrated using methylation sensitive enzymes which 
have CpG in their recognition sequence, that several CpGs 
around the HPRT promoter are methylated on the inactive but 
not on the active X-chromosome (Yen et al., 1984; Lock et 
al., 1986; Wolf et al., 1984). Other X-linked genes for 
which a similar correlation has been observed are the 
housekeeping genes: glucose-6-phosphate dehydrogenase 
(Toniolo 	et 	al., 	1984; 	Wolf 	et 	al., 	1984a) 	and 
phosphoglycerate kinase (Keith et al., 1986). 	It is 
important to note, that X-linked genes without CG-islands 
are still inactivated on the inactive chromosome. 	The 
precise 	interrelationship 	between 	methylation 	and 
inactivation is undetermined. In the mouse embryo 
inactivation of the HPRT gene on the inactive X-chromosome 
occurs several days before methylation is detectable in the 
CG-rich island (Lock et al., 1987). In addition, in the 
early extra-embryonic tissues, inactivation does not appear 
to be strongly associated with methylation (Kratzer et al., 
1983). 
A protein has been identified which specifically binds to 
methylated CpG-containing sequences (Meehan et al., 1989). 
Methyl-CpG binding protein (MeCP) is abundant in a range of 
tissues, but interestingly, is only present at very low 
levels in embryonal carcinoma cells, which are particularly 
active methylators of introduced DNA. 
Methylation is also associated with gene inactivation as a 
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mechanism of parental imprinting (reviewed by Solter, 1987). 
Swain et al., (1987) demonstrated that the expression of a c-
myc transgene, in one line of transgenic mice, was dependent 
upon whether it was inherited from the paternal or maternal 
parent. 	When inherited from the mother this autosomal 
transgene was methylated and not expressed. 	However, the 
transgene was expressed and hypomethylated when inherited 
from the father. The effect of methylating cytosine residues 
on DNA-protein interaction is discussed by Dynan (1989a). 
1.9 	Post-transcriptional regulation of gene expression 
Gene promoters are not the only influences on gene expression 
and the steady-state levels of mRNA in a cell are not solely 
dependent upon the rate of transcription of the 
corresponding gene. Expression may also be regulated by RNA 
processing, translation or post-translational processing. 
The steady-state levels of mRNA are also a function of the 
rate of mRNA turnover (reviewed Ross, 1988). This is a 
possible mechanism for regulating the elevated expression of 
HPRT in brain tissue. There is currently no evidence for 
regulation at the level of transcription initiation in the 
HPRT gene. It has been demonstrated for some housekeeping 
genes that mRNA accumulation is controlled at the level of 
transcript degradation (Carneiro and Schibler, 1984). Ten 
cDNA clones were selected from a library on the basis of the 
abundance of their complementary mRNA. That is, five were 
selected for which the corresponding mRNAs are moderately 
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abundant (220 to 640 copies per L-cell) and a further five 
were chosen for which the corresponding mRNAs are rare (5 to 
76 copies per L-cell). Northern analysis showed each of the 
ten mRNAs is present in a range of tissues. Therefore, all 
ten probably represent transcripts from housekeeping genes. 
Run-off transcription experiments performed on isolated L-
cell nuclei indicated that there was no correlation between 
the relative abundance of a transcript and the rate of 
transcription of each of the ten genes. That is, the 
transcription rate of the genes with moderately abundant 
mRNA was no higher than of genes with rare mRNA, suggesting 
that regulation is post-transcriptional. This contrasts 
with earlier findings that transcriptional regulation was 
predominantly responsible for the control of expression of 
tissue-specific genes (Derman et al., 1981). The relative 
stability of each of the rnRNAs was compared in a kinetic 
labelling experiment. 	L-cells were incubated with [ 32 P] 
orthophosphate for three hours and 24 hours. 	Purified 
polyadenylated mRNA was analysed by dot blot hybridisations. 
Quantitation of hybridisation signals showed that the 
majority of the moderately abundant mRNAs accumulate to a 
higher extent than the rare mRNAs, between the labelling 
times of 3 hours and 24 hours. Carneiro and Schibler (1984) 
concluded that the steady-state levels of the mRNAs studied 
are determined by differential stabilities, rather than 
rates of transcription. 
Most mRNA molecules are protected against exonucleolytic 
attack by poly (A) sequences (Bergmann and Brawerman, 1977) 
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or, in the case of some histone mRNAs which lack a poly (A) 
tail, by stem-loop secondary structures (Georgiev and 
Birnstiel, 1985). More specific elements must be involved if 
controlled mRNA turnover is a mechanism for regulating gene 
expression. In this respect, it is interesting that the 3' 
untranslated region of the HPRT mRNA, which is 545bp long in 
the mouse and approximately 50bp longer in the human, shows 
70% nucleotide identity between the mouse and human 
sequences. Within the 3' untranslated region there are large 
blocks of sequence with absolute identity between mouse, 
human and Chinese hamster. One block of absolute sequence 
identity which is 40 nucleotides long is extremely AU-rich 
(92.5%). Shaw and Kamen (1986) have identified a conserved 
AU-rich sequence from the 3' untranslated region of the 
lymphokine granulocyte-monocyte colony stimulating factor 
(GM-CSF) mRNA, which mediates selective degradation. These 
GM-CSF sequences are 93% conserved between mouse and human. 
Furthermore, similar sequences are present in the 3' 
untranslated regions of numerous other lymphokine, cytokine 
and proto-oncogene mRNAs. The common feature of these 
transcripts is that they all code for transiently expressed 
growth-regulating proteins. The 51 nucleotide long GM-CSF 
AT-rich DNA sequence was synthesised chemically and 
introduced into the 3' untranslated region of the rabbit - 
globin gene, which produces relatively stable mRNA (half-
life greater than 17 hours). In cultured cell transfection 
experiments the -globin transcript containing the AU-rich 
sequence accumulates to just 3% of the level of a control 
-giobin mRNA. The control gene also had a 51bp insert but 
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this insert contained 14 G and C residues interspersed 
throughout the sequence. Shaw and Kamen (1986) demonstrated 
that the effect of introducing the AU-rich sequence is to 
decrease the -globin mRNA half-life. The longest sequence 
motif in common between GM-CSF and the range of lymphokines 
and proto-oncogenes analysed is AUUUA. Although, the most 
common feature is a single adenine followed by three or more 
uridine residues. A cytoplasmic protein which binds 
specifically to mRNAs containing the AUUUA sequence has now 
been identified (Halter, 1989). Using either criterion, the 
HPRT 3' untranslated region has the same sequence elements. 
Controlled rapid degradation of mRNA is an obvious advantage 
for genes that code for proteins involved in the regulation 
of growth. However, it is less obvious why the HPRT gene 
should share this characteristic. The possible role of the 
3' untranslated region in the control of HPRT expression is 
of considerable interest. 
1.10 Project aim 
As described above HPRT enzyme activity is found at 
relatively low levels in all mammalian tissues with the 
exception of the CNS, in which activity is elevated 
(Rosenbloom et al., 1967; Gatensohn and Guroff, 1972). In 
humans, at least, the elevation is concentrated in the basal 
ganglia. This tissue distribution is particularly 
interesting because of the consequences of HPRT deficiency 
on CNS function. At the outset, the aim of this project was 
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to gain further information about the control of HPRT gene 
expression. The detailed study of the mouse HPRT promoter 
has been described. To investigate the control of the brain 
specific elevation in expression we have extended our 
experiments to whole animal systems. 	Two approaches are 
described in this thesis. 	Firstly, the use of transgenic 
mice produced by DNA microinjection into fertilised eggs. 
Secondly, we have exploited gene targeting in embryonic stem 
cells to manipulate the HPRT gene in the mouse germ line. 
Knowledge of the mechanism by which HPRT expression is 
elevated in brain, in addition to being of fundamental 
biological interest, may help elucidate the relationship 
between HPRT expression and Lesch-Nyhan syndrome. It would 
also be a pre-requisite for a successful gene therapy 
strategy. 
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2. 	MATERIALS AND METHODS 
2.1 	Materials 
2.1.1 Suppliers of Laboratory Reagents 
Standard laboratory reagents: BDH, Fisons, Sigma, May and 
Baker, Koch-Light and Bio-Rad. 
Restriction enzymes and DNA modifying enzymes: Bethesda 
Research Laboratories (BRL), Boehringer Mannheim and 
Pharmacia. 
Deoxyribonucleotides: Sigma. 
Agarose (Ultra pure and low melting-point): BRL. 
Bacterial Media Reagents: Difco Laboratories. 
Media Reagents for mammalian cell culture: Flow laboratories 
and Sera-lab. 
2.1.2 E.coli Growth Media 
Solutions were autoclaved and stored at room temperature. 
Luria Broth (LB): lOg Bacto-Tryptone, 5g yeast extract, lOg 
NaCl, made to 1 litre and adjusted to pH7.2 with NaOH. 
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Luria-agar (LB-agar): LB plus 15g agar per litre. 
When required antibiotics were added to media immediately 
before use. 
LB - ampicillin: LB plus 0.05mg/mi ampiciiiin. 
Ampiciiiin stock: 10mg/mi in 1120,  stored at 4°C. 
LB-tetracycline: LB plus 0.025mg/mi tetracycline. 
Tetracycline stock: 20mg/mi in ethanol/water (50%, v/v), 
stored at -20°C. 
2.1.3 E.coli Strains 
RR1: F, hsdS, ara, proA, iacY, galk, rpsL (Smr),  xyl mti, 
supE, X. 	Bolivar et al., (1977). 
J1183: ara, Alac-pro, strA, thi, 080dlacZAM15. 	Vieira and 
Messing (1982). 
2.1.4 ES cell culture media 
Embryonic stem cells were grown in Buffalo rat liver cell 
(BRL)-conditioned medium, without a feeder layer. 	The 
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medium used was Glasgow modified Eagle's medium (Flow 
laboratories) supplemented with 1 x nonessential amino acids 
and 1mM sodium pyruvate, and 5% (v/v) of both fetal calf 
serum and newborn calf serum (Sera-Lab). ES cells were grown 
in the absence of antibiotics in 37°C incubators with 5% CO  
in air. 
BRL-conditioned medium: BRL cells were grown to confluence 
in 75cm 2 tissue culture flasks. The medium was discarded and 
15m1 of fresh medium was added. After 2 days this was 
collected and replaced with a further 15m1 of fresh medium. 
In total 45m1 of conditioned medium was collected from each 
flask. The conditioned medium was filtered (pore size, 0.2 
m) and stored at -20°C. ES cells were grown on gelatin-
coated tissue culture flasks in 60% BRL-conditioned medium, 
40% fresh medium, with 0.1mM -mercaptoethanol. 
HAT-containing 	medium: 	60% 	BRL-conditioned 	medium 
supplemented with 10 4M hypoxanthine, 10 6M aminopterin and 
10 5M thymidine. 
2.1.5 ES cell lines 
E14: A wild-type male ES cell line isolated from strain 
129/01a blastocysts (Handyside et al., 1989). 
E14TG2a: An HPRT deficient mutant ES cell line derived from 
E14 by selection in 6-thioguanine (Hooper et al., 1987). 
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2.1.6 Mouse strains 
Mouse strains, obtained from Olac 1976 Ltd., were a gift from 
M.L. Hooper, Department of Pathology, University of 
Edinburgh. 
129/01a: an inbred strain which is homozygous for the 
recessive alleles chinchilla (Cch)  pink-eyed dilution (p) 
and white-bellied agouti (Aw  ). 
HPRT-deficient mice: mice of the outbred strain MF1, 
homozygous or hemizygous for the hprtbm3  mutant allele. 
2.1.7 Plasmids and Constructs 
pDWM1LS+127/+135, pDWM1O1 and pDWM100 were constructed by 
Carolanne McEwan. 
pDWM1LS+127/+135: this is a linker scanning mutant derived 
from the HPRT minigene pDWM1A1 (Melton et al., 1986). It was 
constructed by annealing a 3' Bal 31 deletion of pDWM1A1, 
with end point +127, to a 5' Bal 31 deletion of pDWM1A1, with 
end point +135, through a lObp BamHI linker. The resultant 
minigene contains 635bp of 5' flanking sequence, the entire 
5' untranslated region, the HPRT coding sequence interrupted 
by the seventh and eighth introns, and the HPRT 3' 
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untranslated region. The sequence differs from wild-type in 
the region of the BamHI linker, as illustrated in Figure 
\ 	. 
pDWutiOl: the structure of pDWM1O1 is illustrated in Figure 
5.1. pDWM101 consists of: a 4.7kb BamHI-EcoRI restriction 
fragment containing exon 2 and derived from the mouse HPRT 
genomic clone, XHPT 1 (Melton et al., 1984); a 3.0kb BglII 
- BamHI fragment containing the HPRT promoter and exon 1, 
derived from XHPT32; and a 1.35kb EcoRl fragment, 
containing exon 3 derived from XHPT1; cloned in pUC8 (Vieira 
and Messing, 1982). The resulting 11.7kb plasmid has the 
same organisation as the equivalent part of the HPRT gene 
itself except that the first intron is reduced from 10.8kb to 
4.1kb in the vector. 
pDWM100: this vector was constructed as a positive control 
for transformation of ES cells. It was derived from pDWM101. 
The 1.25kb XhoI-EcoRI fragment in pDWM101 was replaced by the 
1.8kb XhoI-EcoRI fragment from pDWM1 (Melton et al., 1986) 
which contains the remainder of the HPRT coding sequence and 
the HPRT 3' untranslated region. The resultant 
pDWM100, has HPRT activity and can restore activity to HPRT 
deficient ES cells without a requirement for homologous 
recombination. 
pHPT5: this construct consists of the full-length (1300bp) 
mouse HPRT cDNA cloned by CC tailing into the PstI 
restriction site of pBR322 (Konecki et al., 1982). 
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pHPT4: this construct also consists of the full-length mouse 
HPRT cDNA cloned into the PstI restriction site of pBR322. 
It differs:, from pHPT5 in that it lacks polyA sequences 
(Konecki et al., 1982). 
plasmid 91 (mouse a-actin cDNA): 1350bp of the mouse a-actin 
cDNA inserted into the PstI site of pBR322. This sequence 
will hybridise to two tissue mRNA bands in Northern analyses. 
A band at approximately 2100 nucleotides represents 
cytoplasmic (f3 and -y ) actin mRNA. A band at approximately 
1650 nucleotides represents muscle (a) actin mRNA (Flinty et 
al., 1981). This plasmid was a gift from Kathy Pritchard-
Jones, MRC Human Genetics Unit, Western General Hospital, 
Edinburgh. 
2.2 	Methods 
2.2.1 E.coli culture 
E.coli cells carrying plasmids were cultured in L-broth plus 
antibiotic where appropriate, at 37°C with constant 
shaking. 
2.2.2 ES cell methods 
General culturing: ES cells were grown in 37°C incubators 
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with 5% CO  in air. Tissue culture flasks were gelatin- 
coated before use. 	ES cells were grown in 60% BRL- 
conditioned medium, 40% fresh medium, containing 0.1mM 	- 
mercaptoethanol. 	The medium was changed each day and 
cultures were trypsinised (0.025% (w/v) trypsin, 1mMNa 2 
EDTA, 1% (v/v) chick serum in PBS) and split every 3 to 4 
days. 
Electroporation: vector DNA was introduced into ES cells by 
electroporation (Bio-Rad Gene Pulser). Approximately 5 x 
10 6 cells were resuspended in 0.8m1 of HEPES-phosphate 
buffered saline (pH7.05) (Graham and van der Eb, 1973) with 
20 pg of linearised vector DNA. Cells were given a single 
pulse (800V, path length 0.4cm, 3pF) then allowed to stand at 
room temperature for 10 minutes before plating in non-
selective medium. HAT selection (Littlefield, 1964) was 
imposed after 24 hours. 
2.2.3 Protein Methods 
Isolation of soluble proteins from cultured cells and mouse 
tissues 
Adapted from Wahl et al., (1975). 
Lysis buffer: 10mM Tris.HC1 pH7.5, 30mMKC1, 10mM MgC1 2 , 1mM 
Dithiothreitol (DTT), 0.5% Triton X-100. This buffer was 
kept on ice. 
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The following procedure was carried out in a 4°C ('cold') 
room. Medium was aspirated from cell culture plates. Cells 
were washed twice in PBS, and plates were left to drain. 
0.5m1 of lysis buffer was washed over the surface of the cell 
culture and then left for 20 minutes with regular agitation. 
The lysate was transferred to a microcentrifuge tube and cell 
debris was removed by spinning in a microcentrifuge (17,000 
x g) for 10 minutes at 4°C. The supernatant was transferred 
to a new microcentrifuge tube and stored at -20°C. 
Mouse tail biopsies: 	approximately 1cm of tail was 
mechanically disrupted in 0.125m1 lysis buffer and kept on 
ice for 1 hour. Tissue debris was pelleted by spinning in a 
microcentrifuge for 10 minutes at 4°C. The supernatant was 
stored at -20°C. 
Protein ael electrothoresis 
Protein 	lysate 	samples were 	electrophoresed through 
nondenaturing discontinuous polyacrylamide gels. 
Separating gel solution: 7.5% acrylamide, 0.25% N, N'- 
methylene -bi sac rylamide (bisacrylamide), 5 j/ml riboflavin. 
(Vit.B12.), 100mM Tris.HC1.pH8.1. 40m1 of this solution was 
polymerised by adding 0.3m1 10% ammonium persuiphate and 
0.02m1 TEMED. 
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Stacking 	gel 	solution: 	2.5% 	acrylamide, 	0.625% 
bisacrylamide, 5pg/ml riboflavin, 60mM Tris.HC1 p116.7, 20% 
sucrose. 16m1 of this solution was polymerised by adding 
0.2m1 10% ammonium persulphate and 0.012ml TEMED. 
Well-forming gel: 5% acrylamide, 0.16% bisacrylamide, 125mM 
Tris.HC1 pH7.0. 20m1 of this solution was. polymerised by 
adding 0.15m1 10% ammonium persuiphate and 0.010m1 TEMED. 
The separating gel (16cm x 16cm x 0.15cm) was cast between 
glass plates and overlaid with butanol. After 
polymerisation the butanol was removed, and the stacking gel 
solution was poured to a depth of 3cm. After polymerisation 
the well-forming gel solution was added and the comb was 
inserted. The gel was assembled into a vertical gel kit. 
Sample buffer: 166mM Tris.HC1 p116.7, 25% sucrose, 0.0013% 
bromophenol blue (BPB). 
20 jl of a protein lysate was added to 30 li l of sample buffer. 
The mixture was mixed, spun in a microcentrifuge for 5 
minutes at 4°C and loaded onto a vertical gel. 
10 x Electrophoresis buffer: 0.111 Tris (hydroxymethyl)-
methylamine, 0.75M glycine, 0.15% 	-mercaptoethanol. 
Electrophoresis was carried out in 1 x buffer at 4.5V/cm for 
16 hours, or until the BPB dye front reached the end of the 
gel, at 4°C. 
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HPRT in situ enzyme assa 
A modification of the method of Epstein (1970). 
Enzyme 	assay 	solution: 	2mM 	Na 	5-phosphoribosyl--1-- 
pyrophosphate (PRPP), 50mM Tris.HC1 p117.4, 5mM Mg Cl 2 , 25 
MCi/mi [ 
3H]-hypoxanthine ( 5 Ci/mmol, Amersham). 
After electrophoresis gel plates were separated and the 
separating gel was overlaid with 0.6m1 of the assay solution. 
The product of the reaction, [ 3H] - 5' - IMP was separated 
from the substrates using DEAE Ion exchange chromatography 
paper (DE81, Whatman). This paper was soaked in water and 
laid over the gel and assay solution. The reaction was 
incubated in a humid incubator at 37°C for 2 hours. The Ion 
exchange chromatography retains the charged [ 3H] - 5' - IMP 
ions, but uncharged [H] -hypoxanthine was washed from the 
paper by three rinses in 50% (v/v) methanol/water. The dried 
chromatography paper was exposed to autoradiographic film 
for 3 days at -70°C in the presence of intensifying 
screens. 
2.2.4 DNA and RNA methods 
Large scale preparation of plasmid DNA 
L-broth (5m1) supplemented with the appropriate selecting 
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antibiotic was inoculated with a single colony of the 
plasmid-bearing strain. The culture was grown to stationary 
phase and then diluted into 30m1 of L-broth plus antibiotic. 
This culture was grown for 3 to 4 hours and then diluted to 
500ml of L-broth plus antibiotic, and grown for a further 3 
hours. Cells were harvested by centrifugation at 4,000 x g 
for 10 minutes and then resuspended in 2.5ml of sucrose mix 
(50mM Tris.HC1 pH8.1, 40mM EDTA, 25% (w/v) sucrose). 
Lysozyme (lml of 10mg/mi) and 0.5M EDTA (lml) were added, the 
suspension was mixed gently and left on ice for 10 minutes. 
Then 13m1 of Triton mix (50mM Tris.HC1 pH 8.1, 63mM EDTA, 
0.1% (v/v) Triton X-100) was added and mixed by swirling 
before returning to the ice for a further 10 minutes. The 
lysate was cleared by centrifugation at 23,000 x g for 30 
minutes at •4°C. The supernatant was then mixed thoroughly 
but gently with 15m1 Phenol/STE (redistilled phenol 
equilibrated with 10mM NaC1, 10mM Tris. HC1 pH8.0, 1mM EDTA) 
and centrifuged at 4,000 x g for 10 minutes. DNA was 
precipitated from the aqueous layer by adding 0.1 x volume of 
3M sodium acetate and 2.5 x volume absolute ethanol, and 
leaving for at least 1 hour at -70°C. The precipitate was 
pelleted by centrifugation at 14,000 x g for 20 minutes. The 
supernatant was discarded and the pellet was resuspended in 
12m1 TE (10mM Tris.HC1 pH8.0, 1mM EDTA). 19g of CsC1 was 
added to the DNA suspension and the volume was made up to 26ml 
with TE. 100 pl of ethidium bromide (10mg/mi) was added and 
the density was adjusted to between 1.55 and 1.59 g/ml. 
Supercoiled plasmid DNA was separated from chromosomal and 
nicked plasmid DNA by isopycnic ultracentrifugation at 
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38,000 rpm in a Sorvali Ti50 rotor (140,000 x g) for 48 hours 
at 20°C. DNA bands were visualised under long-wave U.V. 
illumination and the lower (supercoiled plasmid) band 
removed. Ethidium bromide was removed by repeated 
extraction with an equal volume of butanol, and subsequent 
dialysis against TE, at 4°C. DNA was recovered by 
precipitation with sodium acetate and ethanol. 
Alkaline lysis plasmid miniorep method 
Adapted from the method of Birnboim and Doly (1979). 5m1 of 
L-broth plus antibiotic was inoculated with a single colony 
of the plasmid-carrying strain, and grown to stationary 
phase (overnight). 1.5m1 of this culture was transferred to 
a microcentrifuge tube and •spun in a microcentrifuge for 15 
seconds. The cell pellet was resuspended in O.lml of 50mM 
glucose, 10mM EDTA, 25mM Tris. HC1 pH8.0 solution and 
incubated at room temperature for 15 minutes. 0.2m1 of 1% 
SDS, 0.2IINaOH solution was then added, mixed by inversion, 
and kept on ice for 5 minutes. Chromosomal DNA was removed 
by precipitation with 0.15m1 of 3M sodium acetate pH5.0 on 
ice for 30 minutes. The precipitate was pelleted by spinning 
in a microcentrifuge (17,000 x g) for 15 minutes. The 
supernatant was transferred to a fresh microcentrifuge tube 
and spun for a further 10 minutes as above. To the 
supernatant was added 2.5 x volume of absolute ethanol (-
20°C). The mixture was vortexed and kept at -70°C for 30 
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minutes followed by spinning in a microcentrifuge for 6 
minutes. The pellet was washed twice with 70% (v/v) 
ethanol/water. 
Preparation of high molecular weight DNA from cultured 
mammalian cells 
The method of Pellicer et al., (1978). Between 1O 7 and 10  
cells were scraped from culture dishes in 20m1 of PBS at 4 ° C. 
Cells were pelleted by centrifugation in a bench top 
centrifuge at 1300 rpm. The cell pellet was resuspended in 
lOmi PBS at 4°C and peileted again as above. This pellet was 
resuspended gently in lOml hypotonic solution (10mM Tris.HC1 
pH8.0, 10mM NaCl, 3mM MgCl ) and then spun at 1300 rpm for 5 
2 
minutes. 	The pellet obtained was resuspended in lOmi of 
hypotonic solution plus Triton (0.2% Triton X-100) which 
lyses cells but not nuclei, and kept on ice for 10 minutes. 
The suspension was centrifuged at 1300 rpm for 5 minutes in 
a bench top centrifuge. The pellet was resuspended in 7.6m1 
of 10mM Tris. HC1 pH8.0, 400mM NaCl, 10mM EDTA. To this was 
added 0.4m1 of 10% SDS and 0.lml proteinase k (30mg/mi) and 
the mixture was incubated overnight at 37°C. 0.2m1 of RNaseA 
(2mg/mi) was then added and incubated at 37°C for 1 hour. 
More proteinase k (0.lml of 30mg/ml stock) was added and 
incubated for a further hour at 37°C. The sample was then 
extracted with an equal volume of PCA (25 parts redistilled 
phenol:24 parts chloroform:1 part iso-amylalcohol) by gently 
mixing for 15 minutes and spinning in a bench top centrifuge 
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at 4,000 rpm for 15 minutes. DNA was precipitaed from the 
aqueous layer by adding 0.25 x volume 5M NaCl and 2 x volume 
absolute ethanol (-20°C). The DNA precipitate was removed by 
spooling around the sealed end of a Pasteur pipette, and 
washed in 70% (v/v) ethanol/water. The DNA was then dried, 
resuspended in H 2 
 0 and stored at 4°C. 
Preparation of high molecular weight DINA from mouse tails 
Mice were anaesthetised by interperitoneal injection with 
2.5% avertin. Avertin (1,2,3 - tribromoethanol) was 
dissolved at a concentration of 1g/ml in 3° amylalcohol. 
This 100% stock was diluted to2.5% in H 2 0. All solutions 
were stored at 4°C. Mice were injected with between 0.015 
and 0.017ml per gram of body weight. 
1 to 2cm of tail was cut from anaesthetised mice, using a red 
hot scalpel which simultaneously cauterized the cut end of 
the tail. 
DNA was prepared by a method adapted from that of Palmiter et 
al., (1982). 
Tail buffer: 0.3M sodium acetate (not titrated), 10mM Tris. 
HC1 p118.0, 1mM EDTA, 1% SDS. 
1 to 2cm of mouse tail was placed in a 20m1 sterilin plastic 
universal containing 1.5m1 of tail buffer plus 15 p1 	of 
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proteinase k solution (final concentration 0.2mg/mi) and 
incubated overnight at 37°C with gentle shaking. 
Subsequently, each sample was split into two 0.75m1 aliquots 
in 1.5m1 microcentrifuge tubes. One aliquot was stored at - 
20°C, the other was used to prepare DNA. The suspension was 
mixed thoroughly but gently with an equal volume of PCA (25 
parts redistilled pheno1:24 parts chloroform:1 part 
isoamylalcohol). Following a 5 minute spin in a 
microcentrifuge the aqueous (top) layer was transferred to a 
fresh tube and the PCA extraction was repeated. The aqueous 
layer was then extracted with an equal volume of CA (24 parts 
chloroform:lpart isoamylalcohol). 1/30 x volume of 3M 
sodium acetate pH5.0 and 1 x volume of isopropanol was added 
to the aqueous layer to precipitate DNA, which was then 
pelleted by spinning in a microcentrifuge for 30 seconds. 
The pellet was washed twice with 70% ethanol, dried, 
resuspended in 0.2ml 1120  and stored at -20°C. 
Preparation of RNA from cultured mammalian cells or mouse 
tissues 
A modification of the method described in Melton et al., 
(1981). 
Guanidine hydrochloride (GnHC1) solution: 6M guanidine 
hydrochloride, 10mM DTT, 25mM EDTA p117.0. 
7 	8 Between 10 and 10 cultured cells were washed and pelleted 
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in PBS, before homogenisation in lOml of GnHC1 solution. 
Mouse tissue was homogenised in between 20 and 30m1 of GnHC1 
solution. 	Removal and homogenisation of mouse tissue was 
performed as quickly as possible after death. 	In a fresh 
50m1 tube 1/30 x volume of 3M potassium acetate pH5.0 and 1/2 
x volume of absolute ethanol was added to each sample which 
was then left at -20°C for 4 hours. The precipitate was 
pelleted by spinning at 18,000 x g for 20 minutes in a 
refrigerated centrifuge (0°C). The pellet was resuspended 
in GnHC1 solution, precipitated and pelleted again as above. 
This pellet was resuspended in 0.1M Tris. HC1 pH8.9, 0.1M 
NaCl, 1mM EDTA, 1% SDS solution (3 to 5m1 for cultured cells 
and 5 to lOmi for tissues) by vigorous vortexing. An equal 
volume of PCA was added and vortexed thoroughly for 15 
minutes before spinning in a refrigerated bench top 
centrifuge for 15 minutes at 3000 rpm and 10°C. To the 
aqueous layer was added 1/15 x volume of 3M sodium acetate 
p115.0 and 2 x volume of absolute ethanol. This was left to 
precipitate for 4 hours at -20°C and then spun for 20 minutes 
at 18,000 x g in a refrigerated centrifuge (0 ° C). The pellet 
was dissolved in the minimal possible volume of H 2  0 
(approximately 1.5m1 for cultured cells and between 0.5 and 
1.0ml for mouse tissues) and split into 0.5m1 aliquots in 
microcentrifuge tubes. To each aliquot 1/10 x volume of 3M 
sodium acetate pH5.0 and 2 x volume of absolute ethanol was 
added. Samples were left at -70°C for 15 minutes and then 
spun in a microcentrifuge for 5 minutes. The RNA pellet was 
washed twice in 70% ethanol, dried and resuspended in the 
minimal volume of H 2 0. RNA So1uHon were stored at - 
70°C. 
- 49 - 
The concentration of RNA* and DNA suspensions was estimated by 
spectrophotometric analysis and comparison of samples in 
ethidium bromide agarose gels, visualised by U.V. 
illumination. 
Restriction endonuclease digestion 
Enzymes were purchased from Bethesda Research Laboratories 
(BRL). DNA was digested for between 1 and 3 hours at 37°C, 
with the exception of TaqI digestions which were carried out 
at 65°C. 
BRL restriction enzyme buffers were used at 	1 x 
concentration. RNase A was added to a final concentration of 
0.1mg/mi. Reactions were terminated by heat inactivation or 
phenol extraction. 
10 x React 2 Buffer: 50mM Tris. HC1 pH8.0, 10mM MgC1 2 , 50mM 
NaCl. Used for PstI, Hind III, TaqI and XhoI. 
10 x React 3 Buffer: 50mM Tris. HCl p118.0, 10mM MgC1 2 , 100mM 
NaCl. Used for BamHI and EcoRI. 
10 x React 6 Buffer: 50mM Tris. HC1 p117.4, 6mM MgC1
29  50mM 
KC1, 50mM NaCl. Used for PvuII. 
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Agarose gel electrophoresis 
Electrophoresis through horizontal submerged agarose gels 
was used for both analysis and purification of DNA. Ultra-
pure agarose (BRL) was used for analytical gels and low 
melting-point agarose (BRL) was used for preparative gels. 
Agarose gels: 0.8 to 1.5% (w/v) agarose, 1 x TBE,0.5 
ig/ml ethidium bromide. 
10 x TBE: 0.89M Tris. base, 0.89M boric acid, 0.0211 EDTA. 
Gels were run in 1 x TBE electrophoresis buffer. 
Samples were mixed with 0.2 x volume of sample buffer (100mM 
EDTA, 0.1% BPB, 20% Ficoll) and heated at 65°C for 5 minutes 
before loading. DNA was visualised by illumination with 
long-wave U.V. light. 
DNA fragment purification from low melting-Doint aarose 
gels 
The DNA band was cut from the low melting-point agarose gel 
with the minimal volume of agarose, and added to an equal 
volume of 1 x TBE, 0.2M NaCl solution. The agarose was melted 
by heating in a 65°C water bath. Two phenol extractions with 
redistilled phenol equilibrated with 1 x TBE, 0.111 NaCl were 
performed. The aqueous layer was extracted with 4 x volume 
of butanol repeatedly, until the volume of the aqueous layer 
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was reduced to approximately 0.4m1. DNA was precipitated by 
adding 0.1 x volume of 3M sodium acetate and 2.5 x volume of 
absolute ethanol (-20°C). DNA was pelleted by spinning in a 
micrbcentrifuge (17,000 x g) for 6 minutes. The pellet was 
resuspended in 0.lml of 0.3N sodium acetate and 0.25m1 of 
absolute ethanol was added to precipitate DNA for a second 
time. 	The DNA pellet was washed twice with 70% ethanol, 
dried and resuspended in H 2 0. DNA 	solutions were stored at 
-20°C. 
Radiolabelling DNA by random priming 
This method (Feinberg and Vogelstein, 1983) was used to make 
probes for both Southern and Northern hybridisations. 
Approximately 2pg of restriction fragment DNA, purified from 
low melting-point agarose, was used in each reaction. DNA 
was denatured before use by boiling for 5 minutes and then 
incubating for 10 minutes at 37°C. The reaction mixture was 
made by adding in the following order: lOj.il OLB buffer, 2iil 
bovine serum albumin (BSA, lOmg/ml), 32il denatured DNA 
solution , 5 p1 (50p.Ci) a - [32P] - dCTP (3000 Ci/mmol, 
Amersham), 1 p1 (5u) E.coli DNA polymerase I klenow fragment 
(BRL). The reaction was left for 4 hours at room temperature 
and stopped by phenol extraction. 
OLB buffer: 50 p1 solution A (1.25M Tris.HC1 p118.0, 0.125M 
MgCl 2 , 25mM e-mercaptoethanol, 0.5mM each of TTP, dGTP and 
dATP), 125 p1 solution B (2M HEPES (4-(2-hydroxyethyl)-1- 
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piperazine -ethane suiphonic acid) adjusted to pH6.6 with 5M 
NaOH) and 75i1  solution C (random hexanucleotides OD260 m 90, 
in TE). 
The radiolabelled probe was purified from unincorporated 
deoxyribonucleotides by passing through a column of sephadex 
G-50-80 (Sigma). 
Southern transfer hybridisations 
Adapted from the method of Southern (1975). 
20 x SSC: 3M NaC]., 0.3M sodium citrate, adjusted to p117.0. 
Genomic DNA (5pg) was digested by the appropriate restriction 
enzyme(s) (50 u) in 100 p1 reaction volumes, for 5 hours. 
Samples were electrophoresed through 0.8% agarose gels. 
After electrophoresis the gel was soaked for 30 minutes with 
gentle agitation in 0.5M NaOH, 1.5M NaCl. DNA was then 
transferred to Gene Screen Plus (New England Nuclear 
Products) for 18 hours using 0.5M NaOH, 1.5M NaCl as the 
transfer buffer. After transfer the charged nylon membrane 
was neutralised by soaking in 0.5M Tris, 3.OM NaCl pH7.4 for 
15 minutes and dried. 
The membrane was pre-hybridised in 30 to 50m1 of 6 x SSC, 1% 
SDS, 10% dextran sulphate (Sigma) with lOOpg/ml of sonicated 
herring sperm DNA for 2 hours at 65 ° C in a sealed 
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hybridisation bag (BRL). 	After 2 hours the denatured 
radiolabelled DNA probe (approximately 10  cpm per ml of 
hybridisation buffer) was added with sonicated herring sperm 
DNA to total concentration of 250jig/ml. Hybridisation was 
for 18 hours at 65 ° C. Following hybridisation the membrane 
was washed, twice for 5 minutes in 2 x SSC at room 
temperature, twice for 30 minutes in 1% SDS, 2 x SSC at 65°C 
and finally twice for 30 minutes in 0.1 x SSC at room 
temperature. The damp filter was sealed into a polythene bag 
and exposed to preflashed autoradiographic film at -70°C in 
light proof casettes with intensifying screens (Dupont). 
Northern transfer hybridisations 
Adapted from the method of Lehrach et al., (1977). 
10 x MOPS: 0.2M MOPS, 50mM sodium acetate, 10mM EDTA, 
adjusted to p117.0 and autoclaved. 
Formamide sample buffer (FSB): 2.5 x MOPS, 50% deionised 
formamide, 10% formaldehyde. 
30 ig of total RNA in a volume of 204 was added to an equal 
volume of FSB, and heated at 65°C for 5 minutes before snap 
cooling on ice. 0.25 x volume of standard electrophoresis 
buffer (100mM EDTA, 0.1% BPB, 20% Ficoll) was added. Samples 
were electrophoresed through formaldehyde agarose gels (1.4% 
agarose, 1 x MOPS, 0.66M formaldehyde, 0.5 pg/ml ethidium 
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bromide) for 3 to 4 hours at 4V/cm. After electrophoresis 
gels were washed twice in 10 x SSC for 20 minutes. RNA was 
transferred to Gene Screen Plus (New England Nuclear 
Products) with 10 x SSC transfer buffer for 18 hours. After 
transfer the nylon membrane was rinsed in 2 x SSC, dried and 
baked for 2 hours at 80 ° C to reverse the formaldehyde 
reaction. 
Subsequent hybridisation and washing was carried out as for 
Southern membranes except that the hybridisation temperature 
and the temperature of the high stringency wash was 60 ° C 
(rather than 65°C). Autoradiography was carried out at -70°C 
with preflashed film and intensifying screens. 
Single-stranded DNA trobes for Si nuclease Drotection 
analyses 
From the method of Berk and Sharp, (1977). 
Before radiolabelling probe DNA was phosphatased (i.e. 5' 
terminal phosphates were removed). 
10 x Phosphatase buffer: 650mM Tris.HC1 p117.5, 95mM MgC1 29  
50mM DTT. 
Reactions were carried out in 100 p1 with approximately lPg 
restriction fragment DNA, 1 x phosphatase buffer and 125u of 
bacterial alkaline phosphatase enzyme (BRL). Reactions were 
- 55 - 
incubated for 1 hour at 65°C and stopped by thorough phenol 
extraction, butanol extraction and precipitation with sodium 
acetate and ethanol. 
DNA recovered from one phosphatase reaction was end-labelled 
in a kinase reaction. 
10 x oligonucleotide kinase buffer: 0.5M Tris. HC1 pH7.5, 
0.1M McC1 2 , 50mM DTT, 1mM EDTA. 
Phosphatased DNA was added to 1 x oligonucleotide kinase 
buffer, 0.1mM spermidine, 1mM NaPO 4 pH7.0, 50 pCi y-[32P] - 
ATP (5000 Ci/mmol, Amersham) and 10 u of T4 polynucleotide 
kinase (BRL) in a total volume of 501il. The reaction was 
incubated at 37°C for 1 hour. The reaction was then phenol 
extracted, butanol extracted and precipitated with sodium 
acetate and ethanol. The labelled DNA pellet was resuspended 
in 10 p1 of strand separating buffer (SSB; 30% dimethyl 
sulphoxide, 0.03% BPB, 0.05% xylene cyanol, 1mM EDTA, 10mM 
a0H). The sample was incubated at 90°C for 3 minutes and 
Loaded onto a vertical *strand-separating acrylamide gel (8% 
crylamide/bis-acrylamide 39:1, 1 x TBE). The gel was run 
For 18 hours at 1OV/cm. The position of radiolabelled DNA 
as determined by exposing the gel to autoradiography film 
or 20 minutes. 	Both strands of the DNA fragment are 
Labelled. 	The required band on the gel was determined 
)reviously by 0s,say2.r19 eck - strand. Acrylamide 
:ontaining the required (antisense) strand was cut from the 
el and DNA was eluted from it in 3m1 of elution buffer (10mM 
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Tris.HC1 pH8.0, 50mM NaCL, 5mM EDTA) for 18 hours. 	The 
elution buffer was vortexed and filtered through glass wool 
in a lOml syringe. The DNA suspension was phenol extracted, 
and butanol extracted to reduce the volume to imi. 
Si nuclease analysis 
30 pg of total RNA from cultured cells or tissues was 
precipitated with the single-stranded DNA probe in a total 
volume of 0.4m1. All the single-stranded probe obtained in 
a kinase reaction was divided equally between the RNAs under 
investigation. The pellet was resuspended in 35pl of 2 x SET 
(0.3M NaCL, 40mM Tris.HC1 pH8.0, 2mM EDTA). Samples were 
incubated at 90°C for 15 minutes and at 65 ° C for 4 hours. 
Then 0.3m1 of ice cold Si nuclease buffer (280mM NaCl, 50mM 
sodium acetate pH5.0, 4.5mM ZnSO 4 ) containing 50 u of Si 
nuclease enzyme (BRL) was added to each sample. The reaction 
mixture was incubated at 37°C for 15 minutes. Reactions were 
stopped by adding 60 p1 of 100mM EDTA, followed by phenol 
extraction and DNA precipitation with sodium acetate and 
ethanol. Pellets were resuspended in 6pl of Maxam-Gilbert 
sequencing buffer (80% formamide, 0.03% BPB, 0.05% xylene 
cyanol, 100mM NaOH, imM EDTA). Each sample was incubated at 
90°C for 10 minutes and loaded onto an 8.0% acrylamide urea 
sequencing gel. After electrophoresis at 30 W the gel was 
removed from the glass plates, sealed in Saran wrap and 
exposed to autoradiography film at -70°C with intensifying 
screens. 
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Radiolabelled standards for Si analyses 
pBR322 DNA cut with BamHI and MspI was radiolabelled by 
filling in 5' overhangs. 
10 x Nick translation buffer: 500mM Tris.HC1 pH7.5, 100mM 
MgC1 21  500ig/ml BSA. 
DNA was incubated with 1 x Nick translation buffer, 0.2mM 
dATP, 0.2mM dGTP, 0.2mM TTP, 5 u E.coli DNA polymerase I 
klenow fragment (BRL) and 10tCi e -[32P] - dCTP (3000Ci/mmol, 
Amersham) for i hour at room temperature. Cold dCTP was 
added to a final concentration of 0.2mM and the reaction was 
incubated for a further 30 minutes. The reaction mixture was 
diluted with 50p1 of Maxam-Gilbert sample buffer and stored 
at -20°C. 
Densitometric analysis 
Densitometric analysis of autoradiographs was performed 
using a Shimadzu dual-wavelength thin-layer chromato 
scanner, model CS-930, according to the accompanying 
instruction manual. Linearity of densitometric analysis was 
confirmed using autoradiographs exposed to the same source 
for varying lengths of time. 
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3. 	HPRT TRANSGENIC MICE 
A description of the transcriptional control of the 
mammalian X-linked HPRT gene, based on experiments involving 
the transformation of cultured cells with derivatives of the 
HPRT minigene, pDWM1 (Melton et al., 1986), has been 
presented in the Introduction of this thesis. To try to 
validate these findings in vivo and to determine the 
mechanism by which HPRT expression is elevated in brain 
tissue, mice transgenic for an HPRT minigene were produced. 
Transgenic mice expressing human HPRT have been produced 
previously (Stout et al., 1985). The transgene used 
consisted of the human HPRT cDNA under the transcriptional 
control of the mouse meta llothione in- 1 (MT-1) promoter and 
fused to the 3' untranslated region from the human growth 
hormone (hGH)gene. Three transgenic lines were obtained and 
analysed for human HPRT expression. The expression pattern 
in each transgenic line was different, presumably influenced 
by the integration site of the transgene. However, all mice 
examined had elevated human HPRT expression in the CNS. It 
is difficult to interpret this result because an analogous 
construct in which the HPRT cDNA was replaced by the human 
growth hormone gene also gave elevated expression in the CNS 
of transgenic mice (Swanson et al., 1985). This suggests the 
expression pattern is due to the combination of the MT-1 
promoter and the hGH 3' untranslated region rather than the 
HPRT cDNA. 
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The transgene 
The aim of our experiment was primarily to determine whether 
the HPRT minigene contains sufficient DNA sequence to be 
expressed with the same tissue-specific variations as the 
endogenous gene. In particular, we wanted to know whether 
the minigene was expressed at high levels in brain. The 
recipient mice for the transgene have endogenous HPRT 
activity. Hence, it was necessary to use a minigene the 
expression of which would be distinguishable from that of the 
endogenous gene. To satisfy this requirement the vector 
pDWM1LS+127/+135 was used. The structure of 
pDWM1LS+127/+135 is illustrated schematically in Figure 3.1. 
pDWM1LS+127/+135 is derived from the basic HPRT minigene 
pDWM1 (Melton et al., 1986). It was constructed as a linker 
scanning mutant, and is composed of a 3' deletion of pDWM1A1 
with deletion end point at +127 (number relative to the major 
transcription initiation site, +1), ligated through a lObp 
BamHI linker to a 5' deletion of pDWM11 with deletion end 
point +135. pDWM1LS+127/+135 contains 635bp of mouse 
genomic sequence upstream of the major transcription 
initiation site. It contains the entire 5' and 3' 
untranslated regions of the mouse cDNA and the mouse protein 
coding region interrupted by the seventh and eighth introns 
only. The differences between the wild-type DNA sequence and 
the sequence of pDWM1LS-i-127/+135 at the BamHI linker are 
shown in Figure 3.2. These changes make expression from the 
transgene distinguishable from endogenous HPRT gene 
expression. The DNA sequence changes occur at the 5' end of 
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Figure 3. 1. 
Structure of pDWM1LS+127/+135. 	The organisation of the X- 
linked gene is shown. 	Exons 1 to 9 (not to scale) are 
represented by open boxes and numbered. 	EcoRI, R, and 
XhoI, X, restriction sites are indicated and the size of 
each restriction fragment is shown in kb. The cross-
hatched box represents the 635bp of 5' flanking sequence 
which is also present in pDWM1LS+127/+135. The structure 
of pDWM1LS+127/+135 is shown with selected restriction 
sites: 5, SalI; X, XhoI; R, EcoRI; T, TaqI. Restriction 
fragment sizes are indicated in kb. The cross-hatched box 
represents the 635bp of 5' flanking sequence. The stippled 
boxes represent the 5' and 3' untranslated regions. 	The 
open boxes represent protein coding regions. 	The open 
lines represent introns 7 and 8. The position of the BamHI 
linker (B) is indicated by the solid vertical bar, between 
nucleotides +127 and +135 of the wild-type sequence. +1 
indicates the major transcription initiation site. 
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the protein coding region. Hence, protein derived from the 
transgene will have a different amino acid sequence for the 
amino-terminal residues. The mouse endogenous gene codes 
for a protein which has the amino-terminal amino acid 
sequence: methionine, proline, threonine, arginine, serine, 
proline, serine. The initiating methionine is post-
translationally cleaved from the HPRT protein (Wilson et 
al., 1982). Whereas, the transgene codes for a protein which 
has the amino-terminal sequence: methionine, proline, 
threonine, proline, asparbcwkL proline, alanine, serine. 
That is, the three amino acids arginine, serine and proline 
which are basic, polar and non-polar respectively, are 
substituted for proline, asparicadd, proline and alanine 
which are non-polar, acidic, non-polar and non-polar 
respectively. Consequently, the pDWM1LS+127/+135 encoded 
protein has a different isoelectric point and a higher 
mobility on a non-denaturing polyacrylamide gel. than the 
wild-type protein at pH8.1. 
pDWM1LS+127/+135 can transform HPRT deficient Chinese 
hamster,RJK88, cells to HPRT+ at a frequency of per 5 g 
of plasmid DNA. The greater electrophoretic mobility of the 
transgene encoded protein is shown in Figure 3.3. Soluble 
proteins were purified from cultured cells and 
electrophoresed through non-denaturing 7.5% polyacrylamide 
gels. HPRT protein was then visualised by an in situ enzyme 
assay using [ 3H]-hypoxanthine. The first lane contains 
protein derived from a wild-type mouse cell-line, RJK691. 
The second lane contains protein isolated from HPRT 
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Figure 3.2. 
Sequence alterations in pDWM1LS+127/+135. 	The wild-type 
nucleotide sequence of the first seven translated codons is 
shown. Nucleotides +127 and +135 relative to the major 
transcription initiation site are indicated. The sequence 
of the seven N-terminal amino acids is shown. The 
initiating methionine is post-translationally cleaved. The 
nucleotide sequence of the corresponding region in 
pDWM1LS+127/+135 is shown, with the amino acid sequence 
directly below. The lObp BamHI linker is underlined. 
Amino acids: 	Ala, 	alanine; 	Arg, 	arginine; 	Asp, 
aspartic.acid; 	Met, methionine; 	Pro, proline; 	Ser, serine; 
Thr, threonine. 
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Figure 3.2 
Wild-type 
+127 	 +135 
DNA: 	ATO C C G ACC CGC AGT CCC AGC 
protein: [Met.] 	Pro. 	Thr. 	Arg. 	Ser. 	Pro. 	Ser. 
pDWM1LS+127/+135 
+127 	+15 
DNA: 	ATG CCG ACC 
	
CCG GAT CCG AGC . . 
protein: [Met.] 	Pro. 	Thr. 	Pro. 	Asp. 	Pro. 	Ala. 
	Ser. 	. . 
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Figure 3.3. 
Non-denaturing electrophoresis of proteins. 	Proteins were 
electrophoresed through non-denaturing polyacrylamide gels 
and HPRT enzyme was visualised using an in situ enzyme 
assay with [ 3H]-hypoxanthine. 	Protein samples from cells 
and mice are shown. 	Cells: wt, wild-type mouse cell line 
(RJK691); tg, HPRT deficient Chinese hamster cells (RJK88) 
transformed with pDWM1LS+127/+135; wt + tg, a 50% (v/v) 
mixture of protein from the wild-type mouse cell line and 
HPRT deficient Chinese hamster cells transformed with 
pDWM1LS+127/+135. Mice: protein samples from a male (M) 
and female (F) transgenic (tg) mouse are shown alongside 
protein from a wild-type mouse. Protein samples were 
obtained from tail biopsies. 
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deficient Chinese hamster, RJK88, cells transformed with 
pDWM1LS+127/+135. Non-transformed RJK88 cells have no 
detectable endogenous HPRT activity (data not shown). The 
third lane contains a 50% (v/v) mixture of RJK691 protein and 
pDWM1LS+127/+135-transformed RJK88 protein. Thus enzyme 
activity derived from pDWM1LS+127/+135 is distinguishable 
from enzyme activity derived from the endogenous gene in 
cultured cells by its different electrophoretic mobility. 
It should also be possible to measure expression from 
pDWM1LS+127/+135 by analysis of mRNA. Because of the 
differences in DNA sequence between pDWM1LS+127/+ 135 and the 
endogenous gene, mRNA derived from the two genes can be 
distinguished by Si nuclease protection analysis using a 
single-stranded DNA probe that spans the 5' end of the mRNA. 
The basis of this analysis is explained schematically in 
Figure 3.4. 	The results of such an analysis are shown in 
Figure 3.5. 	The DNA probe used was the 424bp BamHI-XhoI 
fragment from the -146 5' deletion mutant (Melton et al., 
1986). The single-stranded DNA probe was end-labelled at the 
Xtiol site (5' end) 271bp downstream of the major 
transcription initiation site. 	Hence mRNA from the wild- 
type mouse cell line RJK691 produces a protected fragment of 
271bp 	(+1). 	Two additional protected fragments of 
approximately 30 bases shorter represent downstream 
initiation sites at +28 and +34 (Melton et al., 1986). The 
2hp fragment represents undigested probe which is 
Treserved probably due to the ability of this fragment to 
protect itself. Other feinter bands are apparently 
Figure 3.4. 
Schematic representation of the use of Si analysis to 
distinguish between mRNA derived from the HPRT transgene 
(b) and mRNA derived from the X-linked endogenous HPRT gene 
(a). Endogenous HPRT mRNA, transcribed from nucleotide +1, 
produces a protected fragment of 271bp. Endogenous HPRT 
transcribed from nucleotides +28 and +34 produces a 
protected fragment 28 and 34bp shorter, respectively. The 
radiolabelled end of the single-stranded (ss) DNA probe is 
indicated by an asterisk. Transgene derived mRNA should 
produce a protected fragment of 136bp irrespective of the 
site of transcription initiation, due to the presence of 
the mismatched sequence at the BamHI linker (B). 
Figure 3.4 
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FIGURE 3.5. 
Si analysis of transgene-derived mRNA from cultured cells. 
Cellular RNA was hybridised to a 424 base single stranded 
probe, which spanned the main transcription initiation site 
and was end-labelled at an XhoI site, 271 bases into the 
gene. 	Hybridisation mixtures were digested with Si 
nuclease. 	Lanes: tg, RNA derived from HPRT deficient 
Chinese 	hamster 	(RJK88) 	cells 	transformed 	with 
pDWMiLS+127/+135; 	wt, RNA from wild-type mouse (RJK691) 
cells; m, molecular weight standards. The size of each 
molecular weight standard is indicated to the right of the 
panel. To the left of the panel, protected fragments 
representing the initiation sites +1, +28 and +34, and the 
136 base protected fragment specific to transgene RNA, are 
indicated. Undigested probe (424 bases) is evident in both 
RNA tracks. 
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artefacts, as they do not consistently appear in Si nuclease 
analyses and have no equivalent in primer extension 
analyses. That is, no products are seen in primer extension 
analyses which could correspond to initiation at the sites 
suggested by these bands. RNA derived from RJK88 cells that 
are transformed with pDWM1LS+127/+135 produces a different 
Si protection pattern. In addition to the bands representing 
the transcription initiation sites at +1, +28 and +34 there 
is a band of approximately 136 bases long. This is the 
distance between the XhoI-site end of the DNA probe (+271) 
and the BamHI linker (+127 to +135) in pDWM1LS+127/+135 (see 
Figure 3.4). The protected fragment of 136 bases, therefore, 
represents Si nuclease digestion at the region of mismatch 
between the pDWM1LS + 127/+135 derived mRNA and the single-
stranded DNA probe, which has the wild-type sequence. Hence, 
the +136bp band is specific for pDWM1LS + 1271+135 derived 
mRNA. Unfortunately, not all of the transgene derived mRNA-
DNA probe heteroduplexes are digested to completion at the 
mismatch region around the BamHI linker. Consequently, the 
transene derLved mDNA ccjnrjhutes 	hc :rt€cted 	inHs 
J11Lh 	epresent 	the 	tranecrpt.(n 
FherefLre. it is not possible to quantify the transgene 
C'e d mDNA relative to the endogenous HPRT mRNA using this 
a ssay. 
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Research Council, Institute of Animal Physiology and 
Genetics Research, Edinburgh Research Station, for carrying 
out the microinjection experiment. 
pDWM1LS+127/+135 DNA was digested with SalI and EcoRI and the 
2.6kb fragment containing HPRT sequences was isolated from 
plasmid DNA by electrophoresis and purification from low 
melting-point agarose. A number of studies have shown that 
prokaryotic vector sequences can be inhibitory to transgene 
expression (Jaenisch, 1988; and references therein). 
Pronucleus stage eggs were obtained from superovulated 
C57BL/6 x CBA F 1 females, after mating with F 1 males, and 
injected with approximately 200 copies of the transgene per 
egg. Injection was into either pronucleus. Injected eggs 
(200) were cultured overnight and subsequently cleaved 
embryos (130) were transferred into the oviducts of 
pseudopregnant MF1 females, obtained by mating with 
vasectomised NFl males. GO mice were screened for the 
presence of the transgene by Southern analysis of tail biopsy 
genomic DNA. Out of 27 GO mice weaned only one, female mouse 
22, appeared to have the pDWM1LS+127/+135 gene integrated 
intact. Figure 3.6 shows a comparison of the Southern blot 
patterns of a wild-type mouse and female mouse 22. Genomic 
DNA was digested with EcoRI and XhoI, and hybridised with a 
full-length HPRT cDNA probe, pHPT5 (Konecki et al., 1982). 
The EcoRI-XhoI double digest generates a 1.75kb fragment 
j:i ure 3.7) in the pDWM1LS+127/+135 sequence which is 
: - :ific to the transgene. The sizes of transgene specific 
Lnds are indicated down the left hand side of Figure 3.6. 
- 
Figure 3.6. 
Southern analysis of transgenic mice. 	Genomic DNA (5j.ig), 
obtained by tail biopsy, was digested with EcoRI and XhoI, 
electrophoresed, transferred and hybridised to a full-
length HPRT cDNA probe, pHPT5. DNA: tg, a mouse transgenic 
for pDWM1LS+127/+135; wt, a wild-type mouse. The sizes 
(in kb) of endogenous gene fragments are indicated to the 
right of the panel. A fragment containing HPRT pseudogene 
sequences is indicated (PG). The sizes of transgenic mouse 
specific fragments are indicated to the left of the panel. 
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Figure 3. 7. 
Schematic 	representation 	of 	the 	tandem 	array 	of 
pDWM1LS+127/+135 transgenes. 	The top line shows the 
position of three transgenes in a head-to-tail tandem 
array. 	The second line shows the restriction sites for 
EcoRI, R, and XhoI, X. 	EcoRI sites are in parentheses 
because 	they 	are 	present 	only 	at 	some 	of 	the 
transgene:transgene junctions. The two lower lines 
illustrate the origins of transgene specific fragments 
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The pattern observed is consistent with several copies of the 
transgene having integrated in tandem (Figure 3.7). At some 
transgene-transgene junctions the EcoRI site at the 3' end of 
the transgene is preserved, at other junctions it is lost. 
Hence a band of 850bp, which represents the sequences between 
the internal XhoI site and the 5' end of transgene (Figure 
3.7), is generated from some copies. Where the EcoRI site is 
not maintained an XhoI-XhoI fragment of 2.6kb (the length of 
the transgene) is produced. Southern blot analysis of XhoI 
digested genomic DNA from mouse 22 produces a hybridising 
band of 2.6kb (data not shown). Because 2.6kb is the size of 
the transgene, all the copies of pDWM1LS+127/+135 must be 
integrated head to tail in tandem. Head to head and tail to 
tail junctions would generate bands of 1.7kb and 3.5kb 
respectively. Bands of these sizes were not seen. 
As well as mouse 22, two additional GO mice were obtained 
that contained exogenous HPRT sequences. One of these mice 
had died within a few hours of birth. Southern analysis (not 
chcn) cf EcoRI-XhoI digested genomic DNA showed that it 
cunt.ai tied the I 75kb fragment from the 3' end of the 
t.ransgene (Figure 3.1), although the 5' end of the transgene 
appeared to be absent. 	The transgene had undergone 
structural rearrangment. 	The second mouse containing 
exogenous HPRT sequences had a single additional band that 
hybridised to HPRT cDNA. However, the size of this band was 
'lie 	rari.c 	i c: 	 iflHlJ:- 	 t 	stied fsr t 	tstitI :55 
the pDWM1LS+127/+135 sequences by mating to C57BL/6 x CBA F 1 
males. Offspring from mouse 22, Gi mice, were screened by 
Southern blot analysis of EcoRI-XhoI digested genomic DNA 
obtained from tail biopsies. Of 23 Gi mice, one male, 22.5, 
and two females, 22.4 and 22.17, had the identical Southern 
blot pattern to mouse 22 (Figure 3.6), demonstrating 
inheritance of the HPRT transgene. Inheritance of exactly 
the same Southern blot pattern is consistent with there being 
a single transgene integration site in this line. 
Considerably less than 50% (3 out of 23) of Gi mice inherited 
the transgene indicating that mouse 22 was probably mosaic. 
Male transgenic mouse 22.5 was used to produce further 
generations to provide material for expression studies. 
Three matings between 22.5 and wild-type females produced G2 
offspring which were screened for the presence of 
pDWM1LS+127/+135 DNA. Twelve mice, eight females and four 
males, out of twenty three were transgenic. Transmission of 
the transgene from male parent to male progeny demonstrated 
that the integration site was not X-chromosome linked. 
Transgene Cotv Number 
The number of copies of the pDWMILS-i-127/+135 transgene that 
had integrated in mouse 22 was estimated by a comparison of 
the Southern blot patterns for TaqI digested genomic DNA from 
a wild-type and a transgenic animal. TaqI digestion of 
u'JM1LS+127/+135 DNA generates an internal fragment of 
- 5b 	i'ure 3.1). 	TaqI digestion of the X-linked 
Figure 3.8. 
Southern analysis to determine transgene copy number. 
Genomic DNA (5g), obtained by tail biopsy, was digested 
with TaqI, elect rophoresed, transferred, and hybridised to 
a full-length HPRT cDNA probe, pHPT5. DNA: wt, a wild-type 
mouse; tg, a mouse transgenic for pDWM1LS+127/+135. The 
hybridising band and the control band used to determine the 






endogenous gene generates the same fragment. 	The 1.35kb 
fragment is present at one copy per genome in TaqI digested 
genomic DNA from a wild-type male mouse. In TaqI digested 
DNA from a hemizygous transgenic male mouse the number of 
1.35kb fragments per genome will be equivalent to the 
transgene copy number plus one, the endogenous gene 
fragment. The number of copies of the 1.35kb fragment in 
transgenic DNA can be estimated from the intensity of that 
band relative to the same band in wild-type DNA on a Southern 
blot. To correct for loading variations between tracks the 
intensity of the 1.35kb band is normalised relative to an 
endogenous gene specific band. The results of this analysis 
are shown in Figure 3.8. The 1.35kb band and the internal 
control are indicated. 	Intensities were measured by 
densitometric analysis. 	In wild-type DNA the intensity of 
the 1.35kb band relative to the control band is 1.8. In the 
transgenic DNA the normalised intensity of the 1.35kb band is 
18.7. Hence there are 10 (18.7 1.8 = 10.4) copies of the 
1.35kb fragment per genome in transgenic mice. Allowing one 
ccpv for the endogenous gene, there are approximately 9 
copies of the pDWMIT,S±127/±135 transgene. 
Tanscene e<oression 
Soluble 	protein was 	prepared 	from tail biopsies of 
i.iansgenic mice and HPRT enzyme activity and electrophoretic 
obility was analysed on non-denaturing polyacrylamide gels. 
gure 3.3 shows the results of such an analysis. The first 
lane shows the position of HPRT enzyme derived from a wild-
type mouse cell line (RJK69I). The second lane shows the 
position of HPRT enzyme derived from the pDWM1LS+127/+135 
transgene when expressed in HPRT deficient cultured cells 
(RJK88). The third lane contains both the wild-type and the 
transgene derived protein. Two lanes containing protein 
derived from tail biopsy of transgenic mice (both male and 
female) are shown adjacent to protein from a wild-type 
sibling. None of the transgenic mice tested showed any 
evidence of transgene derived HPRT enzyme activity. 
Although samples were not matched for protein concentration 
there is little variation between animals in the endogenous 
HPRT signal which provides an internal control. By using 
mixed samples, the sensitivity of the assay was tested. 
Activity as low as 20% of the wild-type level is readily 
detectable. 
Having failed to detect any transgene derived enzyme 
activity in pDWM1LS+127/+135 transgenic mice, analysis of 
HPRT mRNA was carried out. Total RNA was prepared from the 
tissues of transgenic and wild-type mice and analysed by Si 
nuclease protection assays. The results of an Si nuclease 
protection analysis of RNA from the livers and brains of 
wild-type and transgenic mice is shown in Figure 3.9. Si 
nuclease reactions were performed on 30pg of total RNA and 
half a reaction was loaded in each lane. RNA derived from an 
HRT deficient cell line (RJK88) transformed with 
r14M1LS+127/+135 is included as a positive control. 	The 
mjor transcription initiation site (+1) is represented by 
Figure 3.9. 
Si analysis of HPRT mRNA from transgenic mice. 	Cellular 
RNA was hybridised to a 424 base single stranded probe, 
which spanned the main transcription initiation site and 
was end-labelled at an XhoI site, 271 bases into the gene. 
Hybridisation mixtures were digested with Si nuclease. RNA 
derived from the liver (L) or brain (B) of 5 mice is shown. 
Both male and female mice are shown that are either 
transgenic (tg) or wild-type (wt). The positive control 
(P) lane contains RNA from HPRT deficient Chinese hamster 
(RJK88) cells transformed with pDWM1LS+127/+135. The 
negative control (N) lane contains RNA from HPRT deficient 
Chinese hamster (RJK88) cells. The size of each molecular 
weight marker (m) is indicated (in bp). The fragments 
representing the transcription initiation sites (+1, +28, 
+34) and the 136bp fragment specific to transgenic mRNA, 
are indicated to the left of the panel. 
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the band at 271 bases. The doublet approximately 30 bases 
shorter represents the two initiation sites (+28 and +34). 
The band at approximately 136 bases is specific to 
pDWM1LS+127/+135 mRNA. As explained previously the 424bp 
band in each track represents undigested probe. The second 
lane contains RNA from the HPRT deficient cell line RJK88, as 
a negative control. 	As expected no HPRT transcripts are 
evident in this sample. 	The remaining tracks present a 
comparison of RNA from liver and brain tissue of three 
transgenic mice (male and female) with their wild-type (non-
transgenic) counterparts. The transgenic mice are hybrids 
and so to avoid strain specific variations siblings are used 
as non-transgenic controls. 
The elevation in HPRT expression in brain relative to liver 
in normal mice can be seen by comparing the intensity of the 
+1 band for these two tissues in the wild-type male (Figure 
3.9). A wild-type female RNA from brain is also presented. 
The presence of the 136bp band in each of the transgenic 
mouse RNA samples demonstrates that the transgene is being 
expressed. No band is evident in the same position in wild-
type tracks. The intensity of the 136bp band is greater in 
brain RNA than in liver RNA for each of the transgenic mice, 
indicating that the transgene is expressed at a higher level 
'train than liver. 	The relative elevation in brain is 
r:Hmateiv equivalent to that for the endogenous gene. 
The conclusions that can be drawn from this HPRT transgenic 
mouse experiment are limited, because only one transgenic line 
was obtained. Hence the expression of the tranegene was 
studied at just one chromosomal integration site. While the 
elevated expression of the transgene in brain relative to 
other tissues may by due to sequences within the transgene, 
the possibility that the expression pattern observed is due to 
position effects cannot be excluded. The fact that 
transcription is initiated from the transgene at sites 
equivalent to those in the endogenous gene indicates that the 
transgene contains sequences which are able to direct the 
transcription initiation from the sites that are used in vivo. 
The pDWM1LS+127/+135 transgene contains sequences that allow 
it to be expressed in a range of tissues when inserted into 
the mouse genome. 
Figure 3.10. 
Si analysis of HPRT mRNA from a range of wild-type and 
transgenic tissues. Cellular RNA was hybridised to a 424 
base single stranded probe, which spanned the main 
transcription initiation site and was end-labelled at an 
XhoI site, 271 bases into the gene. Hybridisation mixtures 
were digested with Si nuclease. RNA from a wild-type 
female (wt) and a transgenic female (tg) is presented. 
Tissues: B, brain; L, liver; H, heart; Lu, lung; K, 
kidney; 5, spleen. The positive control (P) is RNA from 
HPRT deficient Chinese hamster (RJK88) cells transformed 
with pDWM1LS+127/+135. The size (in bp) of each molecular 
weight marker (m) is indicated to the right of the panel. 
Fragments representing the transcription initiation sites 
(+1, +28, +34) and the 136bp fragment specific to 
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A single HPRT transgenic mouse line was obtained by DNA 
microinjection into the pronuclei of fertilised eggs. The 
transgene used pDWM1LS+127/+135 is a derivative of pDWM1 
(Melton et al., 1986) which is marked so that its expression 
is distinguishable from endogenous HPRT expression. It was 
not possible to detect transgene derived HPRT enzyme 
activity in mice. However, transgene derived mRNA was found 
in all tissues analysed of both male and female transgenic 
mice. The absolute level of HPRT expression from the 
transgene in this line is lower than from the endogenous 
gene. However, the tissue-specific variation that is seen in 
the expression of the endogenous gene, in particular 
elevated expression in brain, was also seen for the transgene 
in brain, liver, heart and kidney. Anomalously high 
pDWM1LS+127/+135 expression was seen in lung and spleen. 
Having the HPRT transgene present in mice with endogenous 
HPRT activity has the advantage that it should be possible to 
directly compare the expression of the transgene with 
expression at the endogenous X-linked gene, which provides a 
perfect internal control. However, in practise Si nuclease 
protection failed to distinguish absolutely between 
endogenous gene and transgene expression. It was found that 
the transgene derived mRNA also contributed to the signal of 
endogenous mRNA in such analyses. For this reason it was not 
possible to quantify transgene expression precisely. At 
time mice deficient for HPRT expression became 
iable (Hooper et al., 1987). Matings were carried out to 
produce mice that carried the pDWM1LS+127/+135 transgene but 
that were also deficient for endogenous gene activity. In 
these mice transgene expression could be assayed without 
complications arising from the endogenous gene activity. 
4. 	TRANSGENE EXPRESSION ON A DEFICIENT BACKGROUND 
To facilitate the analysis of expression from the HPRT 
transgene pDWM1LS+127/+135, matings were carried out to 
generate mice which were transgenic but which were 
deficient for endogenous HPRT activity. HPRT deficient 
mice (Hooper et al., 1987) were kindly provided by Martin 
Hooper, Department of Pathology, University of Edinburgh. 
The characterisation of the molecular genetic basis for the 
HPRT deficiency is presented in Chapter 5. The mutant HPRT 
allele can be traced in mice by Southern blot analysis (see 
Chapter 5). The wild-type locus is denoted Hprtb and the 
mutant locus is denoted hprtb_m3.  Male mice hemizygous for 
the transgene integration site (tg/+) were mated to females 
homozygous for the null HPRT allele (hprt b-m3  /hprt b-m3). 
There are two possible genotypes for each sex in the 
progeny from this mating. All male progeny are deficient 
for the endogenous gene (hprtbm3/Y)  but can be either 
hemizygous for the transgene or not transgenic. All female 
progeny are heterozygous deficient at the X-linked locus 
lIprtC_ffi3/Hprtb) but can also be either hemizygous for the 
transgene or not transgenic. These genotypes can be 
stinguished by Southern blot analysis of tail biopsy 
genomic DNA (Figure 4.1). Genomic DNA was digested with 
EcoRI and XhoI and probed with the full-length HPRT cDNA. 
For each sex it is necessary only to distinguish between 
*ose that carry transgene sequences and those that do not. 
Transgene specific bands are indicated to the left of the 
panel in Figure 4.1. Thus, determining the genotype of 
Figure 4. 1. 
Screening mice for the transgene by Southern analysis of tail 
DNA. Genomic DNA (5 jig) , obtained by tail biopsy, was 
digested with EcoRI and XhoI, electrophoresed, transferred 
and hybridised with the full-length HPRT cDNA probe. The 
sizes (in kb) of hybridising bands from the endogenous HPRT 
gene are indicated to the right of the panel. PG indicates 
the pseudogene containing band (Isamat et al., 1988). The 
sizes of bands specific to transgene sequences are indicated 
to the left of the panel. Both female (F) mice are 
heterozygous 	for 	the 	X-linked 	HPRT 	null 	mutation 
b 	b-m3 (Hprt /hprt 	) and either hemizygous for the HPRT 
transgene (tg/+) or nontransgenic (+1+). Male (M) mice are 
b-m3 
hemizygous for the HPRT null mutation (hprt 	/Y) and 
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progeny is straightforward. 	Deficiency of the X-linked 
endogenous HPRT gene in male progeny is indicated by the 
absence of the 5.5kb and the 6.3kb bands. (This pattern is 
explained in Chapter 5). In females heterozygosity for this 
deficiency is masked by bands representing the wild-type 
allele. 
To generate female mice that were transgenic and homozygous 
for the mutant X-linked HPRT allele a further cross was 
carried out. Male mice hemizygous for the HPRT transgene and 
mutant at the X-linked gene (hprt b-m3 /Y) were mated to female 
mice hemizygous for the transgene and heterozygous for the X-
linked mutant allele (hprtb_m3/Hprtb). Progeny were 
screened by Southern blot analysis of tail biopsy genomic DNA 
(Figure 4.2). DNA was digested with EcoRI and XhoI and 
probed with the full-length HPRT cDNA, pHPT5 (Konecki et al., 
1982). Female offspring can be either homozygous for the 
mutant X-linked I-IPRT allele or heterozygous for this allele. 
In addition they can be either non-transgenic, hemizygous 
for the transgene or homozygous for the transgene. Mice that 
were homczygous for the mutant X-linked gene were 
distinguished from heterozygotes by the absence of the 5.5kb 
and 6.3kb bands. Non-transgenic mice obviously have none of 
the transgene-specific bands. Mice homozygous for the 
transgene have to be distinguished for hemizygous mice on the 
basis of the intensity of the transgene specific bands 
f 2 ure 4.2). The pseudogene containing band (PG) can be 
oei as an internal control for loading. The 2.6kb transgene 
specific band in the second lane of Figure 4.2 appears to be 
Figure 4. 2. 
Screening transgenic mice by Southern analysis of tail DNA. 
Genomic DNA (5pg), obtained by tail biopsy, was digested with 
EcoRI and XhoI, electrophoresed, transferred and hybridised 
with the full-length HPRT cDNA probe, pHPT5. The sizes (in 
kb) of hybridising bands from the endogenous HPRT gene are 
indicated to the right of the panel. The sizes of bands 
specific to transgene sequences are indicated to the left of 
the panel. The female mice shown are either heterozygous (A 
1+) or homozygous (A/A) for the X-linked HPRT null mutation 
b-m3 
(hprt 	), and either nontransgenic (+1+), hemizygous for 
the transgene (tg/+), or homozygous for the transgene 
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twice as strong as the same band in the first track. Hence 
the second track contains DNA from a mouse homozygous for the 
transgene, while the first track contains DNA from a mouse 
hemizygous for the transgene. Relative intensities were 
confirmed by densitometric analysis (see Materials and 
Methods). Similarly, the mice represented in the third and 
fourth tracks of Figure 4.2 are hemizygous and homozygous for 
the transgene, respectively. 
Having obtained transgenic mice that were deficient for X-
linked HPRT activity, tissues for both males and females were 
analysed for HPRT expression. In these mice the only 
potentially active HPRT gene was the pDWM1LS+127/+135 
transgene. Hence, it was not necessary to distinguish 
between different HPRT mRNAs, and HPRT transgene expression 
can be measured by Northern blot analysis. Total RNA (30 
g) prepared from tissues, was electrophoresed on 
formaldehyde agarose gels, transferred and probed with full-
length HPRT cDNA, pHPT4 (Konecki et al., 1982). 
urD:equently, to provide a control for loading, filters were 
strijped of the HPRT probe and rehybridised with an actin 
cDNA (Minty et al., 1981). Actin mRNA levels are not 
equivalent in all tissues and therefore actin does not 
provide a control for comparisons between different tissues 
the same mouse. However, because actin mRNA is at a given 
I evel in a particular tissue it does provide a control for 
cnnari:ns feteeri he amo tiso:e difforot 
a 	:ar:oe 	saues 	frr: a 
female mouse which is hemizygous for the transgene and 
homozygous 	deficient 	at 	the 	X-linked 	gene 
b-m3 b-m3 (hprt 	/hprt 	) is presented in Figure 4.3. 	For 
comparison, RNA from the same tissues of a normal female 
mouse are included. The actin cDNA reprobe of the same 
filter is presented below the HPRT cDNA hybridisation. The 
actin cDNA probe hybridises to both cytoplasmic actin mRNA 
(21OOnts) and muscle actin mRNA (1650nts). The higher 
molecular weight cytoplasmic actin mRNA is used as the 
control for variations in loading. In the left hand panel of 
Figure 4.3 the pattern of wild-type HPRT expression for 
liver, brain, heart, lung and kidney can be seen. These 
relative levels of HPRT mRNA were seen in all wild-type 
animals studied by Northern analysis, and fit the same 
pattern that was seen in Si analyses (Chapter 3). This 
demonstrates that the elevated HPRT enzyme activity seen in 
mouse brains, correlates with elevated steady-state levels 
of HPRT mRNA. 	Band intensities were measured by scanning 
densitometry of autoradiographs (Table 4.1). 	By eye it is 
evident that HPRT mRNA levels are highest in brain and lowest 
in liver. 	ALso, it is clear that heart and kidney have 
approximately equivalent levels of HPRT mRNA, with a 
ightly lower level in lung. Assuming that the loads are 
equal in each track, a comparison of the absolute value for 
the intensity of each HPRT signal obtained by densitometry 
Y"'able 4.1) supports the above conclusion. The value for 
d'J 	in brain is 	hr hii: 	 S 	 sixfold 
the 	tr 	mNA n 	 ) which 
5 the lowest of the tissues analysed. Heart and kidney have 
Figure 4.3. 
Northern analysis of tissue RNA from wild-type and 
transgenic female mice. Total RNA (30pg) was prepared from 
mouse tissues, electrophoresed on formaldehyde-agarose 
gels, transferred, and hybridised with the HPRT cDNA probe, 
pHPT4. The filter was then rehybridised with an actin cDNA 
probe. Tissues from a wild-type female mouse and a female 
mouse hemizygous for the transgene and homozygous for the X-
linked HPRT null mutation are presented. Tissues: L, liver; 
B, brain; H, heart; Lu, lung; K, kidney. The actin cDNA 
probe can hybridise to both cytoplasmic actin mRNA and the 
lower molecular weight muscle actin mRNA. The size of the 
HPRT mRNA is approximately 1500 nucleotides. 
wild- type 
L B H Lu K 
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Table 4.1 	Densitometric analysis of HPRT expression in 
wild-type and transgenic female tissues 
H 	 A 
(HPRT x 10
4
) (actin x 10) 
	
H/A wild-type 
Wild-type: 	Liver 3.2 0.5 6.4 	- 
Brain 18.8 1.9 9.7 	- 
Heart 11.0 4.3 2.5 	- 
Lung 6.0 5.9 1.0 	- 
Kidney 10.9 2.4 4.6 	- 
Transgenic: 	Liver 0.5 1.3 0.39 6 
Brain 0.5 1.4 0.38 4 
Heart 0.5 3.5 0.14 3 
Lung 7.9 6.5 1.2 120 
Kidney 1.7 ( • 73 3 
H and A values were obtained from the scanning densitometer and 
represent the area, in arbitrary units, under the peak 
cerresponding to the HPRT and actin mRNA bands, respectively. 
HA eiulls the value H divided by the value A, i.e. it is the 
ric1.ir:iised HPRT value. % wild-type is the mRNA level in 
trsHenic tissue relative to wild-type expressed as a 
and eais (- A 	ranserc : HA 
intermediate HPRT mRNA levels of 11.0 x 1O 4 and 10.9 x 10 4 
respectively. Lung has a lower level of 6.0 x 10. 
Analysing the same tissues from a female mouse hemizygous for 
the transgene, it is obvious that the transgene is expressed 
at a considerably lower level than the X-linked gene in wild-
type mice. There is one major exception to this, the level 
of HPRT expression in the lung of the transgenic female is 
approximately equivalent to the wild-type level in lung. 
Variations in loading were compensated for by 
standardisation relative to the actin signal. This allows 
comparison of the level of expression in a given tissue in 
the transgenic mouse with the same tissue in the normal mouse 
(Table 4.1). A standardised value of HPRT mRNA levels, 
called H/A, was obtained for each tissue by dividing the 
densitometry value obtained for the HPRT signal by that 
obtained for the cytoplasmic actin mRNA signal (see H/A, 
Table 4.1). For wild-type liver H/A equals 6.4, whereas in 
transgenic liver H/A equals 0.39. From this it can be 
calculated that in the liver of the transgenic female, the 
level of HPRT mRNA is approximately 6% (100 x (0.39 -1- 6.4) ) 
of the wild-type level. In brain H/A values for wild-type 
and transgenic are 9.7 and 0.38, respectively. Thus, in 
brain pDWM1LS+127/+135 expression is 4% of wild-type. 
Calculated similarly, transgene expression in heart is 2% of 
wild-type, and in kidney 3% of wild-type. The level of HPRT 
mRNA in transgenic lung is 120% of the wild-type level. With 
the exception of lung, when examined by eye the transgenic 
tissues appear to have the same pattern of relative levels of 
77 - 
HPRT mRNA as wild-type tissues. 	That is, liver has the 
lowest level, brain has the highest level, and heart and 
kidney have an intermediate level. The absolute levels of 
HPRT mRNA in transgenic tissues are too low for densitometric 
analysis to verify this pattern. 
RNA derived from a hemizygous transgenic male was analysed 
similarly. The pattern and absolute level of expression of 
the pDWM1LS+127/+135 transgene in male tissues was the same 
as in the female tissues described above, including the 
anomalously high level of expression in lung (data not 
presented). 
The analyses so far presented of transgene expression have 
been limited to mice which were hemizygous for the transgene. 
Cells in normal mice only ever contain one active HPRT 
allele. Because the gene is X-linked, males contain a single 
copy and females are functionally hemizygous due to random 
inactivation of the genes on one X-chromosome in all cells. 
The pDTMI LS 135 transgene in this line is integrated on 
an auLos()rne, and should not, therefore, be subject to X-
inactivation. Both males and females which are homozygous 
Sir the transgene should contain two active alleles. To test 
ElliS prediction the level of HPRT expression in mice 
homizygous for the transgene was compared to the level of 
0npression in mice homozygous for the transgene by Northern 
LH .nalysis (Figure 4.4). The mice analysed in Figure 4.4 
all female and were identified by Southern analysis of 
il-biopsy DNA as described previously. 	Densitometric 
Figure 4.4. 
Northern analysis of HPRT expression in hemizygous and 
homozygous transgenic mice. Total RNA (30g) was prepared 
from mouse tissues, electrophoresed on formaldehyde-agarose 
gels, transferred, and hybridised with the HPRT cDNA probe, 
and subsequently with the actin cDNA probe. Liver (L) and 
brain (B) RNA are shown for four mice. Mice: wt indicates a 
wild-type female mouse; L/A indicates homozygosity for the 
X-linked HPRT null mutation (hprtbm3); tg/+ indicates 
hemizygosity 	for 	the 	transgene; 	tg/tg 	indicates 





































Table 4.2 Densitometric analysis of HPRT expression in 
hemizygous and homozygous transgenic females 
H 	 A 	 % 
(HPRT x 10
4 ) (actin x 10 4 ) 	H/A wild-type 
	
Wild-type: Liver 	1.1 	 1.8 	 0.6 	- 
Brain 	5.6 	 3.3 	 1.7 	- 
H P RT 
Deficient: Liver 	- 	 2.0 	 - 	- 
Brain 	- 	 9.8 	 - 	- 
Hemizygous 
Transgenic: Liver 	- 	 2.2 	 - 	- 
Brain 	1.9 	 10.0 	 0.2 	12 
Homozygous 
Transgenic: Liver 	0.5 	 2.2 	0.23 	33 
Brain 	3.3 	 7.8 	 0.4 	24 
H and A values were obtained from the scanning densitometer and 
represent the area, in arbitrary units, under the peak 
corresponding to HPRT and actin mRNA bands, respectively. H/A 
equals the value H divided by the value A, i.e. it is the 
standardised HPRT value. % wild-type is the mRNA level in 
transgenic tissue relative to the wild-type level expressed as a 
percentage, and equals (H/A transgenic - 	H/A wild-type) x 100. 
- 
7 c - 
analysis of the autoradiographs shown in Figure 4.4. is 
summarised in Table 4.2. In the wild-type female the 
approximately 6-fold elevation in HPRT expression in brain 
relative to liver is evident. No HPRT mRNA is detectable in 
either the liver or brain of the HPRT deficient 
b-m3 	b-m3 
(hprt 	/hprt 	) non-transgenlc female. 	HPRT mRNA was 
only detectable in liver from the female hemizygous for the 
transgene with long autoradiography exposure times, and is 
not visible in Figure 4.4. HPRT mRNA is detectable in the 
brain of this animal in Figure 4.4, at a level of 
approximately 12% of wild-type. In the female mouse 
homozygous for the transgene the level of HPRT mRNA in liver 
and brain is 34% and 24% of wild-type, respectively. Hence, 
the level of HPRT mRNA in mice homozygous for the transgene 
i s approximately double the level in mice hemizygous for the 
transgene. As predicted, there is no evidence of 
inactivation of one allele of the transgene in homozygous 
"1 i C P 
in cunc 	luri 	 i HT urarisgene is expressed in 
mont t I snues anni sod at oFprox 	10% of the level of the X- 
linked HPRT gene. 	Anomalously high levels of transgene- 
erived HPRT mRNA are detectable in lung and spleen, but 
cherwise the relationship between the levels of transgene-
:leved mRNA in different tissues has the same pattern as for 
cnc:genous HPRT mRNA. Most interestingly, pDWM1LS+127/+135 
in C:aiel 	n 	he 	ran 	i srucenic mice. 	A 
Jo:i •lisusnn 	nhose neuutn Is sno.-  rsed in Chapter 
1985) the mutant allele present in E14TG2a was designated as 
b-m3 
hprt 
In collaboration with Oliver Smithies, University of North 
Carolina, Chapel Hill, USA, we were able to demonstrate that 
homologous recombination can be used to target specific 
modifications to the genome of mammalian cells (Doetschman 
et al., 1987). HPRT expression in E14TG2a was restored by 
correction of the h prtbm3 allele by gene targeting. The 
targeting vector used contained mouse HPRT exons 1 and 2 
along with the human HPRT promoter. When the experiments 
described below were initiated a few reports had been 
published demonstrating the feasibility of gene targeting in 
ES cells (Thomas and Capecchi, 1987; Doetschman et al., 
1.987). However, at that time no one had succeeded in 
introducing a targeted modification into the mouse germ line 
using ES cells. 
Tre ted currect ien si the P I.1d2a delet ion 
ne veccur pDMiJi, corisrucLed by Laruj.afrfle 1.oan, 
designed to correct the mutant HPRT allele in E14TG2a ES 
cells by gene targeting. Details of pDWFI101 construction are 
,,resented in the Materials and Methods section. The vector 
;nd the gene targeting experiment are shown schematically in 
re 5.1. The structure of the mutant h prt bm3 allele is 
below 	the wild-type 	allele. As described above 	the 
1.4TG2a 	mutation is 	a 	deletion 	of the first 	two HPRT exons 
and at least 12kb of 5' flanking sequence including the HPRT 
promoter region. pDWM101 contains mouse exons 1, 2 and 3 
plus the mouse HPRT promoter. Exons 1 and 2 are necessary to 
replace the deleted coding regions in E14TG2a. The exon 3 
region provides homology with the target locus. The extent 
of homology is between 2.3kb and 4.2kb, depending upon the 
precise downstream end point of the deletion. In pDWM101 the 
HPRT promoter is provided in 635bp of 5' flanking sequence. 
This sequence is sufficient for HPRT expression in cultured 
cells (Melton et al., 1986). 
The 	predicted 	outcome 	of 	correction, 	homologous 
recombination between pDWM101 and the mutant target locus, 
is shown in Figure 5.1. The corrected gene has the same 
structure, called type 1, as the wild-type gene except that 
the first intron is reduced from 10.8kb to 4.1kb. The 
corrected allele has a restriction map which is distinct from 
both the wild-type gene and the deletion mutant allele. 
Hence, correctants can be identified by Southern blot 
ana1vsr. 	In the VcoRI restriction map a novel 10.4kb 
tragmenil 	generated, containing exons 1 and 2, and the 
H3kb band, containing exon 3 is duplicated. In the BamHI 
restriction map a 14.0kb fragment containing exon 1 and the 
duplicated exon 3, is generated, and the 9.5kb fragment that 
ontains just exon 3 in the deleted allele is replaced by the 
a ild-type 7.0kb fragment which contains exons 2 and 3. The 
'ch and the 14.0kb BamHI fragments in the corrected allele, 
he ur ducts of one BamHI site in the vector sequences 
nd one BamHI site in the chromosomal sequences. While the 
Figure 5.1 
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7.0kb fragment is also present in the wild-type gene, the 
14.0kb fragment is diagnostic for targeted correctants. The 
correcting vector, pDWM101, can only restore HPRT activity 
to cells in which Lt undergoes homologous recombination with 
the mutant allele. pDWM101 has no independent HPRT activity 
and therefore will not restore HPRT activity by integration 
into other genomic sites. Consequently, targeted correctants 
can be isolated by subjecting transformed cells to selection 
for HPRT activity, that is, in HAT-containing medium. 
Three gene targeting experiments using pDWM101 were 
performed. Electroporations and cell culturing in the first 
two were carried out by Angela Pow. Analysis of correctant 
gene structures was carried out by myself. The third 
experiment was performed by myself. 
pDWM101 DNA was linearised at the unique XhoI site in exon 3 
before 	being 	introduced 	into 	E14TG2a 	cells 	by 
electroporation. Electroporation conditions were chosen 
that resulted in minimal cell death in control plating 
experiments. As a positive control for transformation 
E14TG2a cells were electroporated with pDWM100 DNA. pDWM100 
was constructed by replacing the 1.25kb XhoI-EcoRI fragment 
in pDWM101 (Figure 5.1) with the 1.8kb XhoI-EcoRI fragment 
from pDWM1 (Melton et al., 1986). Thus, pDWM100 contains the 
entire HPRT coding region and has HPRT activity. It can 
hcreFre istore HPRT activity to E14TG2a cells without a 
nr homologous recomhi nat i rp. 
In the first experiment 4.6 x 10 7 E14TG2a cells were 
electroporated. From these eight HAT  colonies were 
obtained (Table 5.1). The frequency of HPRT correctants per 
cell electroporated is 1.75 x 10 -7  . The frequency of HAT R  
colonies per cell electroporated with pDWM100 DNA was 2.5 x 
10 in this experiment. The ratio of HAT   colonies obtained 
from cells electroporated with pDWM101 DNA to HAT   colonies 
obtained from cells electroporated with pDWM100 DNA was 
0.007. We have called this value the targeting index (Table 
5.1). It gives an indication of the number of targeting 
events relative to the number of random integrations, 
although it does not take into account integrations of 
pDWM100 into sites which prevent expression. 
Southern hybridisations were carried out to analyse the 
structure of the HPRT gene in each of the eight HAT   clones 
and to confirm that gene targeting had occurred (Figure 5.2). 
Seven of the eight HAT   clones had the HPRT gene structure 
predicted for correctants, which we have called type 1 
(Figures 5.1 and 5.2). In the EcoRI digest the new 10.4kb 
band is visible and the intensity of the 1.3kb band is 
increased twofold with respect to the equivalent band in the 
E14TG2a lane. The intensity of the pseudogene band in the 
EcoRI digests allows comparison of the relative loading in 
each track, thus providing an internal control. In the BamHI 
digest the disappearance of the 9.5kb fragment which is 
characteristic of the deletion, and the regeneration of the 
7.0kb wild-type band can be seen. The generation of the 
14.0kb fragment, which comigrates with the pseudogene 
Table 5.1 	Summary of correction experiments 
Number 	Frequency 	 Correctant 
of HAT 	of HPRT 	Positive 	Targeting 	Types 
a b c Expt Colonies Correctants 	Control 	Index 	1 	2 	3 
1 	8 	1.75 x 	2.5 x 1 	0.007 	7 	- 	1 
2 	2 	4.0 x 10- 8 	6.4 x 10- 6 	0.006 	1 	1 	- 
3 	12 	2.2 x 	 6.3 x 10- 6 	0.035 	12 	- 	- 
a Number of HAT   colonies generated per cell electroporated 
with correcting vector DNA. 
b Number of HAT   colonies generated per cell electroporated 
with pDWM100 DNA. 
C Frequency of HAT   colonies generated per cell electro-
porated with correcting vector DNA relative to HAT  
colonies generated per cell electroporated with PDWM100 
HNA (a 'h 
fragment, is indicated by the increased intensity of the band 
at that molecular weight. 
One of the eight HATR clones generated in the first 
electroporation experiment had an HPRT gene with a structure 
different to the predicted structure. We have called this 
structure type 3. In this clone two correcting vector 
molecules have integrated in tandem. The restriction map for 
this clone can be seen in Figure 5.1, as deduced from the 
Southern analysis shown in Figure 5.2. In an EcoRI digest 
the 10.4kb fragment is duplicated and there are 3 copies of 
the 1.3kb fragment, as opposed to two copies in the type 1 
structure and one copy in the deletion mutant. This can be 
seen in the relative intensity of the 1.3kb band in each 
lane. In a BamHI digest, in addition to the 14.0kb and 7.0kb 
fragments seen in type 1 correctants, there is an 11.7kb, 
vector-sized, fragment. This interpretation was supported 
when the same hybridisation membrane was reprobed with pUC8 
DNA (Figure 5.2B). The pUC8 sequence is present within the 
h.kh FcaR fragment and consequently the intensity of this 
band is increased twofold in type 3 DNA relative to type 1. 
In a BamHI digest of the type 3 DNA the pUC8 sequence is 
riresent in both the 14.0kb fragment and the 11.7kb fragment. 
he equal intensities of the 14.0kb and 11.7kb bands in type 
show that there are two copies of the vector integrated. 
there were more than two copies the intensity of the 
H .7Db band would be at least twofold greater than the 14.0kb 
bard. Thus seven of the eight HAT   clones generated in this 
periment were the product of the desired gene targeting 
event. 	One of the eight, 
targeted correction had two 
integrated in tandem. Th 
either by concatamerisation 
homologous integration, or 
recombination events. 
although also the product of 
copies of the targeting vector 
s structure could have arisen 
of two vector molecules before 
by two consecutive homologous 
With the intention of producing a targeted correctant clone 
suitable for injection into blastocysts the above experiment 
was repeated using lower passage E14TG2a cells. 5 x 10 7 
E14TG2a cells were electroporated with pDWM101 DNA. Two HAT  
colonies were generated which were analysed by Southern 
hybridisations. The frequency of HAT   clones per cell 
electroporated with pDWM101 DNA was 4.0 x 10- 8. 	In this 
experiment, the frequency of HAT 
 	clones generated by 
electroporation with the positive control vector, pDWM100, 
NA was 6.4 x 10- 6.  Consequently, the targeting index was 
.H6 (Table 5.1), which is the same as for the first 
experiment (0.007). One HAT   clone generated in this 
e:perinient hd the type 1 HPRT gene structure, which is the 
pFedicterl uulcome homologous recombination. The second 
:f the HAT   clones had a different HPRT gene structure which 
(2. have called type 2 (Figures 5.1 and 5.2). The exon 3 
:)ntaining 1.3kb EcoRl band has the same intensity in this 
clone as in E14TG2a. Hence, in this clone, called correctant 
-1, the exon 3 region is not duplicated as it is in type 1 
c.Frecic:r:.  t.h kb. i r ii 
.1 	t. 	 L(:T 	ITt 	• 	I 
the band is not visibly reduced at this resolution. An 
XhoI digest of clone 2-1 showed that the XhoI site in the 
upstream copy of exon 3 is absent (data not presented). The 
EcoRI site immediately upstream of the plasmid sequence is 
present as indicated by the presence of the 10.4kb EcoRl 
band. The results of Southern analysis of correctant 2-1 are 
consistent with the targeting vector having integrated 
correctly, but with an additional event resulting in a small 
deletion removing the upstream copy of exon 3. The absence 
of the upstream copy of exon 3 does not affect the HPRT 
positive status of clone 2-1 because the deletion occurs 
outside of the functional gene. 
To investigate the frequency with which anomalous structures 
arise in corrected genes, a third electroporation experiment 
was performed. Twelve HAT   clones were obtained from 5.5 x 
IO E14TG2a cells electroporated with pDWM101 DNA. The 
frequency of HAT  	clones per cell electroporated with 
rDWM101 DNA was 2.2 x 	The frequency of HAT   clones per 
cell electroporated with pDWM100 DNA was 6.3 x 10- 6. 
Therefore, the targeting index in this experiment was 0.035. 
This is fivefold higher than obtained in the first two 
experiments, which is within the usual variation seen in 
Lultured mammalian cell transformations. All twelve HAT  
ones generated in this experiment had the type 1 HPRT gene 
sLructure as determined by Southern analysis. None of the 
HPRT correctants produced in the three electroporation 
periments had random integrations of the targeting vector 
Ic addition to the targeted integration. 
Figure 5.3. 
Northern analysis showing expression from corrected genes in 
ES cells. Total RNA (30pg) was prepared from ES cells, 
electrophoresed on formaldehyde -agarose gels, transferred, 
and hybridised with the HPRT cDNA probe, pHPT4, and 
subsequently with the actin cDNA probe. RNA: wt, E14 (wild-
type); A, E14TG2a (HPRT deficient); 2-1, correctant clone 
2-1; 1-6, a correctant clone with the type 1 structure. The 
size of the HPRT mRNA is approximately 1500 nucleotides. 
wt 	A 2-1 1-6 
HPRT- 
actin — --I 	- __.r 
level in E14 cells. 	Possible explanations for this are 
discussed later. 
Screening mice for the HPRT deletion allele 
The experiments described in this thesis depended to a large 
extent on the ability to identify different HPRT alleles by 
Southern analysis, of mouse tail-biopsy DNA. As described 
below, this ability facilitated the generation of an HPRT 
deficient mouse line. To produce an HPRT deficient mouse 
line it was necessary to distinguish between heterozygous 
HPRT deficient (Hprt b  /hprt b-m3) females and females 
homozygous for the wild-type gene (Hprtb/Hprtb).  An example 
of how Southern analysis on tail biopsy DNA allowed female 
mice to be screened is illustrated in Figure 5.4. Genomic 
DNA was digested with BamHI and hybridised with a full-length 
NPRT cDNA probe. The restriction fragment pattern has been 
explained in the context of characterising the E14TG2a 
mutation earlier in this chapter. The characteristic of a 
RamHI digest which makes it suitable is the generation of a 
hand at 9.5kb which is specific to the HPRT deletion allele. 
chereas the 7.0kb BamHI band is specific to the wild-type 
:lele, or the corrected allele. The first three lanes in 
tigure 5.3 contain control DNAs for the screening of seven 
:,-, male mice, lanes four to ten. The first lane contains DNA 
hetrozygous deficient female as indicated by the 
r•reuence 	both the 7.0kb band which is specific to the 
i-ype allele, and the 9.5kb band which is specific to the 
Figure 5.4. 
Tracing the HPRT deletion allele (hprt 
b-m3) 
 in mice by 
Southern analysis. 	Genomic DNA (5pg), obtained by tail 
biopsy, was digested with BamHI, electrophoresed, 
transferred and hybridised with the full-length HPRT cDNA 
probe. The sizes (in kb) of hybridising bands are indicated. 
PG indicates pseudogene containing bands. A female (F) mouse 
which is heterozygous for the hprtb_m3  allele, and two males 
(M), one of which is wild-type (+/Y), and the other of which 
is hemizygous for the deletion allele (A/Y), are used as 
controls to screen seven female mice, which are either wild-
type (+1+) or hemizygous for the hprtbm3  allele (A/+). 
- *Ja - 
mutant allele. The second lane contains DNA from a wild-type 
male. The third lane contains DNA from an HPRT deficient 
male as indicated by the presence of the 9.5kb band and the 
absence of the wild-type specific 7.0kb band. Thus it is 
possible to determine the genotype of each of the seven 
females as indicated above each track. 
6. 	GERM LINE TRANSMISSION AND EXPRESSION OF THE CORRECTED 
The two correctant clones, 2-1 and the type 1 clone, 1-8, 
produced from low passage E14TG2a cells, were assayed for the 
frequency of HPRT deficient cells in their culture 
populations. To do this cells were grown in the absence of 
selection for two weeks and then their plating efficiency in 
medium containing 6-thioguanine (6-TG), relative to their 
plating efficiency in non-selective medium, was measured. 
The relative plating efficiency for 2-1 was 0.03%. This is 
approximately the same as the value for wild-type E14 cells. 
The plating efficiency for 1-8 was 21.0%. Hence, after 2 
weeks of non-selective growth, 21.0% of the cell population 
in the type 1-8 correctant culture was HPRT deficient. 
Southern analysis of DNA from 6_TGR  populations derived from 
the correctant 1-8 culture after twenty four days of non-
selective growth revealed an HPRT gene structure identical 
to that of E14TG2a, the starting deletion mutant (data not 
shown). There were, at the time, two possibilities for the 
origin of these cells. They could arise due to the 
persistence in the HAT culture of E14TG2a cells, surviving 
by metabolic cooperation (Hooper, 1982). Alternatively, 6-
TGR cells might be generated by the loss of pDWM101 vector 
sequences from the genome of corrected cells, perhaps due to 
a reversal of the integrating homologous recombination 
(correction) event. It was decided that clone 1-8 was 
unsuitable for injection into blastocysts. Subsequently, by 
repeating the relative plating efficiency assay on a clonal 
- 
isolate of 1-8, it was shown that the presence of 6-TG' cells 
in the population of correctant 1-8 cells was due to 
surviving E14TG2a cells and not due to instability of the 
corrected gene. 
The oroduction of chimeric mice 
The injection 	of ES cells into blastocysts and the test 
breeding of chimeras was carried out by Alan Clarke, 
Department of Pathology, University of Edinburgh. 
Cells from correctant clone 2-1 were injected into 
C57BL/6/01a x CBA/Ca/Ola F2 blastocysts. These blastocysts 
are homozygous for the wild-type alleles at the c and p loci 
(C/C, P/P) and segregating for the alleles A (agouti) and a 
nonagouti). 	The 2-1 correctant cells are derived from 
strain 129/01a and are therefore homozygous for the alleles 
ch 
C 	(chincilla) and p (pink-eyed dilution), which both 
1in c:t c1ur. 	1 fr AW (white-bellied agouti). 
hence, chi mecc mice cre 4 deritifiable by the presence of 
'ight colouring in an otherwise dark coat. 	From 93 
hastocysts injected, twenty six mice were born. 	Fifteen 
chimeras were obtained, twelve of which were male. These 
male chimeras were tested for germ line transmission of the 
ES cell-derived c ch  and p markers by crossing with strain 
29/01a females. Offspring, which like strain 129 were light 
;ellow with pink eyes were diagnostic of germ line 
n. 	ne 	n echt male chimeras tested showed 
germ line transmission to 21 of 28 offspring. The frequency 
of chimeras per animal born in this experiment was comparable 
to that obtained with the parental HPRT deficient (E14TG2a) 
ES cell line (Hooper et al., 1987). However, fewer injected 
blastocysts survived to term. Nineteen out of 34 E14TG2a-
derived male chimeras showed germ line transmission. 
Correctant 2-1 cells have been shown to have a lower 
percentage of diploid cells than the parental line E14TG2a 
and this may account for the difference in the frequency of 
germ line chimeras generated. In total 75% of offspring 
inherited ES cell derived markers in our experiment. 
E14TG2a-derived chimeras have been obtained which 
transmitted ES cell markers to as many as 100% or to as few 
as 1% of offspring (Hooper et al., 1987). 
The corrected HPRT allele in correctant 2-1 has been 
designated as Hprtbffl4.  Female offspring of the germ line 
chimera are heterozygous for the corrected HPRT allele and 
the wild-type allele. These females were back-crossed to 
their chimeric father to generate a pure breeding line for 
express1n studies. There were two possible genotypes for 
beth male and fernaJe progeny from this cross. Male offspring 
ceuJd be either hainizygous for the wild-type allele or 
Lemizygous for the corrected allele (Hprtm4). Female 
I fspring could be either homozygous for the corrected 
a 
b-m4 b-m4
lele (Hprt /Hprt ) or heterozygous for the 
ccrr 
	
	 b-m4 	bected allele (Hprt 	/Hprt ). 	Southern analysis of 
biopsy genomic DNA was used to distinguish between the 















Figure 6.1. 	Genoinic DNA was digested with EcoRI and 
hybridised with a full-length HPRT cDNA probe. For males it 
was necessary to distinguish between the wild-type gene and 
the corrected gene. In an EcoRI digest the pattern for the 
corrected gene differs from the wild-type gene in that the 
6.3kb and 5.5kb bands are absent and there is an additional 
band at 10.4kb. This pattern is explained in Chapter 5. 
Females that are homozygous for the corrected gene have the 
same Southern pattern as males hemizygous for the corrected 
gene, in an EcoRI digest. That is, the wild-type bands of 
6.3kb and 5.5kb are absent and there is an additional band at 
10.4kb. Females that are heterozygous for the corrected gene 
are indicated by the presence of both the 5.5kb and 6.3kb 
wild-type fragments and the corrected gene specific band at 
10 .4kb. 
Ypresson 	If the corrected HPT gene 	mice 
Total RNA was prepared from tissues of females humozygous for 
ihe corrected HPRT gene (Hprt b-m4  /Hprt  b-m4)  and males 
heoi:gous for the corrected HPRT gene (Hprtbm4/Y). HPRT 
ocuression was assayed in each tissue by Northern blot 
ina1ysis. Figure 6.2 shows a Northern hybridisation of 
issue RNAs from a wild-type female and a female homozygous 
t)r the corrected gene. The wild-type mice used as controls 
tor expression of the corrected gene are strain 129 and 
ierefore isogenic with the corrected mice, which are also 
1 O 	 :ieci O:T 	t he 1 i 	ength 
Figure 6.2. 
Northern analysis of HPRT expression in female mice 
homozygous for the corrected gene. 	Total RNA (30jg) was 
prepared from mouse tissues, electrophoresed on 
formaldehyde-agarose gels, transferred, and hybridised with 
the HPRT cDNA probe and subsequently with the actin cDNA 
probe. Tissues are analysed from a wild-type female and a 
female homozygous for the corrected HPRT allele. Tissues: L, 
liver; B, brain; H, heart; Lu, lung; K, kidney. The size 
of the HPRT mRNA is approximately 1500 nucleotides. The 
actin cDNA probe can hybridise to cytoplasmic actin mRNA 
(2100 nucleotides) and the lower molecular weight muscle 
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Table 6.1 Densitometric analysis of HPRT expression in 
wild-type and corrected female tissues 
H 	 A 
(HPRT x 10
4
) (actin x 10) 
	
H/A wild-type 
Wild-type: 	Liver 1.1 0.4 2.8 	- 
Brain 15.3 3.0 5.1 	- 
Heart 7.0 5.8 1.2 	- 
Lung 3.3 7.7 0.4 	- 
Kidney 7.4 3.8 1.9 	- 
Corrected: 	Liver 0.4 0.6 0.7 24 
Brain 10.7 6.2 1.7 33 
Heart 5.6 10.7 0.5 43 
Lung 4.3 8.9 0.5 114 
K  d n e v 2 
H and A values were obtained trom the scanning densitometer and 
represent the area, in arbitrary units, under the peak 
crresponding to HPRT and actin mRNA bands, respectively. H/A 
equals the value H divided by the value A, i.e. it is the 
:tandardised HPRT value. % wild-type is the mRNA level in 
to wild-type expressed as a 
IA crrrectei 	H 7 	d- vre 	xinn 
mouse HPRT cDNA, pHPT4 (Konecki et al., 	1982), and 
subsequently reprobed with the mouse a-actin cDNA (Minty et 
al., 1981) to allow comparison of mRNA levels for the same 
tissue in different animals, as explained in Chapter 4. The 
wild-type female tissues show the characteristic pattern of 
HPRT expression (see also Figure 4.3). By visual analysis of 
the autoradiograph the following can be inferred. In a wild-
type mouse, liver has the lowest level of HPRT mRNA, while 
brain has the highest. HPRT expression in heart and kidney 
is approximately equivalent and at a level intermediate 
between liver and brain. The level of HPRT mRNA in lung is 
slightly lower than in heart and kidney. In the female 
homozygous for the corrected gene HPRT mRNA levels are lowest 
in liver and highest in brain. The heart and kidney HPRT 
expression levels are approximately equivalent and 
apparently at a correct level relative to liver and brain. 
H owever, the absolute level of expression in each of liver, 
brain, heart and kidney is approximately threefold lower 
than in the equivalent tissues of the wild-type female. In 
the female that is homozygous for the corrected HPRT gene the 
level of HPRT mRNA in lung is anomalous, it is higher than in 
inc;, whereas in the wild-type mouse lung 
jl ~ Toer than both heart and kidney. Thus, with 
he exception of lung the corrected gene is expressed at the 
()rrect relative level in each of the tissues analysed, but 
a reduced absolute level. The actin reprobe shows that 
tr each tissue there is not much variation in loading 
tween 
 
m i ce. 
Figure 6.3 shows Northern analysis of tissue RNAs from both 
a female homozygous for the corrected gene and a male 
hemizygous for the corrected gene. The level of HPRT 
expression for each tissue is approximately equivalent in 
the two animals. Although, the anomalously high expression 
in lung appears less pronounced in the male. Densitometric 
analysis was carried out of the HPRT and actin mRNA levels in 
both Figure 6.2 and Figure 6.3. The results of this analysis 
for Figure 6.2 are shown in Table 6.1. It has been shown that 
the level of HPRT mRNA in correctant ES cells in culture is 
33% of the wild-type level. With the exception of lung the 
expression in each of the tissues of the female homozygous 
for the corrected gene is reduced to a similar level. The 
level of HPRT mRNA in liver is 24% of wild-type. The level 
in brain is 33% of wild-type and HPRT mRNA levels in heart and 
kidney are at 43% and 55% of wild-type, respectively. 
Densitometric analysis confirmed the anomalous expression in 
lung. The level of HPRT mRNA in the lung of the female which 
is homozygous for the corrected gene is 114% of the level in 
the lung of the wild-type female. Thus, the visual 
interpretation 	of 	these 	results 	was 	confirmed 	by 
densitometric analysis. The results of densitometric 
analysis of the experiment shown in Figure 6.3 are summarised 
in Table 6.2. For each tissue the H/A value is similar in the 
male to the female. Thus, HPRT expression in the male 
hemizygous for the corrected gene is equivalent to in the 
female homozygous for the corrected gene. The H/A value of 
0.5 obtained for male lung compared to the value of 0.7 for 
female lung supports the suggestion that lung expression is 
Figure 6. 3. 
Northern analysis of expression from the corrected HPRT gene 
in female and male mice. Total RNA (30pg) was prepared from 
mouse tissues, electrophoresed on formaldehyde-agarose 
gels, transferred, and hybridised with the HPRT cDNA probe 
and subsequently with the actin cDNA probe. Tissues are 
shown from a female homozygous for the corrected gene (C/C) 
and a male hemizygous for the corrected gene (dY). Tissues: 
L, liver; B, brain; H, heart; Lu, lung; K, kidney. The 
size of the HPRT mRNA is approximately 1500 nucleotides. The 
actin cDNA probe can hybridise to cytoplasmic actin mRNA 
(2100 nucleotides) and muscle actin mRNA (1650 
nucleotides) 
Female C/C 
L 	B 	H 	Lu 	K 
Male 	C/Y 
L 	B 	H 	Lu 	K 
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7. 	DISCUSSION 
7.1 	HPRT exnression in transgenic mice 
The use of cultured mammalian cells in DNA mediated gene 
transfer experiments has proved to be a valuable system for 
studying gene expression. Mutational analysis of the 
transfected genes has allowed the identification of cis-
acting DNA elements that regulate expression. This approach 
has been used extensively to analyse the mouse HPRT promoter 
(Melton et al., 1986) as described in the Introduction to 
this thesis. However, the ability to define tissue-specific 
or temporal control elements using cultured cells is 
limited.Presently, the most satisfactory and widely used 
system for studying the tissue-specific and developmental 
control of gene expression is the transgenic mouse (for 
reviews see Jaenisch, 1988; Palmiter and Brinster, 1986). 
The preferred method for producing transgenic mice is by 
direct microinjection of DNA into one of the two pronuclei in 
a fertilised egg. The first step in analysing the regulation 
of expression of a gene is to identify a transgene construct 
which is expressed at levels comparable to and in the same 
tissue distribution as the endogenous gene. Subsequent 
mutational analysis of this 'complete' gene can be used to 
identify important elements more precisely. 
Obviously, it is necessary to monitor the expression of a 
transgene. Usually, the transgene will beintroduced into 
mice which have endogenous expression of the gene under 
investigation. 	A variety of methods of marking transgene 
expression have been used. 	One method is to utilise a 
reporter gene, to which the promoter region being analysed is 
fused. The reporter gene may be the homologous gene from a 
different species, or it may be an unrelated gene which is 
easily monitored, such as a hormone which visibly affects 
physiology, or an oncogene which generates tumours. 
Alternatively, more subtle changes may be preferable. We 
have used an HPRT transgene which as far as possible 
represents the endogenous gene. The use of hybrid constructs 
including non-endogenous genes that grossly affect 
physiology may result in disturbances to the phenomenon 
under investigation. In addition sequences controlling gene 
expression are not confined to the region upstream of the 
transcription start site, as discussed in the Introduction. 
Hence, fusing a promoter region to a reporter gene may 
exclude important regulatory elements. 
As well as being used to study gene expression, transgenic 
mice have been used extensively to study oncogenesis. The 
system has been invaluable in unravelling the actions and 
interactions of oncogenes (reviewed Groner et al., 1987). In 
addition, the microinjection technique has potential 
applications for the germ line manipulation of other 
mammalian species. It may be possible to improve livestock 
animals, (reviewed Pursel et al., 1989) for example, by 
making transgenic cattle with an improved protein content in 
their meat. Another approach under investigation is the 
production 	of 	transgenic 	animals 	which 	secrete 
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pharmaceutically or economically important products in their 
milk. Already, transgenic sheep which secrete human factor 
IX in their milk have been produced (Clark et al., 1989). 
The factors which affect the efficiency of introducing DNA 
into fertilised eggs have been studied in detail (Brinster et 
al., 1985). For optimal integration a few hundred linear 
molecules of the transgene are injected into the male 
pronucleus of fertilised eggs. 	We obtained a single HPRT 
transgenic mouse line. 	For reasons considered below this 
limits what can be inferred from the expression pattern of 
the transgene. In this line approximately nine copies of the 
transgene are integrated in a head to tail array at a single 
autosomal site. Other workers have identified transgenic 
mice with a single copy or greater than 100 copies of the 
transgene, usually integrated at a single chromosomal site 
in a head to tail array (Brinster et al., 1985). In such a 
multicopy array it is not possible to determine if all the 
genes are being expressed equivalently or whether just one or 
a few copies are predominantly expressed. Frequently the 
level of expression is not copy number dependent. Indeed, it 
has been shown in mice transgenic for an elastase 1 gene that 
high copy numbers are detrimental to expression (Davis and 
MacDonald, 1988). It was observed that the rate of 
transcription per copy in mice with 250 copies was 100-fold 
less than in mice with 2 copies. For a copy number below 10 
the level of transgene expression increased with increasing 
copy number. Thereafter, the level of transcription of the 
transgene declined. This effect is not due to the titration 
- 101 - 
of essential transcription factors because the level of 
expression of the endogenous gene remained unaffected by the 
copy number of the transgene. 
We were unable to detect HPRT enzyme activity derived from 
the transgene in transgenic mice. The level of expression 
which we subsequently identified by mRNA analyses is 
probably below the threshold of detection in the enzyme 
assay. 	Transgene derived HPRT mRNA was detected in all 
transgenic tissues analysed. 	As for endogenous HPRT gene 
expression, the level of transgene expression was elevated 
in brain tissue relative to liver, heart and kidney. Thus, 
the HPRT transgene, pDWM1LS+127/+135 contains the regulatory 
elements responsible for the brain specific elevation of 
normal HPRT expression. The responsible signals could 
regulate expression at the level of the rate of 
transcription. Such elements could be situated anywhere in 
the HPRT transgene sequence. While transcriptional 
enhancers are frequently found upstream of promoters they 
can also be situated within or downstream of genes. For 
example the immunoglobulin heavy chain genes have an 
enhancer situated in an intron (Banerji et al., 1983) and the 
human -globin gene has an enhancer situated 3' of the gene 
which contains multiple binding sites for an erythroid 
specific protein factor (Wall et al., 1988). Experiments in 
transgenic mice have also shown that many genes require 
sequences which are situated many kilobases away from the 
gene to control expression with the correct tissue 
specificity. To direct expression to the liver of transgenic 
- 102 - 
mice, the albumin gene requires an enhancer which is situated 
10kb upstream of the promoter (Pinkert et al., 1987). On the 
other hand, much more limited amounts of flanking sequence 
are sufficient to give the correct pattern of expression of 
some genes in transgenic mice. A hybrid gene consisting of 
the bacterial -galactosidase coding sequence and sequences 
from the mouse a -crystallin gene promoter, spanning from 
759bp upstream to 45bp downstream of the transcription start 
site, gave lens specific expression with the appropriate 
temporal control in transgenic mice (Goring et al., 1987). 
Furthermore, a hybrid gene containing 213bp of 5' flanking 
sequence from the mouse elastase 1 gene upstream of the human 
growth hormone structural gene has the elastase 1 pattern of 
expression (Ornitz et al., 1985). That is, human growth 
hormone is detected only in pancreatic acinar cells. Hence, 
it would appear that there are few constraints on the 
organisation of cis-acting regulators of transcription. 
Alternatively, HPRT expression may be regulated at the level 
of RNA processing or mRNA stability, in which case the 
significant 	elements would 	be 	situated within 	the 
transcribed sequences. The high level of sequence 
conservation in the 3' untranslated region of the HPRT gene 
has already been discussed in relation to a possible role in 
gene expression in the Introduction. The steady-state level 
of mRNA from many housekeeping genes is apparently 
controlled by the rate of mRNA degradation rather than 
transcription (Carneiro and Schibler, 1984). If the brain-
specific elevation in HPRT expression is controlled by 
- 103 - 
regulated mRNA turnover then it would be expected, perhaps, 
that very limited flanking sequence would be sufficient. The 
promoter region would need only to contain general 
transcription factor binding sites. All the elements 
required for transcription of an HPRT minigene in Chinese 
hamster fibroblasts are located within 50bp upstream of the 
major transcription site (Melton et al., 1986). This 
sequence contains putative binding sites for the general 
transcription factors Spi and AP2, and may be sufficient for 
correct HPRT expression in vivo, if regulation is 
predominantly post-transcriptional. 
While pDWM1LS+127/+135 expression was elevated in brain 
relative to most tissues, the absolute level of expression in 
each tissue, with the exception of lung, was at least 10-fold 
below the wild-type level. To facilitate the quantification 
of transgene expression, mice were produced which were 
transgenic and which were deficient for endogenous HPRT 
expression. In this situation it is not necessary to 
distinguish between mRNA derived from the transgene and mRNA 
derived from the endogenous gene. However, it is now 
necessary to generate an internal control for variations in 
loading. This was achieved by measuring the endogenous actin 
mRNA (Minty et al., 1981) level in each tissue. 
Standardising the HPRT mRNA level relative to the actin mRNA 
level allowed the direct comparison of the HPRT expression in 
a particular tissue between different mice. However, 
because actin mRNA levels vary between tissues it does not 
provide a standard for comparing the level of HPRTmRNA in 
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one tissue with the level of HPRT mRNA in another tissue. 
Comparisons between tissues rely on the accuracy with which 
it is possible to load 30ig of RNA per track. Consequently, 
the values derived from densitometric analysis for HPRT mRNA 
levels are intended only to support what visual analysis of 
each signal indicates. Differences of less than 10% of the 
wild-type level are not significant. 
With the exception of lung and spleen the HPRT mRNA levels in 
transgenic tissues are considerably lower than wild-type 
levels. Visual and densitometric analysis indicate that the 
level of the transgene-derived HPRT mRNA in each of liver, 
brain, heart and kidney is less than 10% of the wild-type 
level. There are a few possible reasons for this. The HPRT 
minigene, while having the necessary control signals for 
brain-specific elevation of expression, may lack one or more 
control elements which enhance the absolute level of 
transcription in all cell-types. Sequences which are 
located approximately 50kb 5' of and 20kb 3' of the human - 
globin gene are necessary for wild-type levels of expression 
of a -globin transgene (Grosveld et al., 1987). When 
included in a transgene these sequences confer a position 
independent, copy number dependent, high level of 
expression. It has been suggested that these sequences 
contain nuclear-matrix binding sites and we cannot exclude 
the possibility of analogous sequences at the HPRT locus. In 
the pDWM1LS+127/+135 transgene HPRT introns one to six are 
deleted, only introns seven and eight remain. It is possible 
that one or more of the missing HPRT introns is required for 
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correct expression in transgenic mice, although minigenes 
lacking these introns are efficiently expressed in cultured 
cells (Melton et al., 1986). The HPRT promoter is situated 
within a CpG island, as defined by Bird (1986). Because of 
the absence of the first HPRT intron only half of the CpG 
island is present in pDWM1LS+127/+135. This could 
potentially inhibit transcription either by altering the 
topography or the methylation pattern of the promoter 
region. Alternatively, specific introns may be required for 
correct RNA processing or transport. 
Brinster et al., (1988) reported a 10- to 100-fold higher 
transcriptional efficiency for genes containing introns than 
for the same genes without introns in transgenic mice. It 
was found that the presence of introns in four transgenes 
increased both the frequency of obtaining expression in 
transgenic lines and the level of expression in those lines. 
There was no difference in the level of expression between 
the same genes, with or without introns, in cultured cell 
transformation experiments. Clearly when genes are 
introduced into the mouse germ line, and consequently 
experience the influences of development and 
differentiation, they have additional requirements for 
expression than when introduced into terminally 
differentiated cultured cells. Brinster et al., (1980) 
demonstrated with transcription run-on experiments on 
isolated nuclei that an increased rate of transcription was 
responsible for the increased expression of transgenes 
containing introns. One of the transgenes (human -g1obin) 
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is known to contain an enhancer-like element within an 
intron. However, no similar elements have been identified in 
the introns of the other genes used. In these cases, how the 
presence of introns affects the rate of transcription in vivo 
but not in cultured cells is not known'. Using transgenic 
mice, elements in the first intron of the human ADA gene have 
been identified which are' essential for appropriate 
expression of a reporter CAT gene linked to the ADA promoter 
(Aronow et al., 1989). ADA is a housekeeping gene but 
exhibits a level of expression in the thymus which is 100-
fold higher than most other tissues. An intron region 4 to 
10kb downstream of the first exon contains a complex pattern 
of DNaseI hypersensitive sites which vary according to 
tissue and cell type. The inclusion of this region in 
transgene constructs leads to reproducible, high-levels of 
expression in the appropriate tissues of transgenic mice. 
Alternatively, the level of HPRT transgene expression may be 
low because of an inhibitory effect of the chromosomal 
environment into which it is integrated. The transgene may 
have integrated into a transcriptionally silent region. 
This, the least interesting of the possible explanations, 
could be tested by generating more HPRT transgenic mouse 
lines, in which the integration site would be different. 
Unfortunately only one transgenic line was obtained in this 
experiment, and so position effects cannot be ruled out. 
While the level of HPRT transgene expression in the liver, 
brain, heart and kidney is less than 10% of wild-type levels, 
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the level of HPRT transgene expression in lung, and to a 
lesser extent spleen, is anomalously high. Densitometric 
analysis of Northern hybridisations indicates that in lung 
the level of HPRT transgene expression is at least equal to 
and possibly higher than the wild-type level. The simplest 
explanation for this is that the transgene has integrated 
into a position where it is under the influence of an 
endogenous lung-specific enhancer of transcription. This is 
not entirely compatible with the idea that transgene 
expression is low in most tissues because the integration 
site is in a transcriptionally silent region. In addition, 
the finding that the expression of the mutant HPRT locus 
corrected by gene targeting is also slightly high in lung is 
somewhat provocative. Both the HPRT transgene and the 
corrected HPRT gene have the same 650bp of 5' flanking 
sequence. Although, the degree of lung-specific elevation 
relative to other tissues is considerably less for the 
corrected gene than for the transgene, it is tempting to try 
to formulate a single model which would explain both 
observations. 
The transgenic mouse experiment has demonstrated that the 
regulatory signals responsible for the elevated expression 
of HPRT in mouse brains are contained within the HPRT 
minigene. The interpretation of the expression pattern in 
transgenic mice is complicated by the possibility of 
position effects and effects due to transgene copy number. 
These complications are overcome by using gene targeting in 
ES cells to manipulate and study the expression of the 
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endogenous HPRT gene. 
7.2 	Targeted correction of a mutant HPRT gene in ES cells 
The mutation in the HPRT deficient ES cell line E14TG2a was 
shown to be a deletion of the promoter and first two exons of 
the HPRT gene, and hence cannot revert spontaneously. Using 
gene targeting exons 1 and 2 and 650bp of 5' flanking 
sequence were replaced, thus restoring HPRT activity. 
Targeting vectors have been defined as either sequence 
insertion vectors or sequence replacement vetors (Thomas and 
Capecchi, 1987). When homologous recombination takes place 
sequence insertion vectors integrate without the loss of 
chromosomal sequences and a duplication of the region of 
homology between the vector and the target sequences 
results. Homologous recombination with sequence replacement 
vectors leads to the substitution of genomic sequences for 
vector sequences with no consequent sequence duplication. 
The targeting vector, pDWM101, used to correct the E14TG2a 
deletion is a sequence insertion vector. Thomas and Capecchi 
(1987) have shown that, when the amount of homology with the 
target locus is equivalent, both types of vector are equally 
efficient at gene targeting. It is not possible to construct 
a replacement vector analogue of pDWM101 without first 
cloning genomic sequences from upstream of the E14TG2a 
deletion. 
Before introduction into E14TG2a cells the pDWM101 vector 
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was linearised at a unique restriction site in exon 3, that 
is within the region of homology. In yeast transformation 
experiments the generation of free DNA ends within the region 
of homology increases the frequency of recombination between 
10- and 1000-fold, dependent upon the specific vector used 
(Orr-Weaver et al., 1981). For some vectors linearisation 
outside the region of homology increases the frequency of 
recombination 100-fold but for other vectors no enhancement 
is achieved. In cultured mammalian cells the frequency of 
recombination between autonomously replicating (non-
integrated) plasmids is increased by between 5- and 80-fold 
if a double strand gap is introduced into the region of 
homology (Kucherlapati et al., 1984). 
I have attempted to obtain a value for the frequency of 
homologous recombination events relative to random 
integration events, which we have called the targeting 
index. In our experiments cells were electroporated with 
pDWM100 DNA as a positive control for transformation. 
pDWM100 is derived from pDWM101 but, unlike the targeting 
vector, pDWN100 has the entire'HPRT protein coding region and 
consequently has independent HPRT activity. pDWM100 
restores HPRT activity to E14TG2a cells regardless of the 
integration site, provided that expression is not inhibited 
by the chromosomal environment. In three identical 
electroporation experiments the targeting indexes obtained 
were 0.007, 0.006 and 0.035. HPRT was also the target gene 
in experiments described by Thomas and Capecchi (1987). They 
produced a series of vectors to inactivate the HPRT gene in 
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wild-type ES cells. The inactivating vectors each contained 
a modified bacterial neomycin phosphotransferase (neo) gene 
inserted into the eighth exon of the HPRT gene. The neo gene 
used, pMClNeo, is transcribed from the Herpes simplex virus 
thymidine kinase gene promoter. To improve its expression in 
ES cells it also contains a duplication of a 65bp sequence 
from the PyF441 polyoma virus enhancer and a modified 
translation initiation signal. In addition to disrupting 
the HPRT coding sequence, pMClNeo provides a selectable 
marker for transformation. Cells expressing the neo gene are 
resistant to the drug G418. The number of G418 resistant 
colonies generated per cell electroporated with targeting 
vector DNA in these experiments is analogous to the number of 
HAT  colonies generated per E14TG2a cell electroporated with 
pDWM100 in our experiments. Thomas and Capecchi (1987) 
identified clones in which the HPRT gene had been inactivated 
by gene targeting by resistance to 6-TG. In their 
experiments the number of clones which are both G418  and 6-
TGR expressed relative to the number which are G418  is 
equivalent to what we have called the targeting index. They 
have shown that this frequency is dependent upon the extent 
of sequence homology between the vector and the target locus. 
For sequence replacement vectors frequencies ranged from 
1/40,000 for 4.0kb of sequence homology to 1/950 for 9.1kb of 
homology. Using sequence insertion vectors frequencies 
ranged from 1/19,000 for a vector with 3.7kb of homology,, to 
1/1,100 for a vector with 9.3kb of homology. The highest of 
these frequencies is 10-fold lower than the frequency 
obtained with pDWM101, which has between 2.3kb and 4.2kb of 
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homology with the target HPRT gene. 
The experiments discussed above using the HPRT gene 
demonstrate that gene targeting in ES cells can be achieved 
at a frequency which makes it applicable to genes the 
activity of which is not intrinsically selectable. To 
isolate HPRT correctants we have exploited the systems that 
are available to select both for and against HPRT activity in 
cultured cells. Strategies have also been devised to enrich 
for targeting into non-selectable genes. It is possible to 
enrich for gene targeting events by using a targeting vector 
which contains a modified selectable marker that depends on 
chromosomal sequences at the target site for its expression. 
Sedivy and Sharp (1989) used a neo gene which lacked both 
transcription and translation initiation signals to 
construct targeting vectors for inactivation of a polyoma 
middle T antigen (pmt) gene in the MT-1.4 cell line. MT-1.4 
cells are NIH3T3 cells which contain the oncogenic pmt gene 
as a stable haploid locus. Targeted integration generates a 
pmt-neo fusion protein whereas the majority of integrations 
do not result in neo expression. The neo gene used had the 
additional modification of a 'bridge' peptide derived from 
the amino-terminal end of the chioramphenicol 
acetyltransferase gene. This 'bridge' was intended to 
provide a spacer between the neo enzyme and the potentially 
inhibitive influence of the pmt portion of the fusion 
protein. This strategy gave an approximately 100-fold 
enrichment for gene targeting by reducing the frequency of 
random integrations which lead to G418 R.  In the experiments 
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reported by Sedivy and Sharp (1989) the frequency of targeted 
inactivants per G418 R colony was between 1/100 and 1/1000. 
An additional screening was possible in this instance 
because inactivation of the pmt gene lead to a reversal of 
cell morphology to the parental non-transformed phenotype. 
A significant proviso for this strategy is the requirement 
that the target gene is expressed, for transcription and 
translation of the neo gene. 
In similar experiments Dorin et al., (1989) achieved 
targeted integration of a neo gene into the SV40 large T 
antigen. As in the experiments described previously G418 
resistance depended upon endogenous promoter elements and 
read-through transcription. These experiments were 
performed in C121, a human-mouse hybrid cell line in which 
the SV40 large T antigen is constitutively expressed from an 
SV40 array integrated on human chromosome 7. In this 
instance the strategy was particularly successful and 
further analysis of G418 resistant colonies using the 
polymerase chain reaction (PCR) and Southern hybridisations 
showed that 3 out of 11 G418 R clones were correctly targeted. 
As the authors note, this high frequency may be peculiar to 
this experiment perhaps as a result of the multiple copies of 
the T antigen gene present in these cells or as a result of 
the possible recombinogenic function of the SV40 T antigen 
protein. Subsequently, the neo marker on chromosome 7 of the 
targeted clones was exploited to generate human-mouse 
hybrids that contained the target locus and just a small 
fragment of chromosome 7 in chromosome-mediated gene 
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transfer experiments. This may provide a general strategy 
for isolating new regions of the human genome. Jasin and 
Berg (1989) have also achieved enrichment for gene targeting 
by using a defective gene as the positive selectable marker. 
Their target gene was the single integration of the SV40 
early region transcription unit in COS1 cells. As the 
selectable marker the targeting vectors contained the 
bacterial xanthine-guanine phosphor ibosyltransferase (gpt) 
gene, which can be selected for with mycophenolic acid. The 
gpt gene in the targeting vectors has the SV40 early region 
promoter but is transcriptionally impaired due to the 
absence of an enhancer. Homologous integration into the SV40 
locus provides the gpt gene with the SV40 early region 
enhancer and thus restores transcriptional activity. Hence, 
only clones in which homologous recombination had occurred 
or in which the gpt gene had fortuitously integrated into 
another region with activating properties, would become 
mycophenolic acid resistant. The use of the 
transcriptionally defective gpt gene reduced the number of 
mycophenolic acid resistant clones with random integrations 
to approximately 100-fold less than obtained with a fully 
active gpt gene. Southern blot analysis of mycophenolic acid 
resistant clones obtained in six calcium phosphate 
transfection experiments revealed that 25 of 57 were 
homologous recombinants. To study its role in mammalian 
development Joyner et al., (1989) have inactivated the En-2 
gene in mouse ES cells. En-2 is the mouse homologue of the 
Drosophila gene engrailed, which is thought to have a role in 
establishing spatial domains in the developing brain. The 
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strategy they used combined selection for the neo gene with 
screening by PCR. The neo gene Joyner et al., (1989) used had 
independent transcriptional activity due to the presence of 
500bp from the human -actin promoter, and therefore acted as 
a marker for transformation. In the targeting vector, a 
sequence replacement vector, the neo gene was flanked by 3kb 
of homology with the target gene on one side and 700bp on the 
other. The vector was introduced into ES cells by 
electroporation and selection for the neo gene was applied. 
PCR was used to identify targeted clones in pools of G418 
resistant colonies. The two oligonucleotide primers for PCR 
were designed so that amplification could occur only if 
targeted integration had occurred. That is, one primer was 
positioned in the neo gene while the other was positioned in 
the target En-2 locus, outside the region of homology. In 
targeted clones PCR generates an 800bp fragment. In any 
integration other than homologous recombination the primers 
will not be in the correct arrangement to initiate the PCR 
amplification. 
It is generally believed that ES cells are more likely to 
retain their pluripotency if in vitro manipulations are kept 
to a minimum. Joyner et al., (1989) used a strategy which 
avoids the large number of rounds of colony pooling necessary 
in standard sib-selection schemes. Electroporated cells 
were plated at -a dilution to produce approximately ten G418  
colonies per dish. A few hundred cells were picked from each 
colony, pooled, subjected to PCR and analysed for the 
presence of the 800bp fragment diagnostic of gene targeting. 
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Having identified a positive plate colonies were screened 
individually by PCR, and positives were checked by Southern 
analysis. 	The frequency of homologous recombination in 
three experiments was one event per 260 G418  	ES cell 
colonies. 	The highest frequency obtained by Thomas and 
Capecchi (1987) in HPRT inactivation experiments using a 
transcriptionally active neo gene was 1/1000. The frequency 
of random integrations leading to G418  may be lower in the 
En-2 experiment due to the absence of polyadenylation 
signals in the neo gene. AlsO the human -actin promoter is 
weaker than the promoter in pMClNeo. Zimmer and Gruss (1989) 
used PCR alone to screen for targeted clones among cells into 
which vector DNA had been introduced by nuclear 
microinjection. They inactivated the homoeobox Hox 1.1 gene 
in ES cells with the aim of producing mice deficient for this 
function, to elucidate its role in development. The 
targeting vector used contained a minimal amount of non-
homology with the target Hox 1.1 gene, consisting of a 
genomic subclone with a 20bp oligonucleotide introduced at 
one site. The oligonucleotide has two functions. Firstly, 
it changes the reading frame of the lox 1.1 protein coding 
region and consequently leads to premature translation 
termination. Secondly, it provides a site for a PCR primer. 
The second PCR primer is unique to the target gene. Only the 
gene structure which results from homologous recombination 
can give an amplified fragment of 1.1kb from PCR. The 
average frequency of gene targeting that Zimmer and Gruss 
(1989) obtained was 1 event per 150 microinjected cells. The 
authors believe that this represents a ratio of homologous to 
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illegitimate recombination of 1:30, assuming that 20% of 
microinjected cells become stably transformed (Capecchi, 
1980). Although the microinjection procedure is labour 
intensive, it would seem to be practical due to the high 
-targeting frequency it apparently generates. A different 
strategy to enrich for gene targeting events has been 
described by Mansour et al., (1988). In addition to enabling 
selection for cells which have integrated vector DNA, this 
procedure allows selection against cells in which vector DNA 
has integrated non-homologously. The positive selection is 
provided by pMClNeo (Thomas and Capecchi, 1987). This neo 
gene construct which has independent activity is positioned 
in the targeting vector so as to be flanked by sequences with 
homology to the target locus and disrupt the coding sequence 
of the target gene. G418' can result from both random and 
homologous integrations. To enrich for gene targeting a 
negative selectable marker is built into the targeting 
vector outside the region of homology with the target locus. 
Flansour et al., (1988) used the Herpes simplex virus 
thymidine kinase (HSV-tk) gene, with the same promoter and 
enhancer combination used in pMClNeo, as the negative 
marker. Cells which express HSV-tk are selectively killed in 
medium containing 2 x 10 6M gancyclovir (GANC). Because the 
HSV-tk gene is outside the region of homology with the target 
locus when homologous recombination occurs the HSV-tk gene 
does not integrate into the genome. Consequently, cells in 
which gene targeting has occurred do not express HSV-tk and 
are not sensitive to GANC. If targeting vector DNA 
integrates randomly the HSV-tk gene becomes stably 
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integrated into the genome, and cells in which this occurs 
can be selectively killed by GANC. Thus gene targeting 
events are enriched for by selection of transformed cells in 
G418 and GANC. Mansour et al., (1988) tested this strategy 
by inactivating the HPRT gene which can be directly selected 
for using 6-TG. Out of 24 clones isolated by G418 and GANC 
selection, 19 were shown to be homologous recombinants. 
Thus, the positive-negative selection procedure provides a 
2000-fold enrichment relative to positive selection for 
pMClNeo alone (Thomas and Capecchi, 1987). The same strategy 
was used to inactivate the int-2 proto-oncogene (Mansour et 
al., 1988). Four clones were identified with targeted 
inactivation from 81 G418 R, GANCR clones tested. Cells with 
random integrations can survive GANC selection if the site of 
integration inhibits HSV-tk expression or if the HSV-tk gene 
acquires a mutation. The authors claim that the addition of 
a large stretch of non-homology at one end of the integrating 
vector does not affect the efficiency of homologous 
recombination, which conflicts with evidence discussed 
earlier from transformation experiments in yeast (Orr-Weaver 
et al., 1981) and mammalian cells (Kucherlapati et al., 
1984). 
Comparisons between targeting frequencies obtained in 
different experiments are complicated by different selection 
systems, different extents of homology, different cell types 
and so forth. However, it is clear that there are locus 
specific 	variations. 	It 	is 	possible 	that 	the 
transcriptional activity of a gene can influence its 
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accessibility to targeting vector DNA. 	Recent work 
described by Johnson et al., (1989) suggests this is not the 
case. Using the positive-negative selection system (Mansour 
et al., 1988) they compared the frequencies of obtaining 
targeted inactivation of three genes. The three genes were 
c-fos, which is expressed at a low level in ES cells, and 
adipsin and adipocyte P2 ( aP2 ) which are not expressed at 
detectable levels in ES cells. No difference was found in 
the frequency of homologous recombination between these 
genes. The number of targeted inactivants per G148 R clone 
for each gene was comparable to that for HPRT (Thomas and 
Capecchi, 1987). Of more practical significance between 5 
and 10/ of the colonies which were both G418 R  and GANC R were 
targeted. This result is particularly important because it 
means that targeted manipulation of the mouse germ line is 
not confined to genes that are expressed in ES cells. 
I have presented the results of the structural analysis of 
the HPRT gene in 22 HAT   clones obtained in the targeted 
correction experiments. In twenty of these clones the HPRT 
gene had the predicted structure, which we have called type 
1. One example was found of each of two unpredicted 
structures, called type 2 and type 3. The type 3 structure 
has two copies of the correcting vector integrated in tandem. 
In the type 2 structure there has been a small deletion of the 
upstream copy of the duplicated exon 3. This deletion is in 
the region of homology between the targeting vector and the 
chromosomal gene where recombination is initiated. Small 
deletions have also been observed in HPRT inactivation 
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experiments (Doetschman et al., 1988) using a replacement 
vector with a neo gene inserted into the third exon. 
Southern analysis of six targeted inactivants showed that in 
two an EcoRI site at the upstream end of vector sequences was 
absent. The structure of all six targeted clones was 
analysed further by amplifying the upstream boundary between 
vector and chromosome by PCR and subsequent sequencing. The 
two clones lacking the EcoRI site had small deletions (14bp 
and 37bp) which were immediately 5' to the region of 
homology. These small deletions and the type 2 structure we 
have charicterised were only identified because they deleted 
one of the restriction sites used in Southern analysis. It 
is possible that such deletions occur at a high frequency but 
go undetected. The deletions observed by Doetschman et al., 
(1988) may be the result of the low amount of homology 
between the vector and the target gene at this end of the 
vector (132bp). 
Clearly the technology now exists for introducing defined 
mutations into any gene in ES cells provided a genomic clone 
is available. We have demonstrated the feasibility of 
introducing targeted modifications into the mouse germ line. 
This provides a powerful approach for studying mammalian 
gene expression. The function of putative gene regulatory 
sequences can be tested directly by targeting mutations to 
them. Gene targeting used in conjunction with transgenic 
mice should allow very sophisticated gene expression 
studies. Of course, it is also possible to produce mice with 
mutations in any gene which has been identified as defective 
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in a human genetic disease. Thus, mouse models for inherited 
diseases of man can be generated to provide a system for 
testing new therapies. In particular, the development of 
somatic gene replacement therapies should benefit from both 
the availability of mouse models for diseases and the ability 
to make targeted gene corrections. 
In addition, the targeted inactivation of a gene is the best 
way to determine its function if this is not known. This 
strategy is being attempted for many genes thought to have a 
role in development. Recently, the generation of mice with 
a germ line mutation of the c-abl gene has been reported 
(Schwartzberg et al., 1989). Targeted mutation of the c-abl 
gene in ES cells was achieved using a replacement vector 
containing a promoterless neo gene. On average, 1 in 34 
G418  clones were homologous recombinants. Nice 
heterozygous for the c-abl mutation show no mutant 
phenotype. The c-abl gene product is believed to be involved 
in signal transduction. The usefulness of these mice may be 
greatly limited if hornozygosity of the mutation is lethal 
early in development. Disruption of the 2-microglobulin ( 
2-rn) gene has also been achieved and introduced into the 
mouse germ line (Zijlstra et al., 1989). The 2-rn gene 
product is a component of MHC class 1 molecules which have a 
number of functions in the immune system and probably a 
number of other unidentified reactions. Zijlstra et al., 
(1989) used a targeting vector containing a neo gene, which 
lacked polyadenylation signals, to inactivate the 2-m gene. 
PCR was used to isolate ES cell clones with the targeted 
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inactivation. 	One out of twenty five of the G418  clones 
obtained were targeted inactivants. This frequency is high 
and may reflect the presence of a recombination hotspot. In 
addition the lack of polyadenylation signals in the neo gene 
enriches for targeting events approximately fourfold. Six 
male chimeras were obtained which transmitted the disrupted 
2-m gene to their offspring. Nice heterozygous for the 
mutation are phenotypically normal. Homozygotes have yet to 
be generated. 
7.3 	Expression of the corrected HPRT gene 
The expression of the corrected HPRT gene has been analysed 
both in cultured ES cells and in male and female mice. The 
quantification of HPRT mRNA and problems associated with it 
have been discussed in the context of HPRT expression in 
transgenic mice. In cultured ES cells containing the 
corrected gene the level of HPRT mRNA is approximately 
threefold lower than in ES cells containing the wild-type 
gene. In mice with the corrected HPRT gene the level of HPRT 
mRNA in liver, brain, heart and kidney is between 2- and 3-
fold lower than in wild-type mice. However, while the 
absolute level of HPRT mRNA in these tissues is low the wild-
type pattern of relative levels is maintained. That is liver 
has the lowest HPRT mRNA level, kidney and heart have higher 
levels, and HPRT mRNA is most abundant in brain. Like the 
HPRT transgene pDWM1LS+127/+135 the corrected gene contains 
the regulatory information for elevated levels of expression 
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in brain. 	Both the transgene and the corrected gene have 
635bp of 5' flanking sequence. 	Both genes also have the 
natural HPRT 3' untranslated region. 
As for the transgene, there are a number of possibilities why 
the corrected gene is expressed at a lower level than the 
wild-type gene. 	Firstly an important enhancer of 
transcription may be absent. 	The region from 635bp to 
greater than 12kb upstream of the wild-type gene is deleted 
in the corrected allele. Furthermore, 6.7kb of sequence is 
deleted from the first intron of the corrected gene. A 
second possibility is that as a result of the upstream 
deletion new sequences are brought into proximity with the 
HPRT promoter and these may have an inhibitory effect on 
transcription. The corrected gene has 2.7kb of prokaryotic 
vector DNA upstream of the 635bp of HPRT 5' flanking 
sequence. The expression of certain genes in transgenic mice 
is strongly inhibited by prokaryotic sequences (Jaenisch 
1988). 
While the level of H.PRT mRNA from the corrected gene is low 
in liver, brain, heart and kidney, in lung the level of HPRT 
mRNA is close to the wild-type level. The degree to which 
lung tissue is different from other tissues in corrected mice 
is small in comparison with the lung specific elevation in 
transgenic mice. The corrected gene is in the natural HPRT 
location on the X-chromosome and therefore is not subject to 
position effects to the same extent as a transgene. However, 
as a result of the deletion in E14TG2a new sequences are in 
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proximity with the promoter of the corrected gene and these 
could be responsible for the reduced absolute level of 
expression in most tissues and the higher level of expression 
in lung. If the same mechanism is causing the elevated HPRT - 
expression in the lung of both transgenic and corrected mice 
it must be a property of the 635bp of 5' flanking sequence. 
This is the only characteristic which is different from the 
wild-type gene but common to both the corrected gene and the 
transgene. Perhaps the end point of the upstream flanking 
sequence is within a regulatory region. Enhancers are 
modular (Dynan, 1989), they consist of multiple overlapping 
binding sites for different transcriptional activator 
proteins with different tissue specificities. The loss of 
part of a regulatory region may alter its transcription 
enhancing properties. Alternatively, there may be a lung 
specific repressor of transcription upstream of -635bp, 
which is not present in either the transgene or the corrected 
gene. However, the difference in the degree of the lung-
specific elevation of HPRT expression between the corrected 
gene and the transgene perhaps implies that the causal 
mechanisms are different, and that their coincidence is 
merely a red herring. 
7.4 	Concluding Remarks 
We have demonstrated that the brain-specific elevation in 
HPRT enzyme activity in mice (Lo and Palmour, 1979) 
correlates with an elevation in levels of HPRT mRNA. We have 
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also shown that no more than 635bp of 5' flanking sequence is 
required to achieve the elevated expression in brain tissue. 
The interesting possibility that the variations in HPRT 
activity between tissues are regulated by the HPRT 3' 
untranslated region invites further investigation. Using 
gene targeting in ES cells it will be possible to make 
precise alterations to the HPRT 3' untranslated region and 
subsequently observe the effect on the tissue dependent 
variations in HPRT mRNA levels. It will also be interesting 
to analyse the rate of HPRT transcription and HPRT mRNA 
degradation in different tissues. We would predict that 
targeted manipulations of the 3' untranslated region would 
affect mRNA stability rather than the rate of transcription. 
Very sophisticated manipulation and investigation of HPRT 
gene expression is now possible. 
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Summary 
The deletion mutation in the HPRT-deficient mouse 
embryonic stem (ES) cell line E14TG2a has been cor-
rected by gene targeting. The presence of plasmid se-
quences in the correcting vector DNA did not affect 
the frequency of correction. We have characterized 
three different HPRT gene structures in correctants. 
Cells from one corrected clone have been introduced 
into mouse blastocysts, and germ line transmission of 
the ES cell-derived corrected gene has been achieved. 
The corrected gene has the same pattern of expres-
sion as the wild-type gene, with the characteristic 
elevated level of expression in brain tissue. Hence, we 
have demonstrated the feasibility of introducing tar-
geted modifications into the mouse germ line by ho-
mologous recombination in ES cells. 
Introduction 
A strategy enabling precise modifications to be made to 
the mammalian genome would be of benefit both to bio-
logical and medical research. It would become possible 
to manipulate the expression of genes by targeting 
changes to their control sequences. This would be of 
value to the study of gene expression. It could also be of 
potential commercial value if used, for example, in live-
stock animals to increase output, or produce novel ma 
terials. In addition, genes could be inactivated to create 
animal models for human genetic diseases or to study the 
action of developmental genes, while the ability to correct 
mutant genes has implications for gene therapy. An ad-
vantage of being able to target modifications is that genes 
are manipulated in their natural chromosomal environ-
ment, whereas the use of conventional methods for in-
troducing DNA sequences into the germ line (Jaenisch, 
1988) allows no control over the chromosomal site of in-
tegration or the number of copies introduced. At the very 
least, this complicates the interpretation of gene expres-
sion studies and may result in insertion, either into sites 
that are inappropriate for expression or into essential 
genes, with deleterious consequences. 
Several recent advances have made gene targeting in 
the mammalian genome possible. Here we report the 
generation of mice that show germ line transmission of a 
targeted gene modification. This has been achieved using 
homologous recombination in , mouse embryonic stem 
(ES) cells. 
Mouse ES cells can be cultured in vitro and still retain 
their pluripotency (Evans and Kaufman, 1981; Martin, 
1981). These cells, when reintroduced into mouse blasto-
cysts, can contribute to the germ line of the resultant 
chimeras (Bradley et al., 1984). ES cells deficient for the 
enzyme hypoxanthine—guanine phosphoribosyltransferase 
(HPRT; I M P:pyrophosphate phosphoribosylt ran sferase; 
EC 2.4.2.8) have been used to produce mice that transmit 
the same enzyme deficiency through their germ line 
(Hooper et al., 1987; Kuehn et al., 1987). The pathology of 
this deficiency is interesting because in humans the result 
is the severe neurological disorder Lesch—Nyhan syn-
drome (Lesch and Nyhan, 1964; reviewed in Stout and 
Caskey, 1988). Consequently, it is noteworthy that, in nor-
mal individuals, HPRT expression is elevated in brain rela-
tive to other tissues. Hooper et al. (1987) selected for spon-
taneous HPRT-deficient ES cells in culture. Kuehn et al. 
(1987) used multiple retroviral infection of cultured ES 
cells to promote insertional mutation, and subsequently 
selected for HPRT-deficient clones. Neither procedure 
abolished the ability of the mutant ES cells to contribute 
to germ line chimerism. 
Gene targeting, mediated by recombination between 
introduced vectors and homologous chromosomal se-
quences, has been employed in ES cells both to inactivate 
gene function (Thomas and Capecchi, 1987) and to cor-
rect the activity of a mutant gene (Doetschman et al., 
1987). In both cases the target gene was H PAT, which has 
the advantage that it is possible to select either for, or 
against, activity while the ES cells are in culture. Addi-
tional advantages of the system are that the gene is X-linked 
and is therefore hemizygous in male cells, and the struc-
ture of the gene is well characterized (Melton et al., 1984). 
In their gene inactivation experiments, Thomas and Capec-
chi (1987) used vectors containing a modified neomycin 
resistance (neoR)  gene inserted into the eighth exon of 
the HPRT gene. The neoR  gene has the dual function of 
disrupting the HPRT coding sequence and providing an 
additional selectable marker. Homologous recombination 
between such a vector and the chromosomal HPRT gene 
results in the inactivation of the chromosomal gene. Thomas 
and Capecchi (1987) described targeting vectors as either 
sequence replacement or sequence insertion vectors, de-
pending on their mechanism of integration, and found that 
both types worked with similar efficiencies. 
We have previously described the targeted correction of 
an HPRT-deficient ES cell line, E14TG2a, using homolo-
gous recombination (Doetschman et al., 1987). E14TG2a 
was used by Hooper et al. (1987) to produce HPRT-
deficient mice. The characterization of the mutation in 
E14TG2a is presented here. We describe the use of se-
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Figure 1. Targeted Correction of the Deletion in E14TG2a Cells and 
Correctant Structures 
The structures of the wild-type HPRT gene, the E14TG2a deletion, the 
two correcting vectors, and the three correctant types are shown sche-
matically. Closed boxes, endogenous exons; thick closed lines, endog-
enous introns; cross-hatched boxes, promoter regions; thin lines, 
HPRT flanking sequences; jagged line, distant flanking sequence 
brought into proximity as a result of the deletion in E14TG2a; open 
boxes, vector-derived exons; open thick lines, vector-derived introns; 
closed intermediate thickness lines, plasmid sequence. The number 
of each exon is shown directly above it. Selected restriction sites are 
shown: R, EcoRl B, BamHl; X, Xhol. The sizes (in kb) of all EcoRl and 
BamHl restriction fragments containing exon elements are shown be-
tween the restriction sites. The thick closed broken line in the type 2 
and 3 correctants denotes that beyond exon 3, they have the same 
structure as type 1 correctants. With the exception of the plasmid in 
the correcting vectors and the exon elements themselves, the same 
scale is used throughout. 
in E14TG2a, and the identification of three types of cor-
rected clone. Cells from one corrected clone have been in-
jected into mouse blastocysts, and have successfully con-
tributed to the germ line of a chimeric mouse. We have 
crossed this germ line chimera with HPRT-deficient mice 
in order to analyze expression from the corrected gene. 
The corrected gene shows levels of expression equivalent 
to the normal gene, with the same characteristic elevation 
in brain. 
Results 
Characterization of the E14TG2a Mutation 
The structure of the wild-type mouse HPRT gene is shown 
schematically in Figure 1. The coding sequence of the 
gene is divided into nine exons that span approximately 
33 kb of the X chromosome (Melton et al., 1984). We have 
used Southern blot hybridization to characterize the muta-
tion in the male ES cell line E14TG2a, which is deficient 
for HPRT enzyme activity. Tha restriction enzyme sites 
used in this analysis are shown in Figure 1. Southern hy-
bridization of DNA from the wild-type ES cell line E14 and 
from E14TG2a, using a full-length mouse HPRT cDNA 
probe, is shown in Figure 2A. The sizes of the bands are 
indicated, and theexon elements they contain can be 
seen in Figure 1. In the EcoRl-digested E14TG2a lane the 
6.3 kb band, which contains exon 1, and the 5.5 kb band, 
which contains exon 2, are both absent. In the BamHl di-
gest of E14TG2a the doublet band, consisting of the 11.5 
kb fragment, which contains exon 1, and the 11.9 kb frag-
ment, which contains exons 5 to 9, is reduced in intensity 
relative to the wild-type band. The 7.0 kb BamHl fragment, 
which contains exons 2 and 3 of the wild-type gene, is 
replaced by a 9.5 kb band containing exon 3. From these 
results we infer that the mutation in E14TG2a is a deletion 
spanning exons 1 and 2 of the HPRT gene. Using a PvulI 
digest (data not shown) we have mapped the 3' end of the 
deletion to between 1.0 kb and 2.9 kb upstream of exon 3. 
We have used probes from the region flanking the HPRT 
gene to show that the 5' end of the deletion is at least 10 
kb upstream of the gene (data not shown). 
Since the wild-type allele present in strain 129 mice is 
Hprtb, in accordance with the rules of the International 
Committee for Standardized Genetic Nomenclature for 
Mice (Mouse News Letter 72, 2-27, 1985) we designate 
the mutant allele present in E14TG2a as hprtbm3. 
Correction of the E14TG2a Mutation 
by Gene Targeting 
To correct the mutation in E14TG2a we constructed the se-
quence insertion vector pDWM101 (see Figure 1 and 
Experimental Procedures for details of construction). 
pDWM101 contains mouse exons 1, 2, and 3 and the 
mouse HPRT promoter. The exon 3 region provides ho-
mology with the target locus. The extent of homology be-
tween the targeting vector and the genome is between 2.3 
kb and 4.2 kb, depending on the precise 3' endpoint of the 
deletion. pDWM101 contains 650 bp of upstream flanking 
sequence, which is sufficient for HPRT expression in cul-
tured cells (Melton et al., 1986). The anticipated outcome 
of correction has the same structure as the wild-type gene, 
except that the first intron is reduced from 10.8 kb to 4.1 
kb (see Figure 1). The targeted locus has a restriction map 
distinct from both the wild-type gene and the deletion mu-
tant, and thus enables correctants to be identified by 
Southern analysis. We have called the predicted structure 
type one (see Figure 1). In the EcoRl restriction map a 
novel 10.4 kb fragment is generated, containing exons 1 
and 2, and the 1.3 kb band, containing exon 3, is dupli-
cated. In the BamHI restriction map a 14.0 kb fragment, 
containing exon 1 and the duplicated exon 3, is generated 
and the 9.5 kb band, containing exon 3, is replaced by the 
wild-type 70 kb band which contains exons 2 and 3. The 
70 kb and the 14.0 kb bands are the products of one 
BamHl site in the vector and one BamHl site in the ge- 
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Figure 2. Southern Analysis of E14TG2a and 
kb 
Correctant DNA 
Genomic DNA (10 hg) was restricted with 
-14-0/PG  B-9/ 117/115 EcoRl or BamHl, electrophoresed, transferred, 
70 and hybridized. Probes: In (A), a full-length 
-g HPRT cDNA probe was used. In (B), the same 
transfer was reprobed with pUC8. DNA: +, 
E14; A, E14TG2a; 1, a type 1 correctant; 2, type 
2-1; 3, type 3-1. Both a long and a short ex- 
- posure of-EcoRl-digested CorreCtant DNA are 
included in (A). The sizes (in kb) of hybridizing 
bands are shown adjacent to each panel. The 
fragments containing the HPRI pseudogene 
sequences are indicated by PG. The exon ele- 
ments present in each band can be determined 




nome. While the 70 kb band is also present in the wild-
type gene, the 14.0 kb band is diagnostic for targeted cor -
rectants. 
To promote recombination, the vector was linearized at 
the unique Xhol site in exon 3 prior to being introduced 
into E14TG2a cells by elect roporation. The conditions cho-
sen were those that resulted in minimal cell death in con-
trol plating experiments. Correctants were selected in HAT 
medium. Cells only become HATR if the correct targeting 
event takes place between pDWM101 and the defective 
HPRT gene. As a positive control E14TG2a cells were 
electroporated with pDWM100, a fully functional HPRT 
minigene derivative of pDWM101, which can rescue HPRT-
deficient cells without the requirement for homologous 
recombination. 
In the first experiment, which used late-passage stem 
cells, eight HATR  colonies were generated from 4.6 x 10 
cells electroporated (see Table 1). The ratio of HATA  colo-
nies obtained from cells electroporated with pDWM101 to 
HAIR colonies obtained from cells transformed with 
pDWM100 was 0.007 (see Table 1, targeting index). This 
frequency gives an indication of the number of targeting 
events relative to the number of random integrations, al-
though it does not take into account integrations of 
pDWM100 into sites that inhibit expression. Southern hy-
bridization showed that seven of the eight HATR  clones 
had the structure predicted for type 1 correctants (see Fig- 
ure 2). In the EcoRl digest the new 10.4 kb band is visible, 
and the intensity of the 1.3 kb band is doubled with respect 
to the equivalent band in the E14TG2a lane. The intensity 
of the pseudogene band (Isamat et al., 1988) in the EcoRl 
digests allows comparison of the relative loading of each 
lane, thus acting as an internal control. In the BamHl 
digest the disappearance of the 9.5 kb fragment, charac-
teristic of the deletion, and the regeneration of the 7.0 kb 
wild-type band can be seen. The presence of the 14.0 kb 
fragment, which comigrates with the pseudogene frag-
ment, is indicated by the increased intensity of the band 
at that molecular weight. 
One HATR  clone had the structure we have called type 
3 (see Figure 1). This clone has two correcting vectors in-
tegrated in tandem. The effect on the restriction map is 
that, in an EcoRl digest, the 10.4 kb fragment is duplicated 
and there are three copies of the 1.3 kb fragment com-
pared with two copies in type 1 correctants and one copy 
in the deletion mutant. This is evident in the relative inten-
sities of these bands in Figure 2A. In a BamHl digest the 
14.0 kb and 7.0 kb fragments, seen in type 1 correctants, 
are present but there is an additional 11.7 kb, vector-sized 
fragment. This can be seen more clearly in Figure 2B, 
which shows a pUC8 reprobe of the transfer in Figure 2A. 
The pUCB sequence is present within the 10.4 kb EcoRl 
band, and consequently the intensity of this band is dou-
bled in type 3 DNA relative to type 1. In a BamHl digest 
Table 1. Summary of Correction Experiments 
Correcting 	Number of HATR 	Frequency of HPRT 	
Correctant Types 
Experiment 	Vector 	Colonies 	 Correctantsa 	 Positive Control" 	Targeting lndexc 	1 	2 	3 
1 	 pDWM101 8 1.75 x 10 2.5 x iO 0.007 	 7 	- 	 1 
2 pDWM101 2 4.0 x 10-8 6.4 x 10-6 0.006 1 1 - 
3 	 pDWM101 12 2.2 x 10 6.3 x 10-6 0.035 	 12 	- 	 - 
pDWM102 8 1.5 x 	iO 6.3 x 10-6 0.024 8 - 	 - 
Number of HATR  colonies generated per cell electroporated with correcting vector DNA. 
b Number of HAIR  colonies generated per cell electroporated with pDWM100 DNA. 
Frequency of HAIR  colonies generated per cell electroporated with correcting vector DNA relative to HAIR  colonies generated per cell elec-
troporated with pDWM100 DNA (a/b). 
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the pUC8 fragment is present in both the 14.0 kb band and 
the 11.7 kb band. This is diagnostic for the type 3 struc-
ture. The equal intensities of the 14.0 kb and 11.7 kb bands 
in the type 3 lane show that there are two copies of the 
vector integrated. If there were more than two copies the 
intensity of the 11.7 kb band would be at least twice that 
of the 14.0 kb band. There was no evidence either from 
these correctants, or from any of the others we have exam-
ined subsequently, for any random integrations of thecor-
recting vector, which would have been detected as addi-
tional bands hybridizing to the pUC8 probe. 
To generate a corrected ES cell line suitable for rein-
troduction into mouse blastocysts, a second experiment 
was performed using low-passage E14Tt32a cells. pDWM101 
was used as the targeting vector; electroporation of 5 x 
107 cells produced two HATR  clones (see Table 1). South-
ern analysis was used to determine the structure of the 
HPRT gene in these correctants. One clone had a struc-
ture indistinguishable from the seven type 1 correctants 
generated in the first experiment, and so was called type 
1-8. The second HAIR  clone had a subtly different pat-
tern, which we have called type 2 (see Figures 1 and 2). 
In this clone, the exon 3-containing 1.3 kb EcoRl band has 
the same intensity as in the E14TG2a lane, indicating that 
exon 3 is not duplicated. In addition, the intensity of the 
14.0 kb BamHl band is lower than in type 1 correctants, 
although the size of the band is not visibly different at this 
resolution. An XhoI digest for this clone shows that the 
Xhol site in the upstream copy of exon 3 is absent (data 
not shown). The presence of the 10.4 kb EcoRl band indi-
cates that the EcoIRl site immediately upstream of the 
plasmid sequence is present. From this we infer that this 
clone, correctant type 2-1, has the targeting vector in-
serted correctly, but a small deletion has occurred to re-
move the upstream copy of exon 3. Therefore in this cor-
rectant, unlike type 1 correctants, there is no exon 3 
duplication. This does not affect the HPRT-positive status 
of the clone because the deleted exon is not part of the 
functional gene. 
Frequency of 6-Thioguanine Resistant Cells 
in Correctant Populations 
To assay the frequency of HPRT- cells in the two correc-
tant populations (type 1-8 and type 2-1) generated in the 
second experiment, cells were grown in the absence of 
selection for 2 weeks, and then their plating efficiency in 
medium containing 6-thioguanine (6-TG), relative to their 
plating efficiency in nonselective medium, was measured. 
The relative plating efficiency for type 2-1 was 0.03%, 
which is approximately the same as the figure obtained for 
wild-type ES cells. However, the relative plating efficiency 
for type 1-8 was 21.0%; that is, after 2 weeks of growth in 
nonselective medium, 21.0% of the cell population in the 
type 1-8 culture was HPRT deficient. 
To analyze further the presence of 6TGR  cells in the 
type 1-8 population, we used Southern hybridization to ex-
amine DNA from cells grown under different selection 
conditions. The structure of the gene in DNA prepared 
from the type 1-8 culture grown nonselectively for 24 days  
was indistinguishable from the E14TG2a deletion struc-
ture. Thus, when selection is removed from the type 1-8 
culture, cells containing the corrected gene are rapidly 
replaced by 6TGR  cells which are 6TGR  because their 
HPRT gene has the E14TG2a structure. This could be due 
to the persistence in the HATR  culture of E14TG2a cells, 
surviving, since the original isolation of the correctant 
clone, by metabolic cooperation (Hooper, 1982). Alterna-
tively, 6TGR  cells might arise by loss of vector sequences 
from corrected cells, due to a reversal of the original ho-
mologous recombination (correcting) event. These possi-
bilities are under investigation. Whatever the reason, it 
was deemed inappropriate to use the type 1-8 culture as 
a source of cells for blastocyst injections. Hence, the cor-
rectant type 2-1 was chosen for introduction into mouse 
blastocysts (see below). 
The Effect of Plasmid Sequences 
on Targeting Efficiency 
The use of the targeting vector pDWM101 results in the in-
tegration of plasmid sequences into the genome. To deter-
mine whether the incorporation of plasmid sequences 
was detrimental to the efficiency of gene targeting, a third 
experiment was performed (see Table 1). In this experi-
ment E14TG2a cells were electroporated with either 
pDWM101 or pDWM102 DNA (see Figure 1 and Experimen-
tal Procedures for details of construction). pDWM102 con-
tains precisely the same HPRT gene-derived sequences 
as pDWM101, but they are rearranged so that when 
pDWM102 DNA is restricted with Xhol the pUC8 sequences 
are excised. Consequently, correctants generated with 
this vector do not have pUC8 sequences integrated into 
the genome. The predicted, ;type 1, restriction map for 
pDWM102 correctants differs from that for pDWM101 cor-
rectants in the following ways: in the Ec0RI restriction map 
the 10.4 kb and the duplicated 1.3 kb fragments seen in 
pDWM101 correctants are replaced by a fragment of 9.0 
kb, which is equal to their combined size minus the size 
of pUC8 (2.7 kb), due to the absence of the EcoRl site im-
mediately upstream of the promoter (see Figure 1). In a 
BamHl digest the loss of pUC8 and the gain of a BamHl 
site upstream of the promoter results in the replacement 
of the 14.0 kb fragment by a 3.0 kb internal fragment and 
an 8.3 kb fragment extending into the upstream flanking 
sequence. A comparison of the Southern hybridization 
patterns for BamHl-digested DNA from type 1 correctants, 
generated with pDWM101 and pDWM102, is shown in 
Figure 3. 
In the third experiment, 12 HATR  colonies were gener-
ated from cells electroporated with pDWM101 and eight 
correctants were generated from cells electroporated with 
pDWM102 (see Table 1). The frequency of gene targeting 
relative to random integrations, calculated as for pre-
vious experiments, was 0.035 for pDWM101 and 0.024 for 
pDWM102. Thus we conclude that the presence of plas-
mid sequences in the targeting vector does not affect the 
frequency of gene targeting. All correctants generated in 
this experiment had the typel gene structure. 
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Figure 3. Comparison of Type 1 Correctants Produced by Correcting 
Vectors pDWM101 and pDWM102 
Genomic DNA (10 rag) was restricted with BamHl and probed with an 
HPRT cDNA probe. DNA: +, E14; A, E14TG2a; 102, a pDWM102 type 
1 correctant; 101, a pDWM101 type 1 correctant. The sizes (in kb) of 
the hybridizing bands are shown. The pattern is explained in the text. 
Production of Chimeric Mice 
Cells from the correctant clone type 2-1 were injected into 
F2 (C57BL/6/Ola x CBAICa/Ola) blastocysts. The latter 
are homozygous for the wild-type alleles at the c and p loci 
(C/C, PIP) and segregating for the alleles A (agouti) and a 
(nonagouti), whereas the 129/Ola-derived type 2-1 cells 
are homozygous for the alleles c' (chinchilla) and p 
(pink-eyed dilution), which both lighten the coat color, and 
for Aw (white-bellied agouti). Hence, chimeric mice are 
identifiable by the presence of light coloring in an other -
wise dark coat. Twenty-six mice were born from 93 
blastocysts injected. Fifteen chimeric mice were obtained, 
12 of which were male. Male chimeras were tested for 
germ line transmission of the Cch  and p markers, derived 
from ES cells, by crossing with strain 129/Ola females. Off-
spring which, like strain 129/01a, are light yellow with pink 
eyes are diagnostic of germ line transmission (see Table 
2). One out of eight males tested showed germ line trans-
mission to 12 of 16 offspring (see Figure 4). Although type 
2-1 cells have a modal chromosome number of 40 and 
those metaphase spreads with 40 chromosomes have no 
detectable abnormalities in G-banding, only eight out of 
20 metaphases examined had the modal number. Never-
theless, when the male germ line chimera was mated to 
an Fl (C57BL/6/Ola x CBA/Ca/Ola) female, the resulting 
11 fertilized eggs, studied at the one-cell stage, all had 40 
chromosomes (data not shown). 
Germ Line Transmission and Expression 
of the Corrected Gene 
To study the expression of the corrected gene in mice, the 
male chimera showing germ line transmission of cell 
line-derived markers was crossed to homozygous HPRT 
deficient (hprtm31hprtb.m3) females, bred from the series 
of chimeras produced with E14TG2a (see Experimental 
Procedures). The gene pool of these females is derived 
entirely from strain 129/Ola and from the outbred strain 
MR. The latter is a strain of mice whose precise genetic 
status has not been characterized, but coat colors ob-
served in the progeny of crosses are consistent with their 
being homozygous for the albino allele (c/c) and for the 
nonagouti allele (a/a). White homozygous hprtb-m31hprtb-m3 
females were chosen for mating to chimeras; if the geno-
type deduced above for MR is correct, these homozygotes 
must either be of genotype c/c or carry the gene combina-
tion cch/cch,  p/p, a/a (Silvers, 1979). In both cases, host 
blastocyst-derived offspring are agouti or black, while cell 
line-derived offspring are lighter than agouti (Table 2). 
The cell line-derived marker was transmitted to nine of 12 
progeny (see Figure 4). Cell line-derived female offspring 
inherit one X chromosome carrying the corrected gene, 
which we designate Hprtb.m4,  derived from their father, 
and the other X chromosome, carrying deletion hprtb.m3, 
from their mother. Two such females were screened for the 
corrected gene by Southern hybridization of tail DNA (see 
Figure 5). 
EcoRl digests of DNA from these two mice show the 
10.4 kb band diagnostic for the corrected gene. The rela-
tive intensity of this band is reduced in this hybridization, 
with respect to the corrected cell line DNA, because the 
ES cell line is male and therefore contains just one cor-
rected HPRT allele per cell, whereas in the female mice 
only one of the two alleles is corrected. The absence of 
a wild-type HPRT allele in these mice is indicated by the 
lack of the 5.5 kb and 6.3 kb bands. DNA from a heterozy-
gous hprtb.m31Hprtb  mouse is shown in Figure 5, for com-
parison. In BamHI-digested DNA from mice carrying the 
corrected gene, heterozygosity is indicated by the pres-
ence of both the 9.5 kb band, containing exon 3 from the 
deletion, and the 7.0 kb band, containing exons 2 and 3 
from the corrected allele. These two bands are also pres-
ent in DNA from heterozygous hprttm3/Hprtb  mice, but 
Table 2. Expected Phenotypes of Progeny Mice from Test Crosses of Chimeras 
Coat Color 
Host Blastocyst 	 Stem Cells 	 Tester  
F2 (C57BU6IOIa x CBAICa/Ola) 	(Strain 129/01a) 	Femalea Host Progeny Stem Cell Progeny 
C/C 	 cch/Cch 	 . 	 (1) CCh/Cch agouti light yellowb 
p/P p/p P/P 
AW/AW 
c/c agouti or black light chinchilla 
cc/cc agouti or black light yellowb 
p/p 
ala 
a Tester females: (1), strain 129/01a; (2) and (3), differing possible genotypes of white homozygous hprt"31hprt"3 females (see text). 
b These animals are predicted to have pink eyes, the remaining four classes dark eyes. 
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Figure 4. Germ Line Transmission of Coat 
Color Markers from Type 2-1 Chimeras 
Mice are listed from left to right in each case. 
129/Ola female; male type 2-1 germ line chi-
mera; cell line-derived light yellow offspring. 
First two animals as in (a); host blasto-
cyst-derived agouti offspring. (c) White hprfm/ 
hprf 3 female; male type 2-1 germ line chi-
mera; cell line-derived light chinchilla offspring. 
(d) First two animals as in.(c) ; host blastocyst-
derived black offspring; host blastocyst-derived 
agouti offspring. 
the hprtbm31Hprtt.m4  mice are distinguishable by the 
EcoRl digests. 
A Northern analysis of HPRT mRNA from stem cells and 
mouse tissues is shown in Figure 6. The level of the 1500 
nucleotide HPRT mRNA in the corrected cells is indistin-
guishable from the level in wild-type E14 cells. No HPRT 
transcripts are detected in RNA from E14TG2a cells. In 
normal mice the level of HPRT mRNA in brain tissue is 
elevated approximately 5-fold relative to liver tissue (see 
Figure 6). Because HPRT is X-linked, some cells in het- 
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Figure 5. Southern Analysis to Show Germ Line Transmission of the 
Corrected HPRT Gene 
Tail DNA prepared from female mice was digested with either EcoRl 
(left) or BamHl (right) and probed with the full-length HPRT cDNA. 
Lanes: + /+, homozygous Hprl'/Hprt'; LJt., homozygous hprt"3I 
hprt"3 ; A/C, heterozygous hprf131Hprtr;  A/+, heterozygous 
hprtm31Hprtb. The size (in kb) of each hybridizing band is shown. The 
fragments containing the HPRT pseudogene are labeled PG. One of 
the heterozygous hpr 3IHprt" mice shows a previously charac-
terized pseudogene polymorphism (Isamat el al., 1988). 
erozygous mice will be functionally HPRT deficient, be-
cause of random inactivation of one X chromosome in 
each cell. Hence to provide a positive control for HPRT ex-
pression in the two heterozygotes containing one deleted 
and one corrected allele, RNA from two heterozygous 
hprLm3IHprIb mice was included. The pattern of expres-
sion in mice heterozygous for the corrected allele is es-
sentially the same as in mice heterozygous for the wild-
type allele. All heterozygote showed the characteristic 
low level of HPRT mRNA in liver and elevated levels in 
brain. Differences in the degree of mosaicism between 
HPRT-expressing cells and cells in which the wild-type or 
corrected HPRT gene is on the inactive X chromosome 
probably account for the slight variations observed in the 
absolute levels of expression between mice. Thus we con-
clude that the corrected gene functions in the same way 
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Figure 6. Northern Analysis Showing Expression from the Corrected 
Gene in ES Cells and Mouse Tissues 
Total RNA (30 pig) was prepared from ES cells or mouse tissues, elec-
trophoresed on formaldehyde-agarose gels, transferred, and probed 
with full-length HPRTcDNA. Cell ANA: +, E14; A, E14TG2a; C, correc-
tant type 2-1 grown nonselectively. Tissue RNA: Liver (L) and brain (B) 
RNA5 are shown from two heterozygous hprt3IHprta  mice, AR-; 
two heterozygous hprt - /Hprfe-4 mice, A/C; and one homozygous 
I1prtu/Hprtb mouse, +1+. The size of the HPRT mANA is approxi-
mately 1500 nucleotides. 
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as the wild-type gene in mice. That is, the function of the 
mutant gene in E14TG2a has been fully corrected by gene 
targeting. 
Discussion 
In this study we have demonstrated the feasibility of mak-
ing targeted modifications to the mouse genome by ho-
mologous recombination in ES cells. We have used target-
ing vectors of the type defined as insertion vectors 
(Thomas and Capecchi, 1987) to correct an HPRT defi-
ciency in the ES cell line E14TG2a, which has a deletion 
of the first two exons of the HPRT structural gene. Inser-
tion of the targeting vector pDWM101 into the genome by 
homologous recombination corrects the deletion muta-
tion. Three electroporation experiments generated a total 
of 30 HATR  colonies. To give an indication of the number 
of gene targeting events relative to random integrations, 
we have calculated the ratio of the number of HATA  colo-
nies per cell electroporated with pDWM101 to the number 
of HATS colonies per cell electroporated with pDWM100, 
a fully functional minigene derivative of pDWM101, and 
denoted this the targeting index (see Table 1). All elec-
troporations were carried out under identical conditions. 
The 4-fold variation in targeting index observed between 
experiments could not be correlated with the state of the 
stem cell cultures at the time of electroporation. The 
highest targeting index we observed was 0.035, which is 
more than 10-fold higher than the frequency reported by 
Thomas and Capecchi (1987). Neither calculation allows 
for random integrations into regions of the genome that 
prevent expression of the introduced gene. However, a rel-
atively high frequency of targeting events is implied by our 
observations, and those of Thomas and Capecchi (1987) 
and Doetschman et al. (1987), that no random integra-
tions, in addition to the targeting event, have been found 
in any homologous recombinants analyzed so far. This 
suggests that it should prove possible to make targeted 
genome alterations without the risk of deleterious conse-
quences arising from random integrations. 
Southern analysis of the HPRT gene in correctants 
shows that the majority (28/30) have the predicted (type 1) 
gene structure. However, we have identified two correc-
tants that have different gene structures. The type 2 struc-
ture has a deletion of the upstream copy of the exon 3 re-
gion, which may have occurred during, or after, the 
integration event. This could be equivalent to the dele-
tions reported by Doetschmanet al. (1988) during their 
HPRT inactivation experiments: The type 3 structure has 
two copies of the correcting vector inserted in tandem. We 
have shown that there is no significant difference in the 
frequency of correction between a vector that does result 
in the integration of plasmid sequences, pDWM101, and 
one that does not, pDWM102. This is helpful, because 
generally it is easier to construct insertion vectors that do 
result in the integration of plasmid sequence. In both tar-
geting vectors, pDWM101 and pDWM102, the extent of ho-
mology with the target locus is the same (between 2.3 kb 
and 4.2 kb). Others have shown that the greater the extent  
of homology, the higher the efficiency of gene targeting 
(Thomas and Capecchi, 1987). 
Cells from the correctant clone type 2-1, in which the 
corrected gene is essentially as stable as a wild-type 
gene, were introduced into mouse blastocysts. The fre-
quency of chimeras per animals born was comparable to 
the value reported previously for the parental (E14TG2a) 
stem cells (Hooper et al., 1987). We believe that the lower 
frequency of blastocysts surviving to term in the experi-
ments described here reflects difficulties associated with 
establishing the technique in our hands, rather than a 
reduction in the ability of targeted stem cells to contribute 
to the developing embryo. One chimeric male, from eight 
tested, was shown to transmit the corrected gene through 
the germ line. This is a lower proportion than for E14TG2a-
derived male chimeras, of which 19 out of 34 showed germ 
line transmission (Hooper et al., 1987). The reduced ratio 
may be a consequence of the lower fraction of diploid cells 
in type 2-1. In total, the chimera described here transmit-
ted corrected cell line—derived markers to 21 of 28 off-
spring. Chimeras produced with E14TG2a have shown 
transmission of stem cell—derived markers to 100%  of off-
spring and to as few as 1% of offspring (Hooper et al., 
1987). The ES cells used here for blastocyst injections 
were subjected to the mildest electroporation conditions 
possible, and their time in culture was kept to a minimum. 
This may have contributed to the successful production of 
germ line chimerism from the corrected stem cells. 
By crossing to HPRT-deficient females, we have pro-
duced female mice in which the corrected gene is the only 
functional HPRT gene. This enabled us to study expres-
sion of the corrected gene in the absence of a wild-type 
gene. We chose to analyze expression in these females 
because males with a corrected gene would not be avail-
able until the next generation. Mosaicism in the female 
mice, caused by random X inactivation, did not complicate 
the interpretation of the expression data. HPRT is a mem-
ber of the housekeeping class of genes, which are gener-
ally expressed constitutively at low levels in all cell types. 
However, a characteristic of HPRT expression is the eleva-
tion of mRNA levels in brain relative to liver and other tis-
sues. The deletion in E14TG2a extends at least 10 kb up-
stream of the HPRT gene. Correction with pDWM101 
replaces just 650 bp of 5' flanking sequence, which we 
show is sufficient to control HPRT expression with the 
characteristic liver and brain mANA levels. Hence, the 
mechanism by which expression is elevated in brain can 
have no requirement for sequences located more than 
650 bp upstream of the transcription initiation point. In cul-
tured cells 50 bp of 5' sequence is sufficient for a wild-type 
level of expression from an HPRT minigene (Melton et al., 
1986). Although the minigene experiments were subject to 
random integration and variable copy number, the cor-
rected gene in mice is present in only one copy per cell, 
in its natural chromosomal environment. By targeting 
changes both to the promoter and the 3' untranslated re-
gion of HPRT, we hope to determine the mechanism by 
which expression is elevated in brain tissue. 
The brain-specific elevation of HPRT expression is par-
ticularly noteworthy because a deficiency of HPRT in hu- 
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mans is the molecular basis of Lesch-Nyhan syndrome, 
which is characterized by learning difficulties, spasticity, 
choreoathetosis, and compulsive self-injurious behavior. 
Mice deficient for HPRT do not demonstrate the behav-
ioral patterns characteristic of Lesch-Nyhan syndrome. 
This suggests that mice, unlike humans, can tolerate the 
HPRT deficiency, perhaps by utilizing other pathways to 
maintain the levels of purines and neurotransmitters in the 
brain. However, the levels of striatal dopamine are re-
duced by approximately 20% in HPRT-deficient mice rela-
tive to their normal littermates, which compares to a 70% 
to 90% reduction in Lesch-Nyhan patients (Finger et al., 
1988). Hence, we would not expect to observe altered be-
havior in mice with a corrected HPRT gene, although we 
would predict that the levels of striatal dopamine would be 
restored to the wild-type level. 
Although in these experiments the detection of targeting 
events is facilitated by the selection systems available for 
HPRT activity, strategies for targeting into nonselectable 
genes, using vectors containing selectable markers (Jasin 
and Berg, 1988; Mansour et al., 1988; Doetschman et al., 
1988), or the detection of targeted clones by the polymer-
ase chain reaction (Kim and Smithies, 1988), are being 
developed. Consequently, it should soon be possible to 
target modifications to any chosen gene in the mouse 
genome. 
Experimental Procedures 
Production of Homozygous hprtt33Ihprtb-m3  Female Mice 
Mice of inbred strains 129/01a, C57BL/6101a, and CBAICaIOIa and out-
bred strain MF1 were obtained from Olac 1976 Ltd., Bicester, Oxon. A 
male E14TG2a chimera showing 100% transmission of the CCh  allele 
(Hooper et al., 1987) was mated to a wild-type.MF1 female. Female off-
spring, heterozygous for the null hprtm3 allele (generation 1), were 
mated to MF1 males, and male offspring (generation 2) carrying the 
null allele were identified by enzyme assay on blood samples. These 
HPRT-deficient males were mated to MF1 females, and embryos were 
transferred to foster mothers to improve their health status. Heterozy-
gous female offspring (generation 3) were mated to strain 129/Ola 
males. HPRT-deficient male offspring were identified by enzyme assay 
on blood samples, and heterozygous female offspring were identified 
by Southern blot analysis of DNA obtained by tail biopsy (generation 
4). HPRT-deficient males from generation 4 were mated to heterozy-
gous females from either generation 3 or 4. Homozygous hprtm3I 
hprt 13 females were identified by enzyme assay on blood samples, 
and their status was confirmed by tail blots. Segregation of coat color 
markers in these animals, made it possible to choose white homo-
zygotes for mating to chimeras produced with corrected stem cells. 
Embryonic Stem Cells 
The wild-type male ES cell line E14 was derived from strain 129/Ola 
blastocysts by trypsinization of immunosurgically isolated inner-cell 
masses. The dissociated cells were cultured on STO fibroblast feeder 
layers in Buffalo rat liver cell (BRL)-conditioned medium (A. H. Handy-
side, G. T. O'Neill, M. Jones, and M. L. Hooper, submitted). The HPRT-
deficient E141t32a cell line was isolated as a spontaneous 6TGR 
derivative of E14 (Hooper et al., 1987). For all the experiments reported 
here ES cells were grown in BRL-conditioned medium without a feeder 
layer. The medium used was Glasgow modified Eagles medium (Flow 
Laboratories) supplemented with lx nonessential amino acids and 1 
mM sodium pyruvate (Flow Laboratories), and 5% (vol/vol) of both fetal 
calf serum and newborn calf serum (Sera-Lab, Sussex). Batches of se-
rum were chosen for their ability to give good ES cell plating efficien-
cies (typically 10%-30%) without affecting the ability of ES cells to 
differentiate in vitro. Cells were grown in the absence of antibiotics in 
37°C incubators with 5% CO2 in air. 
BRL-conditioned medium was made as follows: BRL cells were 
grown to confluence in 75cm 2 tissue culture flasks. The medium was 
discarded, and 15 ml of fresh medium was added. This was collected 
after 2 days and replaced with another 15 ml of fresh medium. In total, 
45 ml of conditioned medium, rep'resenting 6 days of collection, was 
obtained from each flask. The conditioned medium was filtered (pore 
size, 0.2 pm) and stored at -20°C. 
ES cells were grown on gelatin-coated tissue culture flasks in 60% 
BRL-conditioned medium, 40% fresh medium, containing 0.1 mM 
-mercaptoethanol. Typically, the medium was changed daily and cul-
tures were split every 3-4 days. Under these conditions the cell num-
ber doubled every 24 hr and the majority of cells in the culture had the 
typical stem cell morphology with little spontaneous in vitro differentia-
tion. We considered that the likelihood of obtaining germ line transmis-
sion from corrected stem cells would be enhanced by the use of early-
passage cells and by minimizing their time spent in culture. For this 
reason correctant clones generated in the first electroporation experi-
ment from late-passage stem cells were not used for blastocyst injec-
tions. For the second experiment, E14TG2a cells (passage 25 since the 
isolation of the E14 line) were grown up and the targeting procedures 
and analysis were carried out as rapidly as possible. The cumulative 
passage number of correctant type 2-1 cells at the time of blastocyst 
injection had risen to passage 36. 
Vectors 
The correcting vector used in these experiments, pDWM101, is similar 
in structure to the vector described by Doetschman et al. (1987) except 
that, in pDWM101, all correcting sequences are derived from the 
mouse HPRT gene (see Figure 1). pDWM101 was constructed by first 
cloning a 4.7 kb BamHl-EcoRl restriction fragment, containing exon 
2, and derived from the mouse HPRT genomic clone, ?HPT1 (Melton 
et al., 1984), into BamHl- and EcoRl-cut pUC8 (Vieira and Messing, 
1982). A ao kb Bglll-BamHl fragment containing the HPRT promoter 
and exon 1, derived from Xi-IPT32, was then inserted into the BamHl 
site, and a 1.35 kb EcoRl fragment, containing exon 3, isolated from 
?HPT1, was cloned into the EcoRl site. The resulting 11.7 kb plasmid, 
pDWM101, has the same organization as the equivalent part of the 
HPRT gene itself except that the first intron is reduced from 10.8 kb in 
the gene to 4.1 kb in the vector. The correcting vector can only rescue 
HPRT-deficient stem cells by homologous recombination with the 
defective gene. As a positive control for these correction experiments, 
an HPRT minigene derivative of pDWM101 was constructed by replac-
ing the 1.25 kb Xhol-EcoRl fragment from pDWM101 with the 1.8 kb 
Xhol-EcoRl fragment from the minigene pDWM1 (Melton et al., 1986), 
which contains the remainder of the coding sequence and the 3' un-
translated region. This minigene derivative, pDWM100, is fully func-
tional and can rescue HPRT-deficient stem cells without the require-
ment for homologous recombination. A rearranged version of the 
correcting vector, pDWM102, in which an Xhol digest is used to excise 
the pUC8 sequences prior to recombination, was also constructed: A 
7.8 kb Sail (pUC8 polylinker site to the 5' side of correcting se-
quence)-Xhol (site within axon 3)-fragment from pDWM101 was first 
cloned into a pUC8 derivative, where an Xhol linker had been inserted 
into the Smal site within the polylinker. This plasmid was then linear-
ized at a Sail site immediately upstream of the HPRT promoter region, 
and a 1.25 kb fragment, containing the remainder of exon 3 and the 
following intervening sequence, from pDWM101, was inserted to 
generate the 11.7 kb plasmid, pDWM102, with the structure shown in 
Figure 1. 
Electroporation and Selection for Correctants 
Correcting vector DNA was introduced into ES cells by electroporation 
(Bio-Rad Gene Pulser). Approximately 5 x 106 cells were resuspended 
in 0.8 ml of HEPES-phosphate buffered saline (pH 705) (Graham and 
van der Eb, 1973) with 20 Vg of Xhol-linearized vector DNA. The cells 
were given a single pulse (800 V, path length 0.4 cm, 3 iF), then allowed 
to stand at room temperature for 10 min before plating in nonselective 
medium. HAT selection (Littlefield, 1964) was imposed after 24 hr. 
Southern and Northern Hybridizations 
High molecular weight genomic DNA was prepared by the method of 
Pellicer et al. (1978). Total RNA was prepared from cultured cells, or 
mouse tissues, as described previously (Melton et a]., 1981). GeneScreen 
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Plus (New England Nuclear Products) was used as the hybridization 
membrane. The conditions for transfer, hybridization, washing, and re-
hybridization were those recommended by the supplier. For Southern 
hybridizations the probe was either the purified insert from the mouse 
HPRT cDNA recombinant pHPT5 (Konecki et al., 1982) or plasmid 
pUC8. For Northern hybridizations the probe was the purified insert 
from pHPT4 (Konecki el al., 1982). Probes were labeled by the random 
priming method (Feinberg and Vogelstein, 1983). 
Blastocyst Injections and Production of Chimeric Mice 
Cells for microinjection were washed, trypsinized and resuspended in 
10 m HEPES-buffered Glasgow modified Eagle's medium containing 
10% (vol/vol) newborn calf serum. F2 (C57BU6IOIa x CBAICaIOIa) 
blastocysts were collected on the day of injection by flushing uterine 
horns 3.5 days postcoitum with Glasgow modified Eagle's medium con-
taining 10% (vol/vol) newborn calf serum. Approximately 12-15 cells 
were injected into each blastocyst, using a Leitz micromanipulator and 
needles prepared with a Campden Instruments puller and microforge. 
Injected blastocysts were allowed to re-expand for 1-2 hr following ma-
nipulation and were then implanted into the uterine horns of pseu-
dopregnant C57BU6/Ola mice, mated 2.5 days previously to vasec-
tomized Fl (C57BU6IOIa x CBA/CalOIa) males. 
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